WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS 13th Annual Conference Guide www.sachsforum.com 30th September – 1st October 2013 30th September – 1st INVESTOR FORUM INVESTOR

Hilton Zurich Airport Hotel, Switzerland Hotel, Hilton Zurich Airport BIOTECH IN IN EUROPE BIOTECH BIOTECH IN EUROPE INVESTOR FORUM INVESTOR EUROPE IN BIOTECH t back :: WELCOME next u

Welcome

Sachs Associates are delighted to welcome you to the:

13th Annual SPEAKERS Biotech in Europe Investor Forum 30th September-1st October 2013 Hilton Zurich Airport Hotel, Switzerland

Sachs Associates are delighted to welcome you to the 13th Annual Biotech in Europe Investor Forum. Following the success of previous years, the forum once again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas. PRESENTING COMPANIES This Forum is highly transactional and is comprised of a series of panels and presentations from leading investment, pharmaceutical and biotech companies, each one providing an expert outlook on growth and investment activity in Europe’s Biotech industry. The programme highlights the current issues surrounding the evolving M&A market, the Private Equity & Venture Capital environment and a special session on major trends in Partnering. Plus, this year’s programme features more than 80 company presentations from a range of publicly listed and private life science companies looking to raise finance and/or find partners.

General Information The registration desk will be open from 8am on September 30th and from 8am on October 1st although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session. SUPPORTING ORGANISATIONS Networking at the Forum is facilitated by our online 1-2-1 meeting system, which is available to all participants. A Networking Lunch will be set up in the Zurich A & B rooms. Coffee stations will be set up in the Zurich A & B rooms and the presentation rooms throughout the event.

Request for Presentations Please use the agenda to mark off presentations that you are interested in and email your request to [email protected] after the conference. We will endeavour to send you the requested presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides that are shown during the conference. ORGANISERS WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS t back :: next u For regular updates, sponsorship, presenting and attending opportunities and attending opportunities presenting sponsorship, For regular updates, regarding anyand further information contact of our future events please [email protected] Sian Rodgers on 14th Annual Forum Investor Biotech in Europe 7th – 8th October 2014 • Zurich • Switzerland 7th Annual Life Science CEO Forum European & Investing For Partnering 4th – 5th March 2014 • Zurich • Switzerland this exclusive and highlyevent is a must transactional partnering Back for its seventh year, engage with leading investors and forge new for companies wishing to meet with their peers, partnerships. the forum will provide an excellent platform to gain event, Building on the success of this year’s Networking at the insight into partnering and investment trends in the Biotech and Pharma industry. which is available to all participants. Forum is facilitated by, our online 1-2-1 meeting system The conference will feature presentations up to 80 by large to mid size pharmaceutical companies looking for strategic alliances/partners. leading global investors and Do not miss out on this great opportunity to meet emerging companies, Big Pharma representatives! MedTech & Diagnostics Innovations Summit & Diagnostics Innovations MedTech • Düsseldorf • Germany21st November 2013 leading annual internationalThe Summit is being held to coincide with the tradeshow Medica with together a specialist audience from leading and growthits 135,000 visitors and is designed to bring The program will feature keynotes from and Investment. alliances companies focused on M+A, industry venture investment and leaders and plenary panels on industry acquisitions; public markets, The subjects of regulation and reimbursement will also be and diagnostics. company finance, growth, covered. Apart from the plenary session the program also feature will 20+ public and private company & Device The MedTech presentations focused on innovation and alliances/investment opportunities. Digital Healthcare, Imaging, Cardiovascular, Oncology, and Diagnostics track will cover: presenting Surgical Devices & Implants and Diagnostics. There is a 1-to-1 online meeting system with meeting There will be many opportunities. networking and a conference cocktail reception. there will be networking breaks In addition, rooms provided. will receive Financial Investors Participation will be limited and presentations by invitation. plan an audience of 150 -200 delegates. We complimentary passes. Events Diary Events WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Advent Venture Advent Venture , EPEMED Partners & Chairman Partner, Alain Huriez, Venture life the in financing and development drug bringingmanagement, 2012 in in experience Advent of years 22 joined Alain Vice President Capital and Truffle Associate Partner at and Neovacs, TcLand Expression CEO of including sciences sector, Sorbonne Masters of Pharmaco-Economics from Paris La is a medical doctor and holds an MBA and a Alain at Quintiles. in a large teaching hospital and practiced as a he was head of the emergency room industry, Prior to joining the University. General Practitioner for years. two high biomarkers and forresponsible been has Alain initiativesmedicine, several personalized of areas the within Europe in Association he founded in Personalised Medicine the European value diagnostics work as chairman of EPEMED, through his he co-founded four French biotechnology companies. As an entrepreneur, 2009. Novartis Venture Venture Fund Novartis Managing Director, Anja König, Prior to joining Asia Pacific. presence to Anja is active in Switzerland and Europe and also responsible for expanding the fund’s where she worked with companies a global consultancy, Associate Partner atMcKinsey and Company, Novartis she was an byphysics scientist in a PhD is a König holds and Anja training Emergingand Europe Markets. US, the in care health in F2G and Nabriva and works with Destiny, Heptares, Covagen, Anja serves on the boards of Bicycle, from Cornell University. Therapeutics. Polyphor and Qurient PharmAbcine, Oxagen, Neomics, André Rosenthal is founder and CEO of Signature Diagnostics AG, a cancer diagnostic company focused on prognostic and AG, André Rosenthal is founder and CEO of Signature Diagnostics The biomarker research of Signature is based on a large predictive (companion diagnostic) cancer. biomarkers in colorectal multicenter clinical diagnostic 7.500 patients study in colorectal cancer which has recruited more than of all four prospective, specimens and plasma samples with longitudinal FFPE tumour tissue clinical annotation are used Fresh-frozen, UICC stages. for deep sequencing with the aim of developing accurate tissue and plasma based tests. tumor André´s current interest is translational oncologya focus with on developing novel next generation sequencing (NGS) tests forused circulatingbe on can patientsbased which cancer plasma colorectal from monitoring DNA free also forbut early we develop NGS tests for the prediction of outcome (prognosis) of colorectal In addition, detection of colorectal cancer. Signature tests Diagnostics NGS five of suite a developed has patientscancer forand treatment. to response of prediction the circulatingif test forused sequencing be deep can ultra and an DNA is OncoDetect test plasma Our indications. these in Our ASCO 2013 meeting. This test was presented at the recent monitoring patients with colorectal cancer of stage III and IV. Amsterdam. atprognostic NGS test OncoSelect-III will be presented 17th ECCO meeting in September 2013 in the Human Genome Sequencing Project André was a member of the core team involved in the world wide Between 1989-2003 from 1993 in Germany as a professor at from 1989-93 in Cambridge (UK) with Sydney Brenner and John Sulston, (HUGO), Sequencing Project and He was in charge of the German Human Genome the Friedrich Schiller University in Jena (Germany). in Jena also contributed His team led the chromosome 21 sequencing project in collaboration with Japanese researchers. During 1989-2000 he participated cloning projects in several positional of human chromosome 8 and X. to the sequencing paraplegia (CRASH spastic, MASA syndrome and X-linked of human disease genes including X-linked hydrocephalus, X-linked congenital syndrome type I, tricho-rhino-phalangeal Nijmegen breakage syndrome, syndrome, Turner syndrome), and others. lymphoma, MALT X-linked retinitis pigmentosa 2, stationary night blindness, He is an inventor of many patents and patent original135 peer reviewed André has authored or co-authored papers. applications. Signature André Rosenthal, CEO , Signature Diagnostics AG Dr. Prof. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u e40 million VC CEO, Lanthio Pharma BV Speakers 700 million. Bart has been a biotech CEO for 11 years, in the UK and in the in the UK and a biotech CEO for Bart has been 11 years, licensing deals worth e700 million. financing and to closing pharmaceutical sciences degrees He holds Universities from Dutch Lanthio Pharma as CEO in 2011. Bart joined Netherlands. in Utrecht and Leiden. CBO, Nanobiotix Dr Bernd Muehlenweg, by extended management training at the St. University of Munich, Technical Bernd holds a doctorate in chemistry from the He was responsible for as well as several merger/acquisition and negotiation techniques seminars. Gallen Business School, is co-author of more Mr Muehlenweg several negotiations licences and marketing contracts. and the execution of several He is member of the Pharma Licensing Club of Germany. than 17 publications and 2 patents. where he made significant AG in Munich, Wilex Before Director for joining Nanobiotix Bernd was Business Development therapeuticof of development the market in a leader as diagnostic Wilex molecules and tools in position to contributions for responsible he is where 2011 in Nanobiotix He joined the sustainable ensuring growthCompany of the by oncology. concluding strategic alliances with partners. Bart Wuurman, Bart Wuurman, He gained broad industry has 25 years of International Pharma and Biotech Industry experience. PharmD, Wuurman, Bart to General Management product licensing Organon, and fund raising with ranging from drug development, experience, around raising to instrumental was He AM-Pharma. and Pharmaceuticals DeNovo Antisoma, Medeva, Gründerfonds Management High-Tech Senior Investment Manager, Bernd Goergen, The Gruenderfonds(HTGF) as Senior Investment Manager. works for the High-Tech Ph.D. Bernd Goergen, Since 2008, Biotech analyst combines 5 years of research experience in virology-immunology and in-depth biologist and DVFA-certified expertise from 7 years (1994-2000) international diagnostics marketing for global market leaders in Germany and the US. M&A organised he where bank, German major a of department banking investment the joined he 2007 and 2000 Between Bernd currently manages activities and capital and capital market transactions like IPOs increases for life science companies. serves also He a as portfolioa pharma/biotech. and fordevices companies medical 14 between of 50-50-split a with HTGF board member in 4 of the funds life science firms. Excellentia Global Partners Beth Jacobs, Managing Partner, life sciences investment bank, a global Beth Jacobs currently serves as Managing Partner of Excellentia Global Partners, founded in 2008. Beth has servedin her twenty five years of experience in both investment banking and in the in senior executive roles as Managing York, a life sciences investment bank based in New Beth was a partner at Bio-IB, Prior to 2008, corporate sector. where she shortly after their acquisition of Furman Selz LLC, Director and Co-Head of Global Capital Markets at ING Barings, atcareer her She started Securities Prudential foundedinternationalits led and groupequity institutional for years. 7 over and later same product execution group headed the atboth she foundedwhere internationalthe business, equity institutional Morgan Stanley and Lehman Brothers. a global educational servicesShe currently serves company based in Stockholm on the Board of Directors of EF Foundation, Ambassador for Susan G. founding Global Academy of Sciences, York Board of Governors of the New Mass, and Cambridge, as and Board Leadership Women’s formember Board Harvardthe both Government of School Kennedy forKomen the Cure, Vice Chairman of the Board for the Budapest Festival Orchestra. in conjunction with the School of DC Washington, American University in Beth received an MBA in international finance from She also studied at Centre d’Etudes Internationale in Geneva, from Boston College. cum laude, and a BA, Foreign Service, Switzerland. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers F. Hoffmann-La Roche AG Roche Venture Fund Venture AG Roche Hoffmann-La Roche F. Head, Carole Nuechterlein, she worked in the position, Prior to her current Fund since 2001. Venture Carole Nuechterlein has headed the Roche She joined Roche from SangStat in Fremont Californiapharmaceutical/biotech industry where as an attorney for ten years. she was General Counsel. atworked she there, From SlateArps Meagher group. M&A the in Flom & atworking career her began Carole Skadden Due to her background in research collaborations deals. and licensing California focusing on M&A, Alto, Syntex/Roche in Palo Therapeutic Human Polyclonals. Carole led the negotiation team for the Roche acquisitions of GlycArt and M&A, BioFire Diagnostics and Epic. Ambrx, Alios, She currently servesAileron, as a board observer at University of Michigan. University and a JD from Valparaiso She has a BA from Fund can be foundat www.venturefund.roche.com. Venture More information on the Roche Carlos Buesa, CEO, Oryzon SA Biochemistry Dr Buesa got his PhD in and Molecular Biology University from the Biotech Industry. Carlos is a specialist in the Faculty of Medicine at He was post-doctoral fellow in the in the University of Ghent and in 1993. Spain of Barcelona, later Senior Investigator at Flemish Institute of Biotechnology the (VIB). he has served Since inception he founded Officer and Chairman of the as Chief Executive Oryzon. in 2000, Back in Spain, the companyUnder his leadership rounds and the companyeuros in several funding has got +14M has Board of Directors. based companyevolved from a genomics to a clinical companyprogram with its first in Epigenetics in Oncology in Phase I/IIA. at School in Barcelona and several additional Business the IESE educationthe executive He has taken programme (PADE) international commerce and advanced business development negotiation skills, educational programs in finances, AssociationCatalan of of the VicePresident AssociationBioIndustryof (ASEBIO), Spanish the of member board now is He a of BioRegió and he was also member of the Executive Committee de Catalunya, Biotechnology Companies (CataloniaBio), regional biocluster body thataim of improving of the biotechnology has been set up with the sector in Catalonia. Neurosciences technologies, PaloBiofarma, he sits on the board of other biotech companies like GEADIC Biotech, In addition, Biotech and Oncnosis Pharma. NINFAS VC-seed firms Inveready seed and Inveready Biotech. He is also board member in the Sanofi Pasteur-MSD Sanofi Pasteur-MSD Chris Britten, Head of Business Development, with responsibility for all business and corporate Chris is currently Head of Business Development at Sanofi Pasteur-MSD and is focused on Venture between Sanofi Pasteur and Merck & Co. is a Joint Sanofi Pasteur-MSD development activities. Sciences, Life Vantage Managingthe also is Chris of Director commercialisationand development Europe. the in vaccines of offering strategic and transaction advisory services to the life science sector. Astellas (Europe) in Business and Commercial Development in 2013 following positions at Chris joined Sanofi Pasteur-MSD Advisory practice assisting clients across and several years at Deloitte Corporate Finance where he headed up the Life Science Prior fund-raising). valuation, partnering, divestments, the life science sector in a wide range of transactional activities (M&A, Corporate Development, Business in responsibility increasing atof was roles Chris held he where GlaxoSmithKline Deloitte, to and R&D. Ventures Chris holds a PhD in Biochemistry Finance. and an MBA in WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u ABN AMRO ABN Christina joined the

Partner, Forbion Capital Partners Partner, Speakers Novartis Novartis Pharma AG Head Business Development and Licensing, Corinne Savill, she has In her current position, both the pharmaceutical and biotech arena. Corinne has over 15 years of broad experience in responsibility for deals within Novartis. all Business development and partnering Corinne joined Imutran Ltd in Immunology and a number of academic and pharmaceutical research positions, After a Ph.D. She In 1996 Imutran was acquired by Novartis and Corinne made the COO. a UK based Biotech as Director of Research. managinginvestment account million a CHF 100 Fund, Venture Bio Novartis CEO of the 2001 as the Basel in moved to Corinne then moved to and establishing a new network for Novartis with venture capital companies in the US and Europe. where she was in and Central Europe, Western and Immunology Unit as Regional Business Manager, Transplantation the Evaluationand Search Global up Business head Novartis to with moved Corinne 2005 In regions11 of charge countries. and development where she was responsible for the identification and evaluation of potential license-in or M&A opportunities, In 2010 Corinne became Novartis’s growing the Novartis development pipeline and supporting the business goals of Novartis. forAccess responsible the pricing and market access strategies for the entire portfolio of Global Head of Pricing and Market development and in Market products world-wide. Novartis Pharma’s AG. In June 2013 Corinne was appointed Head Business Development and Licensing Novartis Pharma Christina Takke, Christina Takke, Campos-Ortega at Dr. which she obtained under the supervision of Prof. Christina holds a PhD in Developmental Biology, As an undergraduate Christina studied Molecular Biology/ the Institute of Development Biology of . of the University Bordeaux and at Université de the Institut National de la Recherche University of Darmstadt, Technical Biochemistry at the biotech startup companies atin working with experience she gained After her studies, AgronomiqueMontpellier. (INRA) She evaluated regional a development organization for the biotechnology industry. Germany, in Cologne, Bio-Gen-Tec-NRW companies in the fundraising process. business proposals and assisted the young biotech before Following this assignment she became Principal being promoted to Capital Life Sciences team as an analyst in 2000. forresponsible deal is general Christina as analysisForbion well and At as scouting opportunities investment new of Partner. arGEN-X BV, Amakem NV, Christina currently portfolio serves companies supervisory on the execution. boards of Forbion’s AG as a Board and she was closely involved with GlycArt In recent years she served on the board of Bioceros, AG. and Pieris Observer (sold to Roche in 2005). Fund Manager, Polar Capital Fund Manager, Pinniger, David He has over 12 years’ investment 2013 as a fund managerAugust within the healthcare team. David joined Polar Capital in Davidportfolio was a manager of the International Prior to joining Polar Capital, experience in the healthcare sector. as Abingworth previouslyalso He at working years three spent capitalventure firm at Sciences. Life SV Trust Biotechnology and four years at Morgan venture and specialist funds, an analyst managing biotechnology investments held across the firm’s Charterholder. He is a CFA Stanley as an analyst covering the European pharmaceuticals and biotechnology sector. Alpine Institute for Drug DiscoveryChris Maggos, Alpine Institute for Drug communication, investor relations, in the life sciences industryChris has 20 years of experience development, covering business forAlpine Institute Drug to establish Chris has been working the Most recently, neurobiology. investing and molecular focusedenterprise social a translationalon discovery drug immunotherapeuticsnovel of innovation. open via Discovery, Addex Pharmaceuticals and held the executive management Chris was a member of the board at AIDD, Prior to launching relationspositions of head of investor & communication director of business development (2010-2013). (2007-2010) and a journalist for the biotechnology trade publication BioCentury (2001-2007); an investor atPreviously NYC- a he worked as: Partners (later called Casdin Life Science called Cooper Hill); and a molecular based biotechnology (1997-2000), hedge-fund He is co-author on 12 peer-reviewed (1993-1997). University Rockefeller The neurobiologistatdependence drug studying English Literature University in (where he also completed pre-medical studies). Yale Chris holds a BA from publications. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Chief Scientific Officer, Asceneuron SA Chief Scientific Officer, Dirk Beher, He led the spin-off Asceneuron SA and joined the company as Chief Scientific Officerat its inception. Dirk is a founder of disease portfolio and successfully raised EUR 5M seed funding which materialized in Alzheimer’s proposal for Merck Serono’s disease Alzheimer’s in the field of Dirk has more than 21 years of experience Asceneuron SA in October 2012. the creation of Asceneuron he has held various positions with increasing Prior to and spent over 15 years in pharmaceutical drug discovery. responsibility at geographical major pharmaceutical and biopharmaceutical companies in worldwide locations. Switzerland. Neurobiology Unit at Merck Serono in Geneva, and Parkinson’s Alzheimer’s Dirk was the director of the Previously, disease as a new indication and implemented the project portfolio Alzheimer’s He was responsible for the strategicof build-up pipeline. Asceneuron’s which represents California where he Thousand Oaks, in Inc. Prior to Merck Serono Dirk worked in the Neuroscience Department at Dirk started managed the in vitro pharmacology team and oversaw a diverse CNS portfolio as management team member. United Kingdom in his career in pharmaceutical drug discovery by joining Merck Sharp & Dohme (Merck & Co.) in Harlow, During that time he made key to the clinical γ secretase inhibitor MK-0752 and was finally contributions responsible 1998. for all γ secretase programs. He is an inventor Germany. and a Diploma (M.S.) in Biology from the Ruprecht-Karls University Heidelberg, Dirk holds a Ph.D. publications and reviews. of seven patents and currently authors 47 peer-reviewed VP & President, SR One VP & President, Harland, Deborah One extensive operational, She brings to SR investment office. European Deborah joined SR One in 2005 to establish the firm’s medical affairs and through numerous roles held in clinical development, drug development and licensing experience gained Deborah is currently a member tenure in the pharmaceutical industry. business development during her more than 20 year and Limited, Syntaxin Therapeutics Limited, Bicycle AG, Protaffin Therapeutics Limited, of the Board of Directors of Mission SIX Swiss Exchange, Addex Pharmaceuticals (IPO, She was previously a member of the Board of Directors of f-star GmbH. Euronext Brussels 2007) and Ablynx (IPO, an observer2007) and Pharmakodex Limited (sold to Orexo) and on the Boards of Pharmacologyin PhD her from Pharmacologyin (Hons.) Bath, of University the from BSc. her received Deborah Pharma. 7TM and her MBA from Henley Management College. the University of London, Co-CEO, CSO, Numab CSO, Co-CEO, Urech, David degreemaster his received where he in DavidBiologyMolecular studied atNeurosciences and Zurich, of University the in Howard Riezman at his Ph.D. of the University of Basel where he completed the Biocenter Prof. He then joined 2000. David led the antibody discovery group and became Head of As a Senior Scientist at Esbatech, Biochemistry in 2004. for In this position he was responsible the and member of the Senior ManagementResearch & Development in 2007. He platform technology. evaluation positioning of Esbatech’s of drug targets and the strategy, definition of the scientific transformed an initially discovery 5-people team into an integrated & Development unit consisting of 30 employees. Research During from technologyThis unit covered activities discovery development through antibody and preclinical development. which reproducibly gives David to highly rise developed a novel discovery potent and stable platform, his time at Esbatech, scientific work on the pharmacokinetic properties of antibody fragments his seeding enabled the Further, antibody fragments. TNF-inhibitorythat scFv fragment antibody the first became to be successfully applied topicallyof Esbatechsdevelopment technologiesThe and products developed by David and his team turned out to be the by eye drops in a clinical setting. an antibody fragment Most recently ESBA1008, in September 2009. acquisition by value driving factor for Esbatech’s David is an inventor of over a dozen patentpriority applications group entered a clinical phase 2 trial. developed by David’s journals. peer-reviewed and his scientific work has been published in numerous WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Integrated Medicines Ltd Integrated Managing Director, Blair, D. Dr Edward a company he formed in 2003 to enable Blair is Managing Director of Integrated Medicines Ltd (IML), Dr Edward D. He is also Chief Executive of personalised medicine by combining diagnostic-type testing with new and existing medicines. and a non-executive director (Rem Com Chair) of Immunodiagnostic Holdings PLC, Integrated Magnetic Systems Ltd (IMSL), personalised on lectures also He programme. Enterprise Bioscience in Masters University Cambridge the to scholar visiting a medicines and offers on his best-selling books. occasional bespoke courses based and including a series on companion diagnostic valuation, papers, peer-reviewed Eddie has published more than 40 primary, tuneableincluding aton inventor named is patents, he dozen least one Finally, journals. medicine personalised two of editor is the technology being exploited by IMSL. magnetic proteins, OCT Clinical Trials Head of Business Development, Elena Startseva, Elena is responsible for and management; new business opportunities assessment she As a Head of Business Development, manages She capabilitygeneral OCT development of relationsclient negotiations. budget and advertising, supervisesOCT’s presentations as well as study specific presentationsclients from all over the world. to industryPharmaceutical/CRO the in working started has Elena expertise and deep knowledge a has and CRA as a 2005 in in the field of clinical research. After several years of Elena worked for Quintiles GesmbH as a Clinical Study Manager. Prior to joining the OCT team, Elena has been appointed team. to lead the Business Development experience as a Senior Project Manager at OCT, she completed residencies in Academy, Petersburg Peadiatric Medical Elena holds Doctor of Medicine degree from the St. University. and an MBA degree in International Business from Stockholm’s forensic and general pathology, Dicerna Pharmaceuticals, Inc. Dicerna Pharmaceuticals, CEO, Douglas M. Fambrough, Prior to joining Dicerna, Douglas is a co-founderof Dicerna Pharmaceuticals and joined the company as CEO in May 2010. one of Dicerna’s a decade as a biotechnologyspent over Fambrough venture capitalistOxford with Bioscience Partners, Dr. innovative he specialized in financing life science technology as the first generation companies such At Oxford, investors. DNA Among his other investments are high-throughput Therapeutics (acquired by Merck). Sirna RNA interference company, engineers which antibody Fc domains to enhance drug properties; (acquired bysequencing pioneer Solexa Illumina); Xencor, a developer of antibiotics against pathogens;resistant multi-drug and Solstice Neurosciences Rib-X Pharmaceuticals, Whitehead/MIT Center for Fambrough was a genomic scientist at the Dr. Prior to Oxford, WorldMeds). (acquired by US in Fambrough graduated from Cornell University and holds a Ph.D. Dr. Genome Research (now known as the Broad Institute). Berkeley. genetics from the University of California, Promethera Biosciences MBA, Co-Founder and CEO, Promethera Eric Halioua, Promethera® Eric Halioua is the CEO and co-founder of the Belgian Biotechnology company Promethera Biosciences. develop and commercialize cell therapy products to treat liver diseases in an innovative Biosciences’ mission is to discover, the He is as well Board members the biotechnology company Bioxodes, way using stem cell from healthy human livers. region Biocluster (BioWin). Walloon European Biopharmaceutical Enterprises (EBE) and of the Belgian Myosix is a tissue engineering company Eric is co-founder of two biotechnology companies called Myosix and Murigenetics. The company has been sold to specialising in musculoskeletal cells culture used in the regeneration of the heart muscle. Murigenetics is a Biotechnology company developing therapies for genetic disorders. Genzyme mid-2002. which specializes in the production Vivalis, Eric was also a Board Member of a French public biotechnology company called of avian stem cells lines for the production of vaccines and recombinant proteins. in Paris and Boston during Little based Arthur D. Eric was as well principal of the international life sciences practice of M&A and technology & innovation management for biotechnology and of strategy, He has led work in the areas 11 years. “Centre Européen de Bioprospective” as a strategic Eric also worked marketing manager for the pharmaceutical companies. and as project leader in the corporate R&D centre of Zeneca in UK. Eric holds two master degrees (DEA and Magistère) in Pharmacology and Molecular Biology and a MBA from ESSEC business with an advanced degree from the Health Care ESSEC chair. ), school (Paris, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u PharmaVentures Ltd PharmaVentures Chief Executive Officer, Speakers Esteban is Chief Operations Officer for Oxford Biotherapeutics. Prior to joining OBT, Dr Pombo-Villar was Dr Pombo-Villar at Novartis for over 20 Prior to joining OBT, Esteban is Chief Operations Officer for Oxford Biotherapeutics. Most recently he was Head of the last 12 years of which he focused on all aspects of creating and managing alliances. years, responsible for up to proof-of-concept alliances Alliance Management at the Novartis Institute for Research (NIBR), Biomedical He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz in man. on drug discoveryhe worked At Sandoz leading collaborative projects as well as in 1988. Basel Neuroscience Research in Royal Society of Chemistry. Dr Pombo-Villar is a Fellow of the projects investigating the potential of emerging technologies. Oxford BioTherapeutics Oxford Chief Operations Officer, Esteban Pombo-Villar, Sanofi Transactions, Alliance Management & Head of R&D VP, Grams, Dr Frank In this function he is leading Alliance Management & Contracting. Head R&D VP, Frank joined Sanofi in September 2011 as Alliance Management organization up to POC. the early stage technology contracting activities and the R&D and as such has Asia, Roche Partnering Before coming to Sanofi he has been working for Roche as Executive Director, The office has been been instrumental in setting up the Roche Pharma Partnering office in Shanghai starting in 2008. Australia. presence in the region from China to strengthening Roche’s responsible for both the strategicand life- Drug Delivery Partnering, Global Head, Frank was post, up this Prior to taking managing Alliance Director from 2002, Frank was a Global cycle management activities related to drug delivery partnering. been involved in more than 100 transactions He has Syrrx and Biotie. SGX, Evotec, pivotal research alliances such as Chugai, He is also one of the in- and out-licensing opportunities and also an acquisition. including product and technology deals, initiators of the Greater China Life Sciences Business Plan Competition SEED (www.seedcompetition.com). having previously worked Frank joined the Roche Pharma Partnering team as Head of Opportunity Surveillance in July 2001, in various research functions in Roche and at Boehringer Mannheim GmbH. with summa cum laude from the Frank has a degree in chemistry from the University of Heidelberg and received his Ph.D. University of Munich within the group of Nobel laureate Robert Huber (Max-Planck-Institute for Biochemistry at Technical Germany). Martinsried, Dr Fintan Walton, Dr Fintan Walton, College Trinity educatedwas He atand (US) Michigan of University the PharmaVentures. of CEO and Founder the is Walton Dr and subsequently commercial experience in biotechnology he gained broad in management positions at Bass Ireland), (Dublin, a company focused on co-founded in 1992, CONNECT Pharma Walton Dr As an entrepreneur, and Celltech plc (1982-1992). pharmaceutical and biotechnologyassisting strategicaspects of deal making including in all worldwide companies alliances, His company has worked In 1997 the company became PharmaVentures. Acquisitions and equity financing. Mergers & Clients have for delivering more than 600 assignments companies in 37 countries. with blue chip clients on a global basis, medical device, included major pharmaceutical and biotechnology as well as diversified chemical corporations, companies and private equity and investment/merchant banks, His clients have also included major banks, generic and OTC companies. venture capital groups. he actively participates in many main focus is his role as Chief Executive Officer of PharmaVentures, Although Fintan’s consultancy assignments. Eric Massou, CFO, Poxel Pharmaceuticals Eric Massou, mainlywas he where in charge Young, atauditor external an as & experience and Ernst years’ Mazars 19 Massou has Eric as a financial Eric acquired experience Brenntag or Candia. Black & Decker, of industrial groups as Becton Dickinson, such he There, a plastic packaging company operating in 7 European countries. Packaging, Veriplast controller and group at CFO Charterhouse welcome to projects diligence due vendor major two aspects and monitored financial involved in all recurrent was was on the deal team for Eric charge of all M&A activities and in In addition, as new shareholders. in 2004 and SUN in 2007 and he raised all necessaryto support business growth new monies capex. and finance new industrial external stakeholders, as well as the French College Dublin (Ireland) Trinity the BESS program of Finance atEric received a Master in EM , Eric joined POXEL in January 2011. CPA. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Takeda Research Investment, Inc. Investment, Research Takeda Abingworth Management LLP Management Abingworth Speakers Head Translational Medicine Diabetes R&TM, Sanofi Translational Head Hartmut Ruetten, He worked in the Department of Internal graduatedHartmut Ruetten at in Medicine of Cologne in 1994. the University From 1994 – 1996 he worked as Medicine/Cardiology’ at Clinic II of Medicine at the University of Cologne from 1992-94. with a grant Vane, ‘William Harvey Research Institute’ (London) under the direction of Sir John a post-doctoral Fellow at the he joint Hoechst as a lab head in the cardiovascular In 1996, Society’. ‘Deutsche Forschungsgemeinschaft/Royal from the After the merger of Sanofi- 2004. Aventis, pharmacology department and was appointed as group leader in pharmacology in In 2010 he was appointed as he was appointed as head of the Cardiovascular Department in Frankfurt. in 2005, Aventis The focus of his work Medicine group within the newly formed Diabetes Division of Sanofi-Aventis. Translational head of the The primary task of his group composed of experts in obesity and cardiovascular complications of diabetes. is on diabetes, ‘proof of concept’ in patients. bioinformatics as well as clinical pharmacology is to translate basic research into biomarker, DIRECT (DIabetes he is coordinator of the IMI (Innovative Medicine Initiative of the European Union) consortium: In addition, The overarching institutes and 4 pharmaceutical companies. comprised of 21 academic REsearCh on patient straTification) thatbiomarkers identify diabetesto in are bottlenecks consortium current to this address and of development aims drug develop a stratified medicines approach to the treatment of type 2 diabetestherapies. (T2D) with either existing or novel Partner, Genghis Lloyd-Harris, (CSFB) where he was a Managing in 2004 from Credit Suisse First Boston Abingworth Director in the European Genghis joined Genghis was responsible for coverage of the European biotechnology industry and in London. Equity Research Group based Before first ranked was Biotechnologyfor Pan-European surveys Investor Institutional the in from 2001 to 2003. each year York. the Investment Banking Division in New Health Care Group in he worked for CSFB’s joining Equity Research at CSFB, Novexel, and past directorships have His current included HBI, Australia. Genghis was previously a paediatrician in Melbourne, PhD a Medical Degreeholds a Genghis UK, in the Liverpool of the University from TherapeuticsSyntaxin. and Synosia Solexa, He focuses and an MBA from Harvard School. Business Australia, in Clinical Pharmacologyfrom the University of Melbourne, investment in the UK venture investments via mergers and acquisitions and IPOs as well as venture Abingworth’s on exits of and Continental Europe. Graeme Martin, President and CEO, Martin, Graeme Pharmaceutical Takeda the corporate arm of venture Inc (TVI), Ventures, Takeda Graeme Martin is President and CEO of Dr Martin has overseen investment of $54mm into 19 early and mid-stage in 2003, Takeda Since joining Ltd. Company, and one R&D operations, Takeda many of which have resulted in strategic relationships with biotechnology companies, During more than 30 years R&D management in in 2012. Takeda – was acquired by Inc. Therapeutics, of which – Envoy teams that Dr Martin has led have delivered multinational in Europe and the USA, Pharmaceutical and Biotech companies now marketed worldwide under the brand zolmitriptan, three novel drug candidates and an acute treatment for migraine, He received his publications and book chapters. He is and is the author of more than 85 peer-reviewed name Zomig®. UK and his doctorate from University College, Bachelor of Science degree in Pharmacology the University of Bath, from UK. London, Mr. Suria joined AnaptysBio in December 2008 and has been CEO since 2011. Prior to AnaptysBio, Mr. Suria was at Mr. AnaptysBio, Prior to AnaptysBio 2008 and has been CEO since 2011. in December Suria joined Mr. where he was responsible for partnering and alliance management of next-generation protein therapeutics with Maxygen, Suria was responsible for business development at Mr. Before Maxygen, Astellas and others. Bayer, Sanofi-Aventis, Roche, in M.S. an biochemistry in Kalamazoo College, from B.Sc. a holds Suria Therapeutics. Viron Diabetogenand Biosciences Executive MBA from the Richard Ivey Ontario and an School of Business. Western immunology from the University of AnaptysBio, Inc. AnaptysBio, President and CEO, Hamza Suria, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Atlas Genetics Ltd. Speakers John Clarkson, CEO, John Clarkson, John has a background in genetics and microbiology and has been in healthcare and diagnostics businesses for the past of development the Following Director. Technical was he where co-foundedHe 1999, in plc Sensing Molecular years. 15 he joined the US-based diagnostics company Osmetech as Instrument Systems Director when their DNA analysis system, which is developing molecular Atlas Genetics, John is now Chief Executive of they acquired Molecular Sensing plc in 2004. was Atlas Genetics rapidfortests sexually the as such diseases Chlamydiainfectious diseases transmitted and Gonorrhoea. The company £18.5m in 2011 in a raised founded in 2005 as a joint spin-out from the University of Bath and Osmetech plc. Venture Funds. series B financing round led by Novartis Eclosion2 General Partner, Jesús Martin-Garcia, focusing on Pharma and Food and later at McKinsey & Co. Economic Foundation, World Jesús started his career at the largest and most Switzerland’s becoming the co-founder of LeShop, path, In 1991 Jesús chose the entrepreneurial industries. and investing seed capital and supporting the creation of a number of other start-ups such successful e-commerce company, to translate breakthrough His entrepreneurial drive led to the launch of the Eclosion platform in 2004, VTX. as Silverwire or with a public-private partnership that drives projects from This platform is a unique structure, science into life-altering drugs. These companies that were started as demonstrated by companies such as GeNeuro and GenKyoTex. the lab to clinical trials, as exploratory programs in the incubator are now testing first-in-class drugs in Phase II clinical trials. and an MBA from Harvard Business School. Jesús has a MS in Economics and a Master in Law from University of Geneva, Trade and sits on the Boards of several Industry and ArisGen, He chairs the Board of Eclosion start-ups such as GeNeuro and associations. Senior Director, MorphoSys AG Senior Director, Heinz Schwer, corporate venture activities called Innovation Senior Director of MorphoSys and responsible for Schwer is the company’s Dr. co-founded Heinz Schwer the company He joined Biotechnology in 2010 after he has sold Sloning to MorphoSys. Capital. held the he In the years before, Sloning in 2000 and managed the company as Managing until 2010. Director from 2005 postdoc as years several spent Harvard Schwer the Heinz at Institute OperatingChief as R&D. positions of Head and Officer including a awards, he has received numerous In this time, Institute in Boston. of Medicine and the Dana-Farber-Cancer in Ph.D. He obtained his fellowship for of blood platelets. in the field of leukemia disease and the biogenesis his research a also is He chemistryclinical Henleyfrom MBA an holds and Regensburg ManagementUniversity of the from in UK. College Association of Synthetic Biology. Vice President of the International founding member and Dr. Jaume Masana is Chemical Engineer (Institut Químic de Sarrià, Barcelona). He got a PhD in Organic Chemistry. His He got a PhD in Organic Chemistry. Barcelona). Jaume Masana is Chemical Engineer (Institut Químic de Sarrià, Dr. trying to catalyzedsynthesis asymmetric unique a of development the in consisted thesis doctoral by polypeptides, synthetic and optical purities exceeding 90%, in certain cases method produced new synthetic The mimic natural enzymatic processes. prestigiousresults were published in several articles in the most European Chemistry journals. Management.He also got a MBA and other relevant titles in Business Masana has more than 25 years of experience in the pharmaceutical industry having had responsibilities in a variety of Dr. Business Development and Licensing. research and development of new chemical entities, API production, areas including: He has successfullyall type of pharmaceutical and out) with (in deals and Licensing Co-development numerous completed South Korea). Japan, Europe, Canada, differentcompanies including Big Pharmas and Biotechs from geographic areas (USA, Public Private Partnerships and Joint Alliances, He has also played a keyof innovative role in the development Strategic Ventures. doctors researchers, new biotechs, where a number of pharmaceutical companies, Jaume Masana lives in Barcelona, Dr. intense scientific activities in the Mediterranean and South of Europe areas. and health professionals develop one of the most Licensing & Strategic Partnering Director, Esteve Licensing & Strategic Partnering Director, Dr Jaume Masana, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers CEO, Hermo Pharma Ltd CEO, Juhani Lahdenperä, since February 2010. Juhani has served as the Chief Executive Officer of Hermo Pharma Ltd. Lahdenperä Before joining Hermo Pharma Mr. Lahdenperä holds a degree in biochemistry from the University of Oulu. Mr. that he co-founded a gene expression analysis technology company, served Ltd., as a Chief Executive Officer in Plex-Press he held managerial positions Previously, VC backed organizations. he has 5+ years of CEO experience from Thus, in 2006. Some of this work has been published in high-profile journals Inc.). (Perkin Elmer, Inc. Wallac at the University of Helsinki and such as Nature. Katya joined Capricorn Venture Partners (Belgium) in 2012 as a Partner in the Health Tech Fund. Prior to this, she was forwas she 10 this, to Prior Fund. Tech Health the (Belgium)in Partners Partner a as 2012 in Venture KatyaCapricornjoined She has CA) where she focused investment opportunities. on European healthcare Alta Partners (San Francisco, years with worked in business development and management consulting before starting in venture capital Wisconsin-Madison and received her Bachelor in Cellular and Molecular Biology from the University of Katya obtained a Ph.D. Katya her scientific training as a completed of Science in Biochemistry Moscow University in Russia. with high honors from She post-doctoral fellow at the Department of Microbiology and Immunology at the Stanford University School of Medicine. has co-authored a number of scientific papers. SA (France). Adocia Katya Smirnyagina is independent board member of Capricorn Venture Capricorn Venture Partners Partner, Katya Smirnyagina, Judith Hills PhD, Senior Vice President, Corporate Business Development (CBD) joined Ipsen Biopharm in January 2012. Corporate Biopharm in January Business Development (CBD) joined Ipsen 2012. Vice President, Senior Judith Hills PhD, Vice President of Corporate Strategy at Ipsen and brings her skills and Judith reports to the Executive Based in Slough UK, Judith has led her team to align deal activity to the new companyexperience to lead the team of BD professionals strategy. to execute several early Syntaxin. in the acquisition of R&D deals as well being instrumental Vice President was prior to that, Alliance Management and, she headed up Judith joined Ipsen from GlaxoSmithKline where Judith also worked for from 2002 to 2009 and of Business Development for Emerging Markets R&D. VP Europe Business Development and then as as in her global roles, was instrumental in a number of deals and partnerships, atcareer years other industrial her spent Judith SmithKline BMS, joining Prior to Evaluation. Search & Global President Vice Drug Development roles and latterly from 1987, in pure R&D research as programme leader, Beecham and GlaxoSmithKline, Development. Business Worldwide as Senior Director with therapeutic roles in Judith started her career in industry after completing her PhD at and two postdoctoral research University College London Judith carried out basic science research in GI and CNS disease. UK. positions also at University of London Colleges, therapeutic disease landscape, Judith has a deep understanding of the basic science, As a well-known BD professional, and the current regulatoryintervention and competitor environment. strategies, Vice President, Corporate Business Development, Ipsen Biopharm Limited Corporate Business Development, Vice President, Judith Hills, Forest Laboratories, Inc. Laboratories, Forest Business Development, Vice President Assistant Jonathan Garen, he has worked since where Inc., atVice President of Business Development Forest Laboratories, Assistant Jonathan is an and negotiation of transactions opportunities for new business evaluation, include the identification, His responsibilities 2003. licensing and acquisitions in the fields of neurology, including in a wide range of therapeutic areas and stages of development, Jonathan department was a Director in the Global Licensing Prior to Forest, oncologyand metabolic diseases. inflammation, an online licensing exchange forearly stage TechEx, Vice President of Jonathan was a founder and at Pharmacia Corporation. Jonathan earned his Master Yale University. Associate at the technology office of licensing a Licensing and was opportunities, of Science in Physics from the Massachusetts Institute University and his Bachelor of Yale from of Environmental Sciences Technology. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Heptares Therapeutics Therapeutics Heptares Ltd Co-Founder and Chief Executive Officer, Speakers Keith Blundy, CEO, Cancer Technology Research Keith Blundy, Since then he has overseen the expansion COO in 2004 and was appointed became CEO in 2007. in 1998, Keith joined CRT DiscoveryAstraZeneca and of the CRT Labs to 85 staffsubsequent initiation and discovery of risk sharing with alliances globalisationfurther the and CRT of arm development business a as (USA) Boston in Inc establishmentthe CRT of , TherapeuticsMelbourne, in Pty commercialisationand Cancer of development partner IP a cancer becoming through CRT’s of Australia. After completing a PhD at scholarship in the US on the regulation the John Innes Institute and a post doctoral Fulbright of he spent 10 years managing agricultural and commercialising biotechnology programmes before plant gene expression, transitioning to healthcare through business development. formerly He was a director of KuDOS from the London Business School. Keith has a BSc and PhD in genetics and an MBA Therapeutics Therapeutics Ltd and currently is on the board of Cytosystems Ltd and Cancer Pharmaceuticals Ltd and Chroma Pty. Transgene S.A. Transgene Affairs Manager, Senior Regulatory Magali Gibou, IndustryPharmaceutical the in Affairsexperience years’ 14 than more with professional Magaliin based Regulatory a is European & US Pharmaceutical/Biologics She is specialised in S.A.. Transgene with her most recent position at France, managing She has experience regulatoryAffairs strategies development stages. from preclinical to clinical until Regulatory regulatory national interactions with health authorities and regulatory and MA submissions, operations for projects at global, implying she has hands on management of regulatory affairs for a Drug-CDx program in oncology, Especially, European levels. closed connections with both Drug and CDx regulatory authorities. Malcolm Weir, Malcolm Weir, He was Head of the Biomolecular London. Malcolm has a BSc and PhD in biochemistry and biophysics from Imperial College, with responsibility for 300 people Division of GlaxoWellcome Structure Department and then the Molecular Sciences During this time he led the application of structural biology and modelling engaged in target validation and lead discovery. He joined the structural resulting in the advancement of clinical candidates to a wide range of diseases. to drug discovery, growingbioinformatics from the spin-out stage it to a and drug discovery company Inpharmatica Ltd as CEO in 2000, to order in 2006 in Technology MRC joined He Inpharmatica Galapagosto sold was 2006. in NV company. 100-person Visiting Professor of was elected Malcolm and CEO. as co-Founder TherapeuticsLtd in July 2007, establish Heptares Advisory London in 1997 and is on the Chemistry Boards at the same Biochemistry and Chemical Biology at Imperial College, He served on the Council of the UK Biotechnology and Biological Sciences Research Council from 2004 – 2011. university. Lorenza Castellón, Independent Consultant Castellón, Lorenza covering private & publicly companies listed SMEs Lorenza is a health & biotech equity analyst at Ltd. Equity Development Development in January Prior to joining Equity at 2005 she held similar roles leading international Australia. in Europe and Equity Development brings together investors and companies by of writing and means investment organisations. valuations provide the markets with both facts and opinions along with fair based upon We distributing detailed research. Over the last decade our brand has become synonymous objective research with quality diverse and appropriate metrics. of Our team and we have we are fully the UK and Europe; like them built close links with institutions across regulated. Please visit www.equitydevelopment.co.uk analysts are FSA approved and boast a cumulative of experience. 400 years I am the health & biotech analyst and I have many years of for me. more details and examples of our work or contact experience in the sector having worked for leading international investment organisations. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Merck & Co./MSD Merck Director Business Development, Horst, Manfred Allergic Diseases at the University London and specialised in Montpellier and studied medicine in Munich, Manfred Horst Dr. where he also completed his PhD. Clinic in Montpellier, two years as Basel, years with Ciba-Geigy Manfred spent 7 and Novartis, Fontainebleau, After earning his MBA at INSEAD, 14 years with Merck & Co./MSD. and up until now General Manager in the health insurance business, of a startup he scouts for where Europe, Research External & Licensing as Director function his current in has been Manfred 2004, Since managesLicensing opportunities and alliances in a number of European countries. General Partner, BioMedPartners AG General Partner, Markus Hosang, has strong experience and broad knowledge He Switzerland. AG in Basel, Markus is a General Partner at BioMedPartners manyin and research pharmaceutical in as well as strategicin operationaland capital venture the of aspects business, and strategic alliances, with special expertise in the areas of biotechnologies, product development and marketing areas, where Partner at MPM Capital, Venture a Hosang was Dr. Before joining BioMedPartners in 2004, theranostics/diagnostics. served and portfolioEuropean several of boards the on companies. forco-responsible was flow, he deal European their he held several senior management positions in the Pharma for nearly 20 years, where, he was at Roche in Basel, Previously, and Director of Global Pharma Research StrategicVice President Unit and Chief of Staff to the including R&D organization, Head of Development Projects in Basel and membership of the Global Board of R&D Directors, President of Pharma R&D, of Genetics and Chief Scientific Officer and Head as a Deputy recently, and most Roche Portfolioof the Member Board, and a member of the Roche Genetics Executive Committee. Integrated Medicine, Biochemistryin postgraduatehis pursued and Zurich in ETH the from attraining Stanford University Ph.D. his obtained He Hosang Dr. in Seattle in vascular dieseases. Washington Medical School in neurobiology and subsequently at the University of of the Swiss Foundation for Stipends in Medicine and Biology Trustees served of on the Board of Directors and the Board Suppremol GmbH and AG, He currently is a member of the boards of Okairos from 1994-2002. Treasurer (SSMBS) as its ViaCell), (until its merger with Kourion Earlier he was on the boards of Omrix, Anergis SA (as interim Chairman of the Board). and is coinventor on in peer reviewed journals, He has published more than 30 articles and Neuraxo. Avontec Atugen, IDEA, several patents. Martina Kaufmann Strategic Consulting Martina Kaufmann Strategic Managing Director, Martina Kaufmann, Dr. Martina Kaufmann is founder managing and director of Martina Kaufmann Strategic Consulting offering individual Dr. solutions for personalized medicine. She is a pharmacist with scientific track record in molecular biology and >14 years of hands on experience in personalized medicine from a technology / diagnostic as well as from a pharmaceutical perspective across the lifecycle. background with experience not only in drug development/translational inter-divisional Kaufmann has a comprehensive, Dr. and business project management, sales, but also in marketing, and molecular imaging, molecular diagnostics, medicine, development in biotech start-up as well as global pharmaceutical organizations. She established and implemented consolidated project specific biomarker / diagnostic strategies various oncologyfor as well as for market adoption and lifecycle management of development projects in exploratory and full development, Herceptin®/HER2. e.g. marketed targeted therapies/companion diagnostics, enabled entrymarket microarraya of protein based imagingmolecular in experience has also She agent development, profiling system in Europe and successfully launched a microarray based pharmacogenetic profiling system. immatics biotechnologies GmbH immatics biotechnologies Director & Head of Finance, Mark Bleckmann, where – over the Mark Bleckmann started his career atIBM, Following degrees in business administration philosophy, and In his last position at course of 9 years – he held roles of escalating in various finance and planning functions. responsibilities largest outsourcing contracts at the time. IBM he was Finance Managerand one of Europe’s of the Frankfurt office forimmaticsresponsible joined is He he where 2008 managingin mattersfinance administrativeall other as well as and raising €54m. In 2010 immatics successfully closed a C financing round, functions of the company. WELCOME SPEAKERS SPEAKERSPRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Peter plays an important role in supporting innovation in Northwestern Switzerland. His main focus is life sciences start-ups. focus His main is life sciences start-ups. Peter plays an important role in supporting innovation in Northwestern Switzerland. This company was founded to support in 1996 with the aim Life Sciences Start-up agency”. the Basel “EVA Peter is CEO of In addition he is CEO of the access to a high value network and providing seed money. life sciences start-ups with coaching, joint venture of the University of is a The BASEL INCUBATOR which he helped to establish 2 years ago. BASEL INCUBATOR, complement To Basel-Stadt. of Canton the and (FHNW) Switzerland Northwestern of Sciences Applied of University the Basel, Club in Switzerland focusing Angel’s the only Business Angel Club, Business Peter is the president of the BioValley his activities, has a PhD in chemistry Peter from the University of Basel and joined Ciba-Geigy / Novartis entirely on life sciences / MedTech. Throughout his professional career he had managerial positions with worldwide responsibility in 1984 as a research chemist. production and communication and was the CEO of the subsidiary manufacturing, regulatory affairs, technical development, in 2006. He joined EVA of a sector of Novartis in Germany. EVA – the Basel life sciences start-up agency EVA CEO, Peter E. Burckhardt, Curetis AG Curetis CEO, Oliver Schacht, He served as CFO of AG. Oliver is a well-known expert in the diagnostics industry with a distinguished career at Epigenomics He has an extensive track record in strategy USA). (Seattle, Inc. Germany) and as CEO for Epigenomics, AG (Berlin, Epigenomics Oliver Schacht holds and alliance negotiation. M&A, finance, fund-raising (including IPO), development and implementation, as well as Administration and London, from the European School of Business in Reutlingen a diploma in European Business During his tenure at Mercer Management Consulting, degree from the University of Cambridge (UK). and Ph.D. a Master’s To and other sectors. biotechnology, growth strategies and reorganization in pharmaceutical, he worked on projects in M&A, he brings a strong background in the molecular diagnostics industry ranging from technology development through Curetis, discovery and clinical validation to the market launch of molecular tests. Novo A/S Novo Novo Seeds, Investment Director, Nanna Lüneborg, investment team in March 2012. Nanna joined the Novo Seeds where she was healthcare venture fund, a London-based Apposite Capital, she worked for A/S, Prior to joining Novo deal structuring responsible for aspects of investment activities, of new investment opportunities and involved in all diligence two also gained experience in portfolio She management through observer roles on three companyboards, and execution. she worked at Cancer Research in her career, Earlier and a medical device company. of which were in drug development projects during her MBA studies. and healthcare venture and as a consultant on various biotech UK as a research manager, Wellcome from University College London as a a PhD in Neuroscience from University of Oxford, She holds a 1st class BA where she was a Sainsbury Scholar. and an MBA with distinction from University of Cambridge, Scholar, Trust Avilex Pharma and Galecto Biotech. and as an observer on the Board of Directors of Affinicon, Nanna serves on the board of CFO, Medigene AG CFO, Peter Llewellyn-Davies, AG with Peter Llewellyn-Davies was appointed as Chief Financial Officer and Member of the Executive Board of Medigene He has over 25 years of experience in senior positions in medium-sized companies in the effect from 1 October 2012. AG in Munich and was WILEX he was CFO of Prior to joining the company, commercial as well as the financial sector. human resources and investor legal, finance, controlling, responsible for a broad range of functions including accounting, Over this time August 2012. Executive Management Board from 2006 until the end of Wilex’s He was a member of relations. and a key strategic transactions and acquisitions as well as their integration, he was instrumental in the initial public offering, Managingwas he DairyMüller of Director atDirector Executive Finance and (UK) Süd- this, to Prior capitalof range measures. Llewellyn-Davies read business Mr. where he oversaw the international expansion of the Munich-based company. AG, Chemie and has a certificate in Gallen (Switzerland) and Munich, St. (UK), and controlling in London marketing banking, management, business studies from the University of London. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Wellington Partners Wellington General Partner, Rainer Strohmenger, most experienced venture capitalists Europe’s Rainer Strohmenger is one of Dr. With over 20 investments in start-up companies, 2000. he became a Partner in December in 1997, Partners (www.wellington-partners.com) Wellington Joining in life sciences. His more than sixteen years of investment activity have involved financing of some of the most successful European biotech, and diagnostics companies. medtech, www. ATLN; (SWX: investment in Swiss biotech player Wellington’s Strohmenger co-managed In the late 1990s Dr. forresponsible was also He today companylisted a capitalization market a with Euros. billion six than more of actelion.com), (acquired Wavelight NOE; www.noemalife.com), NoemaLife (Borsa Italiana: the investments in Grandis (acquired by Novartis), immatics acquired by Bausch & Lomb), Vision; www.technolaspv.com; Perfect Technolas Vision (now 20/10 Perfect Alcon), by on Wellington represents and laboratoriesmtm as well as by(acquired www.mtmlabs.com), Roche; (www.immatics.com) Oxford (www.invendo-medical.com), invendo medical the boards of the portfolio companies Implanet (www.implanet.com), and Genticel (www.genticel.com). Quanta Fluid Solutions (www.quantafs.com) Immunotec (www.oxfordimmunotec.com), primarya with research medical in involved was Strohmenger focus cardiovascular on Dr. Partners, Wellington joining to Prior Germany. physiology and in research on health economics at the Ludwig-Maximilians-University in Munich, both from Ludwig-Maximilians-University in in economics, in medicine as well as a M.Sc. Strohmenger holds a Ph.D. Dr. USA. Boston, and was trained at the Entrepreneurship Center of the MIT, Germany, Munich, married and has three daughters. Rainer Strohmenger is 46 years old, Dr. Before co-founding the company, Pierre-Olivier was Senior Consultant in Strategy and Development at KPMG in Lyons, Pierre-Olivier was Senior Consultant in Strategy at and Development KPMG in Lyons, Before co-founding the company, “France of the Board of Directors of Vice-President Pierre-Olivier is where he was in charge of the Health division. France, Pierre Olivier has a DEA (post-graduate degree) in Management Science the French association for biotechnology. Biotech”, degree in Pharmaceutical Industry ManagementManagement) from the IAE (School of Business in Lyons, and a Master’s France. ERYTECH Pharma SA ERYTECH EVP & COO, Goineau, Pierre-Olivier VP, Global Head Business Development Pharma, QIAGEN Global Head Business Development Pharma, VP, Rainer Metzger, business development, solution-driven executive with achievement record in global leadership, A proficient, PhD: Rainer Metzger, and execution of successful organizational development programs and product for pharmaceutical and diagnostics companies. forresponsible QIAGEN with Pharma initiationDevelopment the Business Head Global and managementof global VP, Currently from 2011-2013 Pharma Partnerships Global Head VP, partnerships fordiagnosticscompanion programspreviously and as Global VP, at2010 working From 2002 to various functions as Roche in company. a DANAHER LEICA BIOSYSTEMS, with Head Oncology Molecular Diagnostics in Roche Diagnostics; Head Clinical Biomarker Business Development Diagnostics, in entrepreneurial functions From 1992 - 2002 working Program and Head Global Biomarker Operationsin Roche Pharma. Marketing and CEO functions. with several Biotech companies in Business Development, CEO, Antisense Pharma GmbH CEO, Dr Philippe Calais, has over 25 years of He 2012. Pharma since March 1, Antisense is Chief Executive Officer of Calais Dr Philippe P. Antisense Prior to joining America and Europe. industrybiopharmaceutical and pharmaceutical North experience in both Canada. largest technology the transfer organization located in Montreal, President and CEO of Univalor, he was the Pharma, focusing on managedhas servedHe and Canada in companies biopharmaceutical companies, science life to consultant a as combined His management expertise, company deployment and sales optimization strategies. corporate strategic positioning, of covers the full scope and Roche, with large pharma companies such as ICI Pharmaceuticals with extensive experience commercialization strategic as well as partnership and franchise the drug chain – from discovery to clinical development, France. Tours, Rabelais, F. He has a degree and doctorate U. in pharmacy from the marketing for several therapeutic areas. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers F. Hoffmann-La Roche Ltd. Hoffmann-La Roche F. Global Business Development, Strategic Initiatives, Project Leader, Seong Chen, After working Analyst. Technology CA) in 2002 as Office (Berkeley, Technology Seong Chen started at Roche Diagnostics Chief the Strategic Switzerland in 2007 to lead Pricing & Commercial Seong relocated to Rotkreuz, 5 years in Pricing and Finance, Seong has developed pricing strategies and supported many new In this role, Affairs group at Roche Professional Diagnostics. Basel to lead a division Seong has beenappointed the Project Leader in Roche Diagnsotics, April 2011, Since product launches. initiative in Pricing & Reimbursement. Australia and received a MBA from University of Berkeley, Seong studied Electrical Engineering at University of Melbourne, Seong worked at Schlumberger and Boston Consulting Group. Prior to Roche, California. Biocartis CEO, Executive Chairman & Rudi Pauwels, (Belgium) Rudi Pauwels a researcher at is a pharmacist who started as the Rega Institute for in Medical Research Dr. an academic research center that is internationally known forantiviral its pioneering work in the field of Belgium, Leuven, chemotherapy. have a number of which Rudi mainlyFor more than two decades focused of anti-HIV drugs, on (i) the search and development been approved on the market and (ii) the development of diagnostic and introduced tools to allow personalized HIV treatment. entrepreneurial career is driven byHis research as well as his and the passion to advance and significantly medical needs impact medicine. He (co)-founded several biotech companies: VP Research CSO, later & CEO, extended to HCV – Co-Founder mainly HIV, Antiviral Drug R&D: – Tibotec 1994: CSO Co-Founder & Chairman, Virco – HIV pharmacogenomics– 1995: Board discovery drug target – Chairman, functional genomics: joint-venture, Tibotec-Crucell Galapagos Genomics – 1999: member early Hopkins: Virco projects and research at John’s OncoMethylome Sciences/MDxHealth – Originating from 2003: biomarkers of cancer Biocartis – Diagnostics – Executive Chairman (CEO until end 2011) 2007: awards He received several for his scientific and Rudi is (co-)author of more than 150 publications in peer reviewed journals. Belgium. entrepreneurial initiatives; amongst others an honorary doctorate at the University of Ghent, F. Hoffmann-La Roche Ltd. Hoffmann-La Roche F. Global Head of Strategic Partnering, Holland, Sarah team’s Her Switzerland. Strategic forPartnering in Basel, based Roche Partnering head, Global the is Holland Sarah support for transactional all pharma M&A projects include broad strategic landscapes and late of M&A stage opportunities, and development and spin-outs and strategic partnerships, initiatives to generate income through divestments, transactions, In 2010 the team acquired world-wide rights to danoprevir delivery of creative deal structures to address key business needs. Sarah has held various 2005, Since joining Roche in Marcadia Biotech. from Intermune and supported the acquisition of disease of range a in projects led has and Partnering, CNS of Head Global as such development, business in responsibilities including the Plexxikon deal on b-raf inhibitors. areas, AstraZeneca for a hormonal agent for breast cancer during US Sarah was Global Brand Director at Prior to joining Roche, including Global Strategic Planning She held various commercial and strategic roles over her ten years there, and EU launch. she held local and international AstraZeneca, Before Pricing Strategist and Health Economist. Manager for early compounds, biotech and pharmaceutical companies. sales and marketing roles in diagnostics, and first and her D.Phil 2004, until Fellow Visiting a was she where Business School, Manchester from MBA gained her Sarah degree at Oxford University. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u apceth GmbH & Co. KG apceth GmbH & Co. Chief Business Officer, NEWRON PHARMACEUTICALS SPA NEWRON PHARMACEUTICALS CEO, Speakers Stefan Weber, Stefan Weber, He had been Chief Financial Officer 2012. was appointedExecutive Officer of Newron effective Chief June 1, Weber Stefan degree business management in from FernUniversität Hagen Stefan holds a master’s April 2005. of the Company since He has more than 25 years of industry in finance and has been serving experience as Chief Financial (Diplom-Kaufmann). a Group, he was with Lohmann From 1987 to 1999, Officer of public and private biotechnology companies since 2000. Head of Finance His final position was consumer products. technical and medical, worldwide producer of pharmaceutical, was he appointed chemistryfine a 1999, in provider development and scale-up process Girindus, joining After the group. of a company active in the Chief Financial Officer of Biofrontera, he was From 2001 to 2005, 2000. Chief Financial Officer in has been responsible for executing numerous ransactions of substantial deal Weber Stefan drug discovery and development. to He has executed IPOs equity and mezzanine financing as well as national and European grants. debt, including M&A, value, of disinvestments and strategic He furthermore has been involved in a number the stock exchanges in Frankfurt and Zurich. is German. Weber Stefan restructurings. Executive Vice-President & Chief Financial Officer, Transgene Vice-President & Chief Financial Officer, Executive Stéphane Boissel, business deals structuration and negotiation, VP & Chief Financial Officer in charge of finance, Stéphane Boissel is Executive VP was he 2010, and 2002 Between Relations. Investor and departments) purchasing and IT legal, administration(personnel, IPO and was responsible for negotiating business & Chief Financial Officer of Innate piloted the company’s Pharma where he Stéphane worked as an investment banker in the Lazard Group and Between 1995 and 2002, development agreements. Stéphane within PWC. financial auditor a 1990 as in career his began He fourspent in Singaporeyears Kong. Hong and Lyon and Paris has an MBA from the University of Chicago GSB) and has degrees (Booth in finance from the universities of member and helds a DSCG. He is a SFAF Dauphine. Torreya Partners Torreya Partners Europe, Torreya Principal and Head of Stephanie Léouzon, advisory a life sciences boutique firm which she joined Partners, Torreya Stephanie Léouzon is Principal and Head of Europe for Previously she worked in Health Care Investment She also serves on the Board of Directors of Immunovaccine Inc. in 2012. Advisor. most recently at Credit Suisse as a Managing Director and Senior Banking in the US and Europe from 1989-2010, and been involved in valued at over $65billion, She has advised life sciences clients on more than 20 strategic transactions, over 45financing transactions to provide over $10 billion to health care clients. Virginia in 1989 and a degree from the Darden Graduate School of Business at the University of Stephanie earned an M.B.A. Holyoke from Mount College in 1985. cum laude, degree, B.A. Dr. Stefanos Theoharis, Dr. Prior Development. where he was Head of Business Pharma, Antisense joined apcethTheoharis in 2013 from Stefanos Dr. based in Basel. Hoffmann-La Roche (Roche), for F. Technologies he was Business Development Director of Emerging to that, cell and He has a PhD in in London. with Lazard, focusing on life sciences, Analyst, he was an M&A Before joining Roche, where he subsequentlyFellow in several academic worked as a Research gene therapy from Imperial College London, departments. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u CEO, Epigenomics AG CEO, Speakers CEO, BioCrea CEO, Kronbach, Tom in Therapies Corp. which he established as a Management assets from Biotie buy-out of Kronbach is CEO of BioCrea, Tom ideas were combined with a productive CNS-discovery and new scientific and business Team A new Management 2010. Since then new Cognition Program by Boehringer Ingelheim in 2012. of BioCrea’s The first success was the acquisition group. disease were established. Depression and Huntington’s Autism, projects for Epilepsy, Tom was Previously, / and GlaxoSmithKline. has initiated and fostered Boehringer Ingelheim, partnerships with Tom AG. and co-founder and CSO of elbion Therapies Corp. the CSO of Biotie Meyer A. with Urs Post Doctoral Fellow He was a Germany. Tubingen, in Chemistry of the University from holds a Ph.D. Tom Associate in Molecular and Experimental Medicine Switzerland and was Research in Pharmacology at the University of Basle, Davis then joined Goedecke-Parke Tom CA. The Scripps Clinic and Research Foundation in La Jolla, Johnson in at with Eric F. where he had increasing Germany, a Degussa company in Radebeul, -AWD, Asta Medica Germany and then in Freiburg, responsibilities up to being Head of R&D. Delenex Therapeutics AG Therapeutics Delenex MD, Chief Medical Officer, Thomas Jung, Prior , Switzerland. Zurich He is Chief Medical Officer at Delenex, Medicine Specialist. Translational experienced Jung is an Dr. he was responsible for where all proof of Switzerland, Basel, Medicine EU at Novartis, Translational to that he was Head of neuroscience respiratory diseases, gastro-enterology, autoimmunity, including manyin studies concept area’s disease major Jung of the ImmunologyAs Global Head Development Dr. and Infectious Diseases Franchise and muscular -skeletal diseases. was leading large multi-disciplinary development programs teams involved in 11 major drug to from proof of concept studies molecular low with both manyconducted Jung studies, concept of proof successful Dr. Novartis At authorization. marketing He was the driving force registration behind the successful of ILARIS ( Canakinumab ) for Cryopyrincompounds and biologicals. and type disease Still’s Associatedand forSyndromes Periodic other diseases such as gout, of its clinical utility in expansion Vienna, Dr Jung conducted immunologicalAs a physician -scientist research at the Novartis Research Institute in 2 diabetes. and USA the National and Research Center in Denver, Jewish Medical USA, the DNAX Research Institute in PaloAlto, Austria, Jung is a board certified dermatologist he and Dr. he obtained his MD degree. from which Germany, the University of Marburg, Germany. Associate Professor‘s position at the University of Gottingen, also holds an Business Development, AM-Pharma Business Development, Knoterus, Tim AM-Pharma team in June 2012 and is responsible for Business Development. joined the Tim a venture capital company investing in Venture, Aescap Associate at worked as Senior Tim AM-Pharma, Prior to joining been involved in the investment in and support of several portfolio where he has companies. European life science companies, both from Utrecht University (NL). has a MSc in Science and Innovation Management and a MSc in Drug Innovation, Tim Dr Thomas Taapken, Dr Thomas Taapken, 2011 as Chief April 1, He joined Epigenomics on AG since September 2012. Epigenomics is CEO of Taapken Thomas Dr. where he held the position of CFO and was a member of the Executive Therapies (Finland), from Biotie Financial Officer. Therapies following a business combination between Biotie He was appointed to this position in 2008, Team. Management His extensive international experience in the life sciences industry Thomas had been CFO since 2005. where and elbion NV, Capital and San Francisco- from 2003 to 2005 Venture includes previous positions as investment partner at DVC Deutsche in the U.S.A. He also worked several years at Sanofi-Aventis based US venture capital firm Burrill & Company from 1998-2002. as well as in the areas of corporate & business development and managing corporate venture capital activities, and Germany, divestitures, mergers, he has been involved in numerous transactions spanning acquisitions, Throughout his career, research. as well as private and public offerings. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u to-BBB technologies BV to-BBB technologies CEO, Speakers Torreya Partners Torreya Principal, Wilder Fulford, an international Partners, Torreya the London branch of Partners Europe, Torreya Wilder Fulford is the foundingpartner of Dr. Fulford Dr. financings and other transactions. alliances, licensing, advisory firm assisting Life Science companies with M&A, After completing his PhD in molecular of all kinds around the globe. has had a long career advising healthcare companies before career as a on embarking forcapitalist, worked venture he a as years few a biologyat 1986, in University Rockefeller the Merrill Lynch, and London at Salomon Brothers, York He has run healthcare M&A or coverage groups in New an M&A advisor. He has participated in close to 100 financing and M&A transactions America and (most recently) Deutsche Bank. Bank of aboutand mandatesa dozen in London, in team full Partners has a Torreya aggregatean with billion. $100 of excess in value and medical devices, vaccines, specialty pharma, so far in 2013 in biotechnology, and has closed five transactions execution, completed over 100 Life Sciences assignments in the 6 years since inception. Partners has Torreya Globally, OTC. PIQUR Therapeutics AG PIQUR Therapeutics Chief Executive Officer, Vladimir Cmiljanovic, analytical & biochemistry) essential medicinal, Vladimir has hands-on experience in the range of chemistry disciplines (organic, and recognized experts from Vladimir built up the team of well-known to the discovery of PI3K-Akt-mTOR pathway products. For his scientific contribution industry leading next generation PI3K agents. the field and is leader of the team creating PIQUR’s of the University of Basel Award research field he was with the Camille and Henryawarded in 2009 Dreyfus in PI3K-AKT-mTOR was the winner Vladimir In 2010 forand University of Basel Excellence Scholarship the Novartis and in 2011 with Life Sciences. Kick for PIQUR business idea. the development of the Venture of the Swiss Willem obtained a MSc degree in biomedical sciences from Utrecht University, and an Executive MBA degreeExecutive MBA and an NIMBAS/ from Willem obtained a MSc degree in biomedical sciences from Utrecht University, He began his professional career in clinical research at Glaxo and joined Genzyme in 1994 with Bradford University. Willem subsequently worked in several sales responsibility for post-registration clinical trials for orphan diseases in Europe. the end of 2003 he assumed global responsibility for marketing in the orphan Towards and marketing positions at Genzyme. In 2006 he transitioned to become General MA. worldwide headquarters in Cambridge, disease business unit in Genzyme’s Willem raised ±$10M of During his tenure at to-BBB Willem joined to-BBB as CEO in 2009. Manager of Genzyme Netherlands. several of development enabledThis growth organizationthe people, of 20 over to 10 from privategrants. in ±$5M and equity products 2B3-101 and 2B3-201. CNS product candidates and initiation of clinical studies for to-BBB’s Willem van Weperen, Willem Weperen, van CEO, Anergis CEO, Vincent Charlon, 20 years of global Dr Charlon brings over Anergis in January Officer (CEO). 2009 as Chief Executive Vincent Charlon joined at HoffmannResearch La Roche Basel as Clinical From 1990 to 1998, managementclinical development and experience. development Dr Charlon held clinical of Clinical Research, as Director Nutley,USA, Scientist and then at Hoffmann La Roche Inc. of an He was the first author approved global new drug application anti- for an responsibilities for international several projects. antihypertensive and anti-anginal meetings with the US FDA and European new chemical entity and was involved in numerous research organization the contract Charlon was CEO of Hesperion Ltd., Vincent From 1998 to 2006, regulatory authorities. Vincent Charlon In this capacity, products. ATLN] [SWX, Actelion’s conducted all initial clinical trials for(CRO) who designed and biggest sales well over product with Actelion’s today Tracleer® in pulmonary hypertension, designed the first clinical trials of Charlon developed Hesperion as a profitableVincent CRO from 3 to 200 employees located in eight country CHF 1 billion/year. America and Two third of Hesperion clients were small biotech companies from North serving over a hundred clients. offices, as well as the also realized two company Dr Charlon acquisitions and integrations into Hesperion, During that time, Europe. drug repositioning start-up companyVincent Charlon was CEO of the LS Pharma In 2007-2008, sale of Hesperion to Cerep SA. Anergis. International SA before joining WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Activiomics Ltd Activiomics www.activiomics.com FINANCIAL SUMMARY IP Group. investor: main Privately owned, PROFILE COMPANY label-free mass spectrometry technologies that enables it a suite of advanced, Activiomics has developed that proteins and phosphoproteins correlate with the directly clinical samples, from to identify and quantify, progression with the administration of disease and/or of drugs. The company is applying technologies these to the establishment assets comprising of a pipeline of biomarker with their companion diagnosticthe identified proteins and phosphoproteins along antibody reagents. The company also partners with the pharmaceutical and biotechnology industry to provide drug profiling and drug mode of action information. GSK and UCB Celltech, the company has secured 8 collaborations including those with , date, To Kyowa Hakko Kirin. MANAGEMENT CEO Dr Kevin FitzGerald, COO , Torbett Dr Neil YEAR FOUNDED 2009 EMAIL [email protected] TELEPHONE +44 207 882 5718 ADDRESS Science Centre Vane John Charterhouse Square London EC1M 6BQ UK CONTACT Kevin FitzGerald PhD MBA, CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

€10.7 million through a Series B equity round. ActoGeniX NV ActoGeniX www.actogenix.com FINANCIAL SUMMARY €20 million of which ActoGeniX raised €23 million (approximately million), US$35 Within a year of its inception, European biotech start-ups. one of the largest among A equity round, was obtained through a Series announced the approvalActoGeniX of a €3 million (approximately million) grant US$4.4 from In July 2007, to support its innovative (IWT), in Flanders Technology the Institute for Innovation Promotion of by Science and therapeutic activities during a two-year period. drug development the Company announced that €15.5 million it had raised an additional In the first quarter of 2009, new investor Biovest including (approximately from its strong syndicate US$20 million) of life sciences investors, (Belgium) as well as the existing investors. to support awardedActoGeniX was a €0.9 million grant (US$1.3 million) by IWT, In the second quarter of 2009, ActoBiotic™ for the treatment in cancer patients. of oral mucositis a novel AG013, the clinical development of In April ActoGeniX 2013, raised Biotech Fund syndicate as Gimv, includes companies such of experienced life sciences investors ActoGeniX’s (France) and Ventech (The Netherlands), Venture Aescap LSP, (Belgium), BioVest Baekeland Fund, Flanders, Saffelberg Investments. PROFILE COMPANY ActoBiotics™, ActoGeniX is a biopharmaceutical company focused development and commercialization on the of immunological and mucosal diseases. orallyof class novel a available for biopharmaceuticals treatmentthe GI, of MANAGEMENT Dr Bernard Coulie, Chief Executive Officer and Chief Medical Officer Dr Anjan Aralihalli, Chief Business Development Officer Development Technology Director Sr. Dr Lothar Steidler, Dr Pieter Rottiers, Director Preclinical Operations Dr Sam Corveleyn, Director CMC and Qualified Person Director Legal & IP Mr Emil Pot, Administration Hijfte, Director Finance and Van Ms Magda

YEAR FOUNDED 2006 EMAIL [email protected] FAX +32 9 261 06 19 TELEPHONE +32 9 261 06 00 ADDRESS 4 Technologiepark 9052 Zwijnaarde Belgium CONTACT Dr Bernard Coulie, CEO and CMO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

CSO CEO Adrenomed AG Adrenomed www.adrenomed.com FINANCIAL SUMMARY Privately funded by founders and angel investors. Actively fundraising for program clinical to clinical POC (Q3/2015-2018). PROFILE COMPANY established by a experienced scientific and senior company, AG is a lean virtual biotech Adrenomed Andreas and Dr. Wegener Bernd La Jolla and Dr. Scripps Institute, Bartfai, Tamas entrepreneur team of Prof. AG. the latter beeing former both executives of BRAHMS Bergmann, Our mission is to develop innovative first-in-class drugs that mortality in life-threatening reduce the acute care is Adrenomed with high unmet need and limited treatment options. conditions like sepsis and kidney diseases, pursuing a unique and highly innovative approach by attacking the underlying disease biology in a novel and safe way and with a proposed disease-modifying mechanism. (ADM) is a strong vasodilatory Adrenomedullin The target peptide and an important regulator of vascular tone ADM may associated be involved in severe hypotension with organ excessive However, and blood pressure. ADM levels in patients have been shown to be the strongest risk factor for death. failure and elevated is a highly antibody designed specific and potent humanized monoclonal Adrecizumab Our lead compound Adrecizumab a new drug represents ADM with the potential for use in acute hypotensive indications. to target antibodies which are designed to control harmful class of first-in-class modulating (non-neutralizing) This groundbreaking and patent protected target function. excess target activity whilst maintaining beneficial in acute kidneymode-of-action has shown excellent preclinical efficacy injury and sepsis and offers a favorable We expect to start First-in-Man clinical testing end of 2015. safety profile. MANAGEMENT Dr Bernd Wegener, Dr Andreas Bergmann, CBO Dr Frauke Hein,

YEAR FOUNDED 2009 EMAIL [email protected] FAX +49 (0) 3302 20 77 815 TELEPHONE ++49 (0) 3302 20 77 814 ADDRESS Neuendorfstraße 15a 16761 Hennigsdorf bei Berlin Germany CONTACT PhD Frauke Hein, Chief Business Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Algiax Pharmaceuticals GmbH Pharmaceuticals Algiax www.algiax.com FINANCIAL SUMMARY of privateA financing from a consortium and state- in Series The company 4,3 million Euro’s has already raised approvalbacked investors to get the for the lead compound forphase. entering the clinical financing will be under The new 2 of funds. Algiax is looking for a further 6-8 Mio. start phase I/II To March 2014. Series B financing is due to start in participationinvestors. of the current PROFILE COMPANY It April 2011. Algiax is an independent biotechnology Pharmaceuticals GmbH company that was established in is dedicated to the discovery and development of innovative products in the field of nervous system disease or dysfunction with a strong focus on neuropathic pain. AP-325 is in lateby preclinical development and is ready to enter clinical trials lead compound The company’s the secondaryThe primary indication cord injury is spinal indication is neuropathic pain, for which mid-2014. Algiax created has a strong and effective protection of intellectual Algiax has an orphan drug designation. that are currently in the early development phase but have a Algiax has identified NCE’s Next to that property. huge potential for future. an even stronger pipeline in the near in discovery/preclinical With our lead compound ready to progress and several NCE’s into clinical development Algiax advantage is well positioned to take of the market opportunity not only in the field of development, neuropathic pain but also in other unmet nervous system disorders. MANAGEMENT Chief Executive Officer Dr Jürgen Schumacher, Chief Financial Officer Stefan Fischer, Head of R&D Dr Guido Koopmans, Associate Head of R&D Dr Birgit Hasse,

YEAR FOUNDED 2011 EMAIL [email protected] FAX +49 – (0)211 617 851 50 TELEPHONE +49 – (0)211 617 851 0 ADDRESS 15a Max-Planck-Str. 40699 Erkrath Germany CONTACTS Stefan Fischer, CFO Dr Guido Koopmans, Head of R&D WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

MISSION Institute forAlpine Drug Discovery (AIDD) is to perform translational drug discoveryThe goal of the in open during lead innovation collaborations candidates, academic researchers and to sell resulting drug with early-stage AIDD will identify academic research with Specifically, industry. to the pharmaceutical optimization, leverage our proven discovery and development competencies to via collaboration, therapeutic potential and, AIDD generate candidates high value drug that or spun out of can be out-licensed to pharmaceutcial partners startup companies) during lead optimization. (e.g. into special purpose vehicles AIDD will initially with potential as immunotherapeutics seek to prioritise targets With regard to therapeutic focus, to AIDD will be opportunistic with regard and inflammation although disease; auto-immune, for oncology, therapeutic focus. Alpine Institute for Drug Discovery Discovery for Drug Institute Alpine WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

ALRISE Biosystems GmbH Biosystems ALRISE www.alrise.de FINANCIAL SUMMARY Vita Giuseppe • Dr. Venture Beteiligungsgesellschaft • Creathor • IBB Current Investors: EUR 5 million previous financing rounds: investments from Total 1.4 million (break-even) EUR Revenue in 2012: are committed to participate • Up to EUR 10 million • Current investors Additional capital requirement: • Financing of own clinical development programs capital: Intended use of additional PROFILE COMPANY The peptide and small molecule drugs. ALRISE develops controlled release depot formulations for protein, business is its patented drug delivery technology for the encapsulation of hydrophilic ALRISE’s cornerstone of ALRISE not only offers or hydrophobic drug substances in biodegradable polymeric or micro particles. nano but also provides a platform from which products can be developed to meet the ever a unique technology, mission is to make its innovative ALRISE’s companies. and generics biotech, increasing needs of pharma, encapsulation technology available and ultimately to a broader user spectrum to create benefit for patients strengths Among ALRISE’s are: worldwide. Unique technology: Its ImSus® platform technology is an elegant solution to ALRISE is positioned in the sweet spot of drug delivery. covering the future trends in pharma and biotech and small molecules, peptides, optimizing delivery of proteins, simplicity – its one pot process which Among some of the keyaspects are the technology’s drug development. manufacturing costs relativeshortens product development time-lines and lowers to competing technologies –, and its release durations and administration routes, its flexibility allowing it to be applied to diverse drug classes, categorical elimination harmful. of carcinogenic solvents and management: Solution to product lifecycle With the pharmaceutical industry facing increasingly difficult pipeline challenges many are turning to lifecycle Large pharma management franchises. revenue from these successful of blockbuster products to extend the examples of which are already companies are developing controlled release formulations key of products, This translates or Lupron Depot (Abbott). Bydureon (Eli Lilly), marketed Risperdal Consta (Johnson & Johnson), ALRISE which offer the key to product and into significant opportunities for drug delivery companies such as pipeline extensions. MANAGEMENT Dr Celal Albayrak, CEO Business Development Dr Volker Rindler, Dr Heiko Seemann, Formulation Technology

EMAIL [email protected] [email protected] FAX +49 (0) 30 94 89 24 82 TELEPHONE +49 (0) 30 94 89 24 83 Dr Volker Rindle +49 (0) 30 94 89 24 85 r ADDRESS 10 Robert-Roessle-Str. 13125 Berlin Germany Director Business Development CONTACT Dr Volker Rindler, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

AM-Pharma www.am-pharma.com FINANCIAL SUMMARY in 2011. Raised EUR 29.2 million PROFILE COMPANY Alkaline companyAM-Pharma is a biopharmaceutical focused development of on the preclinical and clinical AM-Pharma Phosphatase as protective treatment of acute kidney injury and inflammatory bowel diseases. Alkaline of the Phase II trials with bovine Based on the strong results The Netherlands. is based in Bunnik, AM-Pharma developed an innovative KidneyAcute Injury and a Phase II trial in Ulcerative Colitis. Phosphatase in Alkaline Phosphatase will be used in future This recombinant Alkaline Phosphatase. recombinant form of human the development AM-Pharma enabling raised €29.2M in Q4 2011, AM-Pharma trials and for commercialization. in a phase I study forAM-Pharma started recruiting healthy volunteers its In September 2013, through phase II. Acute Kidney Injury. lead program in

YEAR FOUNDED 2002 EMAIL [email protected] [email protected] [email protected] FAX +31 302 289 220 TELEPHONE +31 302 289 222 ADDRESS Rumpsterweg 6 3981 AK Bunnik The Netherlands CONTACTS Erik van den Berg CEO Knotnerus Tim BD WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

AnaptysBio, Inc AnaptysBio, www.anaptysbio.com PROFILE COMPANY is a privately-held company focused on the generation of antibody Inc. AnaptysBio, Founded in 2005, leader in the use of somatic and the hypermutation (SHM) for discovery antibody and optimization. therapeutics, which couples fully libraries with in vitro somatic human antibody proprietary platform, SHM-XEL AnaptysBio’s replicates key features of hypermutation cells to generate (SHM) in mammalian high affinity lead candidates, By harnessing the natural and overcomes limitationsthe human immune system of prior antibody technologies. for SHM-XEL allows the selection of optimal mechanism of antibody maturation under controlled conditions, and manufacturability. epitope diversity cross-reactivity, function, as high affinity, antibody properties such AnaptysBio has established is currently around the use of SHM and broad intellectual property building a pipeline including differentiated programs in cancer immunotherapy, of novel therapeutic antibody product candidates, The Company has and antibody-drug conjugate fibrosis applications. muscle wasting disorders, inflammation, and DTRA. DARPA Gilead, Celgene, Novartis, Roche, previously announced pharma partnerships with Merck, Major Frazier investors Ventures, Avalon Ventures Healthcare in AnaptysBio and include Alloy Ventures, Novo A/S. visit www.anaptysbio.com. For more information, MANAGEMENT Hamza Suria, President & CEO David King, Chief Scientific Officer Head of Finance Chuck Covington,

YEAR FOUNDED 2005 EMAIL [email protected] [email protected] FAX 858-362-6296 TELEPHONE 858-362-6295 ADDRESS 10421 Pacific Center Court Suite 200 CA 92121 San Diego, CONTACTS Hamza Suria, President & CEO Cindy Stewart, Executive Admin WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Anergis SA Anergis www.anergis.ch FINANCIAL SUMMARY from venture capitalCHF 22M funding received and private investors PROFILE COMPANY Anergis biopharmaceutical company SA is a Swiss-based specializing in the discovery and development of novel Anergis´ based on its proprietary vaccines are Continuous allergy the most frequent allergies. vaccines targeting Allergies are the most prevalent and the fastest growing chronic Overlapping Peptides (“COP”) technology. with over 500 million people affected. world, conditions in the industrialized development. is in Phase II clinical pollen allergy, birch to treat a vaccine AllerT, lead-product Anergis’ its vaccine candidate for the treatment of patients with allergy to ragweed pollen has received positive AllerR, Anergis’ vaccine AllerDM, FDA for the final preclinical and early clinical program and feedback from the U.S. Anergis is progressing through preclinical development. candidate for patients with house dust mite allergy, BioMedInvest and other Sunstone Capital, PME-Vinci Capital, has raised over CHF 22 million from Renaissance and Defi Gestion. Ventures investors including Esperante COPs Anergis sequence of the allergen in separate COPs reproduce the full-length amino acid long peptides. COPs Therefore, the antibody class responsible for eliciting allergic hypersensitivity. do not cross-react with IgE, Studies can be safely administered at injections only. to the allergen after few high doses to induce tolerance in animals and in humans have confirmed the safety (no immediate allergic reaction) and of COPs in vitro, ANERGIS and cytokines immunogenicity (production of specific IgG4 antibodies against the original allergen) of a trend for symptom improvement was observed during the season and AllerT, In a Phase I/IIA trial with COPs. long term follow-ups of the same patients demonstrated that antibodies against the birch pollen major allergen two and four seasons after bet v 1 were still significantly elevated placebo-treated in comparison with patients, AllerT. the very short one-time preseasonal treatment (5 SC injections in 2 months) with AllerT multicentre European trial is underway with randomized, placebo-controlled, A large double-blind, AllerT using recommended regulatory endpoints of combined symptom and to demonstrate the efficacy of this trial are Results of the natural during birch pollen season. i.e. medication scores in real-life conditions, AllerT for and/or to finance it through a Phase III Anergis intends to partner At this time, expected in Q3 2013. round B with current and new investors. MANAGEMENT CEO PhD, Vincent Charlon, CSO PhD, Christophe Reymond, Founder Allergy Expert, MD, François Spertini, MD, Clinical Development Gilles Della Corte, Product Development PhD, Eva Castagnetti, Regulatory Affairs PhD, Gerard Farmer, Business Development PhD, Jean Paul Rohmer, Finance MBA, Zoltan Czigler,

YEAR FOUNDED 2001 EMAIL [email protected] FAX +41 21 651 9221 TELEPHONE +41 21 651 9220 ADDRESS BioPole III Route de la Corniche 9B CH-1066 Epalinges Switzerland CONTACTS Vincent Charlon PhD, CEO Zoltan Czigler MBA, Finance Director WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Antisense Pharma GmbH Pharma Antisense www.antisense-pharma.com FINANCIAL SUMMARY Privately held company. fund. Equity lead investor is MIG BayernOthers are S-Refit and Kapital. PROFILE COMPANY thatTGF-ß inhibitors stimulate the human unmatchedAntisense Pharma has an commitment to developing pipeline of novel oligonucleotides and We are advancing a unique immune system to effectivelyfight cancer. are focused on the We combination and improve patient modalities to transcend clinical response outcomes. ability to suppress a key pathwaycancer that in plays a significant role in a tumor’s TGF-ß, various isoforms of the immune system and avoid detection. MANAGEMENT Chief Executive Officer Dr Philippe Calais,

YEAR FOUNDED 1998 EMAIL [email protected] FAX +49-89-890 831-491 TELEPHONE +49-89-890 831-0 ADDRESS Leopoldstrasse 254-256 80807 Munich Germany CONTACTS Dr Philippe Calais CEO Dr Andrea Kottke Affairs & Head Medical Communication WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

apceth GmbH & Co. KG & Co. KG GmbH apceth www.apceth.com FINANCIAL SUMMARY Privately held company. PROFILE COMPANY Apceth is a clinical stage company biopharmaceutical in the Munich area focused development of native on the ATMPs). Therapy Medicinal Products”, and genetically therapeutics modified cell (“Advanced stem cell biology combine the principles of adult with pioneering technologies standards for and the highest We according to European and international guidelines. quality management, GMP manufacturing and using our expertise, offer contract GMP manufacturing and related servicesWe to customers around the world, high standards and state-of-the-art of more than 600 m2 of cleanroom area (class ISO8, GMP/BSL2 facilities native Our manufacturing license covers and genetically laboratories. quality control units and R&D ISO5), ISO7, Act (AMG). according to §13 and §20b of the German Medicines modified cell therapeutics, the first company are worldwide to receive approval for a phase I/II clinical trial with genetically modified We mesenchymal stem cells for the treatment gastrointestinal cancer (start 10/2013). of advanced our first clinical phase I/II trial for the treatment of critical limb ischemia with our somatic cell In parallel, therapeutic is currently ongoing. MANAGEMENT CEO MD, Christine Günther, CSO PHD, MD, Professor Ralf Huss, CFO Helmut Jeggle,

YEAR FOUNDED 11/2007 EMAIL [email protected] [email protected] FAX +49 (0)89 7009608 - 130 TELEPHONE +49 (0)89 7009608 - 0 ADDRESS Location Munich / Grosshadern Max-Lebsche-Platz 30 D-81377 Munich Germany Location Munich / Ottobrunn Haidgraben 5 D-85521 Ottobrunn Germany Chief Business Officer CONTACT Stefanos Theoharis, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u continued... g-secretase inhibitors. 

Our Business Model approach is the enhancement of the value of our assets by progressing our high quality lead Asceneuron’s Once this stage we will has been reached disease and tauopathies. Alzheimer’s compounds to clinical testing for Our unbiased approach allows us to capitalize on explore a variety of options such as partnering or outlicensing. the renewed interest for improved symptomatic treatments and in addition to take advantage of the increased industry focus on tau targeting approaches. Asceneuron SA Asceneuron www.asceneuron.com FINANCIAL SUMMARY Ventures. to dateAsceneuron SA has raised EUR 5M seed funding from Merck Serono PROFILE COMPANY The Company dis-ease drug Alzheimer’s Asceneuron was formedOcto-ber 2012 through the spin-off in of Merck Serono’s The company highly comprises a experienced management team discovery portfolio research group. and Asceneuron and drug discoverycombining both scientific fundraising background. expertise with a business and disease and related neurodegenerative diseases such as Alzheimer’s develops effective therapeutics for tauopathies. Asceneuron aspires to become a leading biotech company By focusing on areas of high unmet medical need, Due to increasing life expectancy, specialized in small molecule drug discovery for neuro degenerative diseases. imposing a major problems of this century, disease is viewed as one of the largest healthcare Alzheimer’s Current treatment options provide world. and developing Western economic burden on societies in the limited benefits supporting the urgent need and better toleratedfor more efficacious medicines that address symptomatic relief as well as disease progression. Asceneuron team of eight people is located at the Science Park of the Ecole Polytechnique Fédérale The worked forThis team has already more than four years on the key molecules since the inception Lausanne (PSE). At the PSE we operate in a state-of-the-art to the Brain Mind facility in proximity of our drug discovery programs. Institute. & Product Information Technology unbiased approach is to develop both symptomatic disease modifying treatments and for Asceneuron’s the are targeting the decline in cognition, We disease based on known pathophysiology. Alzheimer’s accumulation of tau protein into neurofibrillary tangles and the generation of toxic amyloid-ß 42 peptides. For the disease trials. Alzheimer’s Our molecules are predicted to provide an earlyconcept for proof of larger treatment of tauopathies we are targeting the pathology tau in Progressive of toxic Supranuclear Palsy and orphan drug status.Frontotemporal dementia with the aim to achieve Asceneuron will initially focus programs on moving three preclinical with significant commercial potential lead small molecule Asceneuron’s All of disease from lead optimization testing. into clinical Alzheimer’s for compounds have CNS drug properties with demonstrated target engagement in the brain upon a single oral dose in preclinical models. is aimed at improving Our M1 muscarinic acetylcholine receptor positive allosteric modulator (M1 mAChR PAM) Cholinergic signaling is a key pathway that cognitive function by stimulating cholinergic neurotransmission. Therefore we anticipate a greater probability of has already been successfully exploited for drug development. success for new and better tolerated drugs that target this clinically validated pathway. carbohydrateThe O-GlcNAcase inhibitor pre-vents the removal of O-linked ß-N-acetylglucosamine moieties from the micro-tubule-associated tau protein thereby reducing the formation of neurofibrillary tangles. Neuro-fibrillary tangles are a key hallmark of the pathology and major contributor to the neurodegeneration in will actively the orphan drug path explore for our O-GlcNAcase inhibitor We disease and tauopathies. Alzheimer’s program with the aim to get an early proof of concept in a major tauopathy. our g-secretase modula-tor reduces the production of toxic amyloid-ß 42 peptides without inhibiting the Finally, This can be predicted to lead to an efficient amyloid-ß lowering drug whilst avoiding the y-secretase enzyme. mechanism-based toxicities observed with

YEAR FOUNDED 2012 EMAIL [email protected] FAX +41 21 693 8247 TELEPHONE +41 21 693 8242 ADDRESS PSE-B EPFL 1015 Lausanne Switzerland CONTACT PhD, Dirk Beher, Chief Scientific Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u secretase inhibitor MK 

secretase programs.  secretase modulator programto secure the progression and of the M1 mAChR  Head of Discovery Christoph Wiessner (PhD), Previously he was a director in of DiscoveryAsceneuron and Head of the company. Wiessner is a founder of Christoph and Lead Target and headed the CNS at Merck Serono (2008-2012), “Neurodegenerative Diseases” Area Therapeutic the a vaccine for There he also led the drug discovery team for CAD106, Discovery Unit at Novartis in Basel (1996-2008). He obtained and contributed to several CNS projects that entered into clinical testing. Disease currently in Phase II, Alzheimer’s the He then joined Germany. Frankfurt, his PhD in the department of Nobel laureate Hartmut Michel at the MPI for Biophysics, this and concluded Germany, Cologne, department of Konstantin-Alexander Hossmann at the MPI for Neurological Research, He authored 59 peer- work with a habilitation in Experimental Neurology at the Medical Faculty of the University of Cologne. reviewed publications and book chapters. PAM in clinical development. We are initially of EUR 10M to move the O-GlcNAcase seeking additional funding We in clinical development. PAM program 1 clinical studies. through Phase and to progressinhibitor into clinical testing the M1 PAM MANAGEMENT Chief Scientific Officer Dirk Beher (PhD), 0752 and was finally responsible for all He is an inventor of Germany. in Biology and a Diploma (M.S.) Ruprecht-Karls University Heidelberg, from the Dirk holds a Ph.D. publications and reviews. seven patents and currently authors 47 peer-reviewed Advisor Executive Chairman of the Board & Business Armstrong (M.D.), Frank M. to Board level in the Pharmaceutical Executive who has worked medically qualified, Armstrong is an experienced, Frank Consultant and Board Member to Life Advisor, He currently works as an Independent Switzerland and Germany. US, UK, Most recently he led Medical Science and Innovation (MSI) in R&D Science Companies through his own consulting company. Medical Organisation atZeneca. Worldwide at Development Bayer and the Worldwide at Merck Serono and previously led and Product Development in large and small companyHe has extensive experience of all aspects of Medical Development He has environments where he has led successful product approvals for the US and EU across a range of therapeutic areas. Professional a profitable, been the CEO of 5 Biotechnology companies (public and private) and was CEO of Fulcrum Pharma, In 2007 he led the sale of 454 Life Sciences for CuraGen to Roche sold to Private Equity Investors. Services Company, Frank has experience as a Non-Executive Director in the UK and USA with private and a NASDAQ listed for $154 million. a Board Member at Summit PLC He is currently Chairman of Xceleron, companies and as Chairman of a Charitable Institution. Actino Pharma and a Member of the SAB at Partners. Healthcare Royalty and We view both our M1 mAChR PAM and the O-GlcNAcase inhibitor programs as highlycompetitive with first in PAM view both our M1 mAChR We class potential. cognition program to reach clinical testing optimal resourcing of the M1 mAChR PAM Our current funding allows to ensure support of the highly Asceneuron seeks additional funding innovative latest of 2015. in the first quarter the O-GlcNAcase inhibitor and He led the spin-off proposal for Asceneuron SA and joined the company as Chief Scientific Officer. Dirk Beher is a founder of disease portfolio and successfully which materialized raised EUR 5M seed funding in the creation Alzheimer’s Merck Serono’s disease and spent Alzheimer’s field of Dirk has more than 21 years of experience in the Asceneuron SA in October 2012. of over 15 years in pharmaceutical drug discovery. He was responsible for the Switzerland. Dirk was the director of the Neurobiology Unit at Serono in Geneva, Merck Previously, Asceneuron’s as a new indication disease implemented the projects which represent and Alzheimer’s strategic build-up of pipeline. California where he Oaks, Thousand in Amgen Inc. Department atPrior to Merck Serono Dirk worked in the Neuroscience Dirk started in pharmaceutical drug discovery by joining Merck oversaw a diverse CNS portfolio as management team member. During that time he made key contributions to the United Kingdom in 1998. Sharp & Dohme in Harlow, Asceneuron SA Asceneuron www.asceneuron.com

YEAR FOUNDED 2012 EMAIL [email protected] FAX +41 21 693 8247 TELEPHONE +41 21 693 8242 ADDRESS PSE-B EPFL 1015 Lausanne Switzerland CONTACT PhD, Dirk Beher, Chief Scientific Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

e18 m in the company. € Athera Biotechnologies AB Biotechnologies Athera www.athera.se FINANCIAL SUMMARY Sea Foundation Baltic and KCIF Co- AB (publ), including Karolinska Development Current shareholders, have invested approximately AB, investment Fund in the project forFuture development costs the antibody therapy will be co-financed program, by the EU FP7 Athera has an exclusive option agreement Ingelheim. with Boehringer CARDIMMUN. AB. Athera Biotechnologies AB owns 65% of Karolinska Development PROFILE COMPANY PC-mAb is a fully neutralizes a key human monoclonal antibody which driver of vascular inflammation, and will be indicated for secondaryphosphorylcholine after prevention to improve outcome (“PC”), levels of antibodies to phosphorylcholine Low endogenous (“anti-PC”) have patients. revascularisation in PAD This program is in IND-enablingstudies and the been linked to a higher incidence of secondary events in CVD. start of Phase I studies is expected in 2014. Athera has developed a proprietary enhance clinical success by properly target population, selecting the To companion diagnostic CVDefine® kit to identify patients low anti-PC levels in need of receiving PC-mAb with The kit is CE-approved. therapy. Athera is a biopharmaceutical company focused targeted anti-inflammatory on developing bio-therapeutics The Company and companion diagnostics for the prevention and treatment of cardiovascular disease (“CVD”). harnessing breakthrough innovations made at the world-renowned initiated its current program in 2005, supported by an PC-mAb, The company currentlyhas a proprietary pre-IND program, Karolinska Institute. approved proprietary companion diagnostic kit. MANAGEMENT Athera is managed by the pharmaceutical and diagnostics a team of senior professionals from industries in has nearly Schmidt 30 years Ms. Carina Schmidt. is led byThe core team CEO, a semi-virtual organization. international marketing and product mainly in business development and management, industrial experience, During 15 years she has worked with Pharmacia Biotech/Amersham management within the biotech area. Later she founded Grasp Bioscience and co-founded BioBusiness Partners Biosciences (now GE HealthCare). interim CEO and business advisor to several where positions included management consultant, Scandinavia, biotech start-ups. YEAR FOUNDED 2002 EMAIL [email protected] TELEPHONE +46 76 1938 190 ADDRESS 4th floor Sankt Eriksgatan 117, 11343 Stockholm Sweden CONTACT Carina Schmidt, CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u cial revenues in cial revenues , complex h moderately et penetration by 2020 – by et penetration , via distributor ect sales in UK,   obtain CLIA waiver 2018 (applicable to US only)  for US and Rest of Europe  4% in Europe and US 10% in UK, First commer UK in 2015 and launch in Rest of Europe and US in 2016 (FDA) Launc Dir Mark Assumptions • • • •

R&D Director Finance Director Technical Director Technical £0 £80m £70m £60m £50m £40m £30m £20m £10m Daniel Adlerstein, Daniel Adlerstein, Affairs Director QA & Regulatory James Castelow, COMPANY PROFILE COMPANY Atlas Genetics Ltd is a UK-based clinical diagnostics company that has developed a rapid solution to point-of- low fully integrated & easy to use, multiplex, is fast (30 mins), The io™ system care (POC) molecular diagnostics. focusing on sexually and hospital transmitted infections disease tests, A menu of infectious cost and accurate. Other application areas include pharmacogenomics and industrial acquired infections has been developed. microbiology. and completed a £18.5 series B financing in 2011 led by Novartis The company was established in 2005, BB Biotech Life Science Partners (LSP), Corp, and including Johnson & Johnson Development Funds, Venture and Consort Medical plc. MANAGEMENT Chief Executive Dr John Clarkson, Karen Yates, Business Development Director Nick Higgins, Ben Arlett, Atlas Genetics Atlas www.atlasgenetics.com FINANCIAL SUMMARY Revenues for sexually infection tests: transmitted YEAR FOUNDED 2005 EMAIL [email protected] [email protected] TELEPHONE +44 1225 717930 ADDRESS Derby Court, Epsom Square, Trowbridge BA14 0XG, UK CONTACTS Dr John Clarkson Chief Executive Karen Yates Finance Director WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

CFO Biocartis NV Biocartis www.biocartis.com PROFILE COMPANY healthcare outcomes byBiocartis aims to improve enabling medicine anywhere, the practice of personalized is to establish Biocartis’ ambition a new gold standard in diagnostic testing. anytime. Biocartis’ innovative and diagnostic research systems are characterized by and simplified multiplex detection (especially less hands-on time and minimize sample requirements workflows which require for tumor biopsies). assays Biocartis develops which have health economic value. high clinical utility and compelling Additionally, Oncology is the primary focus of Biocartis as this is one of the greatest for unmet needs personalized medicine. address the growingBiocartis is well suited to need for individualized diagnosis and treatment of cancer patients. Biocartis is a rapidly growing company; to date Biocartis staff includes over 170 people. MANAGEMENT Executive team CEO Rudi Pauwels, Hilde Windels, Assay Development Head of Erwin Sablon, CSO Geert Maertens, General Counsel Inge Basteleurs, Director Quality & Regulatory Chris Heymans, Director of Operations Chris Gabriëls, CCO Ulrik Cordes, CTO Nader Donzel,

YEAR FOUNDED 2007 [email protected] EMAIL TELEPHONE Switzerland +41 21 694 04 30 Belgium +32 15 632 600 ADDRESS Biocartis SA EPFL – Quartier de l’Innovation, Bat G 1015 Lausanne Switzerland Biocartis NV Wittelaan 11 B3 Generaal De 2800 Mechelen Belgium CONTACT Rudi Pauwels CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Executive Vice President Chemistry & Development Executive BioCrea GmbH BioCrea www.biocrea.com FINANCIAL SUMMARY funded by income project Private Company, PROFILE COMPANY Dpression or Autism, molecule drugs forBioCrea develops new small debilitating CNS diseases such as Epilepsy, disease. Huntington’s drug candidates track record in the development of CNS team has an exceptional and has The company’s and Wyeth Pfizer, partnered extensively pharmaceutical companies such as Boehringer-Ingelheim, with major Germany. biocrea is based in Radebeul, GlaxoSmithKline. MANAGEMENT Chief Executive Officer Kronbach, Tom Chief Scientific Officer Dr Martin Gunthorpe, Prof Simon Ward,

YEAR FOUNDED 2010 EMAIL [email protected] [email protected] FAX +49 351 4043 3216 TELEPHONE +49 351 4043 0 Kronbach, Tom +49 351 4043 3332 ADDRESS BioCrea GmbH Meissner Strasse 191 01445 Radebeul Germany CONTACT Kronbach, Tom CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

BioLineRx Ltd. BioLineRx www.biolinerx.com FINANCIAL SUMMARY 2013 30, June, • $23 million cash as of • 43 employees is approximatelyAnnual cash burn $12 million • PROFILE COMPANY BioLineRx is a publicly-traded biopharmaceutical development company dedicated a portfolio to building of The as well as those with advantages over currently available therapies. products for needs, unmet medical Company in-licenses novel compounds primarily institutions and biotech companies based from academic and then partners with pharmaceutical develops them through pre-clinical and/or clinical stages, in Israel, companies for commercialization. advanced clinical development and/or BL-1040 for including: current portfolioand pre-clinical projects, consists of a variety of clinical BioLineRx’s to which has been out-licensed prevention of pathological cardiac remodeling following myocardial a infarction, and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin Ikaria Inc. which is expected to commence a pivotal CE-mark registration trial in late 2013; BL-8040 for treating lesions, and which is in the midst of a Phase 2 study; acute myeloid leukemia (AML) and other hematological cancers, which is expected to commence a Phase 1/2 study in late 2013. BL-7010 for celiac disease, or download the investor relations mobile please visit www.biolinerx.com For more information on BioLineRx, and events. press releases, SEC documents, which allows users access to the Company’s device app, App Store as well as the Google Play Store. IR app is available on the iTunes BioLineRx’s MANAGEMENT Chief Executive Officer PhD, Kinneret Savitsky, MBA, Chief Financial and Operating Officer CPA, Philip Serlin, MD, VP Medical AffairsMoshe Phillip, VP Research and Development PhD, Leah Klapper, VP Business Development MBA, David Malek,

YEAR FOUNDED 2003 EMAIL [email protected] [email protected] FAX +972-2-548-9101 TELEPHONE +972-2-548-9100 CONTACTS Kinneret Savitsky CEO Philip Serlin Chief Financial and Operating Officer Yudelman-Schori Tali ADDRESS 19 Hartom Street Jerusalem 91450 Israel Executive Management Assistant WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

BioScale www.bioscale.com FINANCIAL SUMMARY across 10 countries thus Instruments deployed Commercial growth stage. backed through 4 rounds. Venture BioScale is currently a financing round that finalizing is anticipated to be its generating consumable stream. far, seeking last money into round. Most of round complete, last private financing. PROFILE COMPANY ‘gold standard’ for of specific proteins, detection and measurement BioScale is rapidly emerging a new as and rare cells. bacteria, AMMP is embodied Membrane MicroParticle (AMMP™) assay. Acoustic BioScale has invented the proprietary able researchers and clinicians are to achieve more ViBE, With BioScale’s ViBE™ product line. within BioScale’s BioScale’s measurements in the most complex of biological and sample-robust samples. reproducible, sensitive, AMMP technology is a unique BioScale’s initial focus is in oncology and is rapidly markets. expanding into other In the hands of top key opinion non-optical (acoustic) homogeneous assay that easily enables new assays. ‘gold standards’ BioScale outperforms the currently recognized and industry, government, leaders in academia, on all important performance dimensions. ‘razor/blade’ business where a growing installed base of instruments generates a business model is a BioScale’s ‘open system’ capability as well as kits. BioScale sells healthy consumable stream per machine. BioScale is also BioScale is first selling research use applicationsno regulatory where approval is required. already in CLIA labs clinical applications and CROs and is soon to launch and partnerships. MANAGEMENT CEO and Founder Mark Lundstrom, CTO Dr Brett Masters, VP of Product Development/Operations Dr Michael Miller, CSO Dr Martin Latterich,

X YEAR FOUNDED 2002 EMAIL [email protected] +1 617 249 1550 FA TELEPHONE +1 781 430 6888 ADDRESS BioScale 4 Maguire Road MA 02421 Lexington, USA CONTACT Mark Lundstrom CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Chairman of the Board and CEO Tomas Bubinas, site COO Bubinas, Tomas is responsible for all operational and biotechnology activities who has over ten years of pharmaceutical experience. Tomas acquisition and after Sicor’s joined Sicor Biotech, he After starting his career in public accounting with Coopers&Lybrand, TEVA Director at Most recently he served as Sr. Pharmaceuticals expanded his role into the Pharmaceutical group. TEVA by he was responsible for CMO relationship management. where, Biopharmaceuticals USA, R&D Director Ph.D., Edita Mištinien, Edita has more than 15 years experience in the biopharmaceutical industry and has worked with genetically modified R&D Director and is the leader behind She serves as Biotechpharma’s microorganisms and recombinant proteins since 1997. and our scientific activities working together with our clients’ scientists to solve challenges in biopharmaceutical development subsequently worked as R&D Manager biotech, Edita worked in Sicor Inc. manufacturing of their biopharmaceutical products. one of the she has been working as R&D Director at For the last three years 3P Biopharmaceuticals, Pharmaceuticals. TEVA at leading European CMOs. Vladas has served as Chairman of the Board for biotech companies Biofa and Biotechna until 1999, as well as General Vladas has served as Chairman of the Board for Biofa and Biotechna until 1999, biotech companies Algirdas Bumelis received Vladas In 2004 Prof. until 2012. TEVAPharmaceuticals) Manager of Sicor Biotech (later member of in science and technology of Lithuania in recognition of his achievements in developing and producing Award the science recombinant proteins. Biotechpharma Biotechpharma www.biotechpharma.lt PROFILE COMPANY new laboratoryBiotechpharma owns a brand complex and state-of-the-art facility (constructed and production is led by Biotechpharma with advanced scientific an experienced team of professionals validated in 2012). The team ensures industry or Ph.D.) in their area of expertise and extensive experience. M.Sc. degrees (e.g. timely of every and quality execution project. of expertise: Areas cell banking; • cell line development and process development; • high productivity biosynthesis • efficient protein refolding development; and downstream processes • technology transfer; • process characterization and validation; • cGMP compliant analytical services ; • stability studies; • stable protein formulation development; • drug substance and drug product cGMP manufacturing; • project management. but not limited Utilizing one-stop-shop concept the company range of services provides full including, and optimization; production strain development; upstream and downstream process development to: Phase I-III and commercial). preclinical, (Proof-of-concept, manufacturing of drug substance and drug product MANAGEMENT Vladas Algirdas Bumelis,

YEAR FOUNDED 2004 EMAIL [email protected] [email protected] FAX +370 5278 9305 TELEPHONE +370 5255 9140 Vladas Algirdas Bumelis +370 6987 2022 ADDRESS 4 Mokslininku str. Vilnius, LT-08412 Lithuania CONTACTS Vladas Algirdas Bumelis WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

BioVariance GmbH GmbH BioVariance www.biovariance.de/blog/en/ PROFILE COMPANY bring data from We offers innovative data analysis servicesBioVariance for Drug Discovery and Development. One key focus is dataexperiments in context with available and come thereby up with testable hypotheses. In These efforts by are supported in-house software developers. interpreting NGS data for pharmacogenomics. this area we currently with 3 Big Pharma companies. work In parallel we are currently (supported by developing a grant from the Bavarian a knowledge Government) but this knowledge into clinical usage, The objective is to bring platform for medicine for personalized children. the same can also be appliedin Pharma. MANAGEMENT Managing Director Dr Josef Scheiber,

X YEAR FOUNDED 2012 EMAIL [email protected] +49 89- 1896 58299 FA TELEPHONE +49 89 1896 58280 ADDRESS 4/V Garmischer Str. 80339 Munich Germany CONTACT Dr Josef Scheiber Managing Director WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Bioxodes Bioxodes www.bioxodes.com PROFILE COMPANY Godfroid at Edmond the Ectoparasite Bioxodes was created the results of work conducted by to exploit Prof. in collaboration with prestigious academic part of the University of Brussels (ULB), Molecular Biology Unit, Notre Dame de la Paix Namur, the Facultés Universitaires research units at Catholique the Université de Louvain, goal is to The company’s Switzerland. all in Belgium and the Université de Neuchâtel, the Université de Liège, from natural and other bioscience products derived develop a range of pharmaceutical sources. a unique antithrombotic peptide offering a remarkable and unprecedented initial focus is Ir-CPI, The company’s benefit and hemorrhagicbalance between antithrombotic side effect.

EMAIL [email protected] ADDRESS Parc d’activités économiques du WEX, 11, Rue de la Plaine, B-6900 Marche-en-Famenne CONTACT Oliver Boucher WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u e9.7 M. € e700 k to set-up the companyand complete process €

optimization  CEVEC investors of Initial funding from existing COMPANY PROFILE COMPANY GmbH and focusesCAP-CMV GmbH is a spin-out of CEVEC Pharmaceuticals exclusively on the development The approach of CAP-CMV is of a novel vaccine protecting against (HCMV) infection. human Cytomegalovirus which is currently one of the most convincing technology “HCMV dense bodies (DB)”, the use of non-infectious unique human cell line expression In combination with CEVEC’s approaches to develop an efficient CMV vaccine. suspension culture the novel vaccine can be produced at industrial scale using a serum free, system (CAP®), line as well as the CAP® cell vaccine (product code CAP-CMV-001) The novel dense body based environment. are protected by a strong patent portfolio. MANAGEMENT CEO Kintzel, Wolfgang CSO Dr Gudrun Schiedner, • Investors: Peppermint, Creathor, NRW.Bank, KfW, SKBB and private investors KfW, NRW.Bank, Creathor, Peppermint, • Investors: Necessary milestone-driven funding (until exit in 2018): • Sought: CAP-CMV GmbH CAP-CMV www.cevec.com FINANCIAL SUMMARY • Privately funded GmbH •

YEAR FOUNDED 2013 EMAIL [email protected] [email protected] FAX +49-221-4602-0801 TELEPHONE +49-221-4602-0800 ADDRESS CAP-CMV GmbH 62 Gottfried-Hagen-Str. D-51105 Köln CONTACT Kintzel, Wolfgang CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Cardiox Corporation Cardiox www.cardiox.com FINANCIAL SUMMARY informed by research studies and armed with market With recently obtained international regulatory clearance, internationally Cardiox is launching in 4Q13, Leads generated Medical Meeting interactions, via preclearance and in the United States regulatory upon clearance. reaching cash flow rising to $7 million in 2014, sales are forecast $1 million in 2013, to exceed Worldwide breakeven and profitabilityin late 2014. PROFILE COMPANY Cardiox Corporation is a diagnostic now embarking on commercialization medical device start-up of its first in clinical and regulatory for liver function testing, next product, with its for cardiac shunt detection, product, development. Cardiox’ proprietary technology of an provides non-invasive detection and measurement of small amounts indicator dye injected via IV. low-cost procedure for shunt enables a highly sensitive, the FDS Flow Detection System, Cardiox’ first product, Call points include detection that a nurse or physician can perform setting in in an office about 15 minutes. Interventional and Echo-cardiologists as well as Stroke Neurologists. the market opportunity for cardiac shunt detection exceeds $1.2 billion worldwide. In the aggregate, Assessment system that enables real-time measurement Liver Function Next on the product line-up is the LFA system provides historically important The LFA of global liver function by rate. determining the ICG clearance simply and consistently at the bedside! with hundreds of clinical studies documenting their use, clinical metrics, Hepatologists and Gastroenterologists. Call points include Liver surgeons, the market opportunity for liver testing exceeds 1.1 million patients and $1.5 billion worldwide. In the aggregate, MANAGEMENT President & Chief Executive Officer Larry Heaton, VP & Chief R&D and Engineering Officer Sr. MD, Bob Lash, Officer Technology Founder & Chief Phil Eggers, Finance & Chief Financial Officer VP, Sr. Kelley, Tom Operations VP, Sr. Blair, Tony Quality & Regulatory VP, Karen Matis,

YEAR FOUNDED 2008 EMAIL [email protected] [email protected] FAX +1 614 791 8221 TELEPHONE +1 614 791 8118 Heaton II Larry C. +1 614 791 8118 ext 7001 +1 614 973 9126 cell Kelley Tom +1 614 791 8118 ex 7100 ADDRESS Cardiox Corporation 4100 Horizons Drive Suite 100 Ohio 43220 Columbus, CONTACTS Heaton II Larry C. President & CEO Kelley Tom & CEO VP Sr. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u co-founder and Operations Director at Cell2B. co-founder and Operations Director at Cell2B.

co-founder, President of the Board and Executive Vice President at Cell2B. Vice President at Cell2B. President of the Board and Executive co-founder, PhD, David Braga Malta, being the co-inventor of patent animal-free stem cell products, He has made significant scientific achievements in developing PCT/US2013/030305 filed by MIT and licensed Cell2B. by Rui Horta e Costa, Chief Financial Office at Cell2B. he was the Managing Director of UBS Investment Banking sectors, With 30-years of experience in the financial and industrial he was the CFO of EDP and executive board Before UBS, for EMEA. Team Division in London and the head of the Utilities respectively. both leading companies in energy and food sectors, member at Nutrinvest, Pedro Andrade, PhD, He is the co-inventor of patent PCT/PT2013/000017 in the field of dynamic cell processing filed by IST and licensed by Cell2B. co-founder and Scientific Director at Cell2B. PhD, Francisco Santos, Since 2007 stem cells and in translatingHe has expertise over 8-years in processing mesenchymal it into clinical practice. he has been working with the Portuguese Institute of Oncology to apply in Lisbon these cells to patients with severe grades of GvHD. Dr Couto co-founded Cell2B and served as CEO since then. Her expertise is in business and clinical development for emergent Dr Couto co-founded Cell2B and served as CEO since then. with work done University of Lisbon, Technical in Bioengineeringfrom She received her Ph.D. namely cell therapies. therapies, at MIT in Boston. Cell2B www.cell2b.com PROFILE COMPANY It was biotech developer of cell therapiesCell2B is a Portuguese-based for immune and inflammatory diseases. incorporated in 2011 with technology developed by its founders Massachusetts Institute of and licensed from the An early clinical study of the technology Técnico (IST) in Lisbon. and Instituto Superior (MIT) in Boston Technology resulted in in three patients already suffering from Graft-versus-Host-Disease, showed that it was safe and, Orphan Key manufacturing and regulatory have milestones been achieved. response. either complete or partial designation has been granted in Europe. MANAGEMENT Chief Executive Officer at Cell2B. PhD, Daniela Couto,

YEAR FOUNDED 2011 EMAIL [email protected] FAX +351 23 141 0933 TELEPHONE +351 23 141 0906 ADDRESS Biocant Park, Lote 4A Núcleo 04, 3060-197 Cantanhede, Portugal CONTACTS Daniela Couto, CEO David Braga Malta, President and EVP WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u 49.1 million (~ USD 65 million). The company is based in e49.1 million (~ USD 65 million). €

Medical Director Dr Klaus Brinkmann, Director Sales Head of BizDev Dr Helmut Hilbert, Director Finance Heiko Schorr, Holzgerlingen near Stuttgart, Germany. Curetis has signed collaboration agreements with Heraeus Medical, signed collaboration Curetis has agreements with Heraeus Medical, Germany. Holzgerlingen near Stuttgart, as well as several international distribution agreements. Sanofi Pasteur and Cempra Inc. MANAGEMENT CEO PhD, Oliver Schacht, CTO Andreas Boos, COO Johannes Bacher, Director Bio-Assay Dev Dr Gerd Lüdke, Dr med Anne Thews, Curetis AG Curetis www.curetis.com FINANCIAL SUMMARY in equity capitalRaised EUR 49.1 million Fund; Venture Capital; aeris Roche HBM Partners; BioMed Invest; LSP; Forbion; Investors include: KfW CD-Venture; PROFILE COMPANY AG is a molecular diagnostics company which focuses on the development and Curetis Founded in 2007, The fast and cost-effective products for diagnosing infectious diseases. severe commercialization of reliable, AG enable rapid multi-parameter pathogen in and antibiotic resistance detection diagnostic solutions of Curetis a process that today can take up to days or even weeks with other techniques. only a few hours, Curetis has raised total funds of over date, To

YEAR FOUNDED 2007 EMAIL [email protected] [email protected] FAX +49-7031-49195-19 TELEPHONE +49-7031-49195-10 ADDRESS Curetis AG Max-Eyth Strasse 42 71088 Holzgerlingen Germany CONTACT PhD, Oliver Schacht, CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

MANAGEMENT President & CEO Peter Ohnemus, COO Manuel Heuer, dacadoo www.dacadoo.com FINANCIAL SUMMARY Private company PROFILE COMPANY secure and fun waymanage to your personal health from a wireless, easy-to-use, dacadoo has developed an The platform calculates Health Platform. chronic disease perspective called the dacadoo wellness and lifestyle, The dacadoo Health Score is a number from 1 (poor) to 1,000 (excellent). Score, your personal dacadoo Health dacadoo By integrating networking principles, gaming and social the key indicator health status. of your current fitness, motivates you to be active in an easy way by automatically and comparing your personal health, tracking has been developed byThe dacadoo Health Score dacadoo in collaboration with a professor lifestyle and sport. The score is based on several tens of millions of person-years and former long-term scientist at MIT in Boston. of clinical data and incorporates manycardio and cerebrovascular risk studies in addition of the well-known The company is currently engaging with strategic partners from the quality of life questionnaires. to dacadoo’s media and health insurance industries to serve both corporate and fitness, healthcare, telecommunications, USA. Switzerland and in San Francisco, dacadoo has offices in Zurich, private clients.

YEAR FOUNDED 2010 EMAIL [email protected] FAX +41 44 251 00 72 TELEPHONE +41 44 251 23 23 ADDRESS Othmarstrasse 8 8008 Zurich Switzerland CONTACTS Peter Ohnemus, President & CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u (DLX105) formulated in a α

is sufficient for a clinical effect. A new proof of concept study in psoriasis using topical A new proof is sufficient for a clinical effect. α platform. platform.  gel. This randomized, placebo-controlled proof of concept study is currently running in Switzerland. In psoriasis, In psoriasis, placebo-controlled proof of concept study is currently running in Switzerland. This randomized, gel. repeat plaques mediated injections of DLX105 into the dermis of psoriasis a clinical response showing that TNF- local inhibition of DLX105 formulated the middle of 2014. proof of concept results in in a gel has started and will deliver Delenex has assembled an internationally with lots of years of experience gained in both the recognized team For more details please It operates out of laboratories and offices in Schlieren/Zürich. pharma and biotech world. review the company website www.delenex.com. MANAGEMENT MD, Executive Chairman Thomas Hecht, CFO Jakob Schlapbach, CMO MD, Thomas Jung, CSO PhD, Kretzschmar, Titus Delenex Therapeutics AG Therapeutics Delenex www.delenex.com FINANCIAL SUMMARY completed in MayA round financing 2011; 30.2 MCHF Series PROFILE COMPANY It AG is a clinical stage Swiss biotechnology company established in September 2009. Therapeutics Delenex validated is focussing of single chain therapeutic on the development antibodies discovered by its proprietary, PENTRA gastro- organs such as lung, While antibodies forDelenex is developing those topical and local use in man. Delenex has focussed on delivering the bladder and skin are amenable for topical/local therapy, intestinal tract, draining Disease, In Crohn’s Psoriasis. Disease and Crohn’s novel concept of topical antibodies in fistulising abdominal and perianal fistulas were treated frontrunner anti-TNF- with Delenex’

YEAR FOUNDED 2009 EMAIL [email protected] FAX +41 (0) 44-730-5181 TELEPHONE +41 (0) 44-730-5186 ADDRESS Delenex Therapeutics AG 27 Wagistrasse CH-8952 Schlieren Switzerland CONTACT MD Thomas Jung, Chief Medical Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Executive Chairman CEO Lothar Wieczorek has been at the forefrontof the development of medical devices and products in the US and European Lothar Business has held senior positions in R&D, where he Pharmaceutical and Diagnostics industries throughout his 30-year career, Affairs. Strategic Planning and Medical Development, Stavros Therianos, Ph.D. Stavros is Therianos is one of the principal founders of Diagnoplex and has been with the company since 2005. Stavros Prior to the a consummate entrepreneur who brings his talent and passion to Diagnoplex science and business activities. USA. professor at he was an assistant the University of Rochester Medical Center, founding of Diagnoplex, Diagnoplex SA Diagnoplex www.diagnoplex.com FINANCIAL SUMMARY “A” CHF 15 million in series PROFILE COMPANY are a dedicated and multi-disciplinaryWe team united in bringing true innovation cancer care. to personalized develop blood-based cancer we workflow and state-of-the-artUsing our unique molecular biostatistical tools, This is an area of increasingly focus Our initial is on systematic screening for colorectal cancer. diagnostic tests. and one that an estimated represents need as a result of an ageingurgent and unmet medical population, market opportunity of $3.5 billion. and non-invasive blood test developed for is a convenient the systematic Colox, Diagnoplex lead product, The gene signature underlying Colox detects early and screening of colorectal cancer (Colorectal cancer). advanced disease stages reliability. with outstanding results and MANAGEMENT Lothar Wieczorek, Ph.D.,

YEAR FOUNDED 2005 EMAIL [email protected] FAX +41 219 89 2001 TELEPHONE +41 219 89 2000 ADDRESS 4 Vuillette Chemin de la CH-1000 Lausanne 25 Switzerland CONTACT Stavros Therianos CEO Diagnoplex SA, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

CBO Dicerna Pharmaceuticals, Inc Pharmaceuticals, Dicerna www.dicerna.com FINANCIAL SUMMARY • Dicerna is privately held in capital• Has raised $110 Million since founding • Most recently million financing in July closed a $60 2013 PROFILE COMPANY including is creatingDicerna Pharmaceuticals RNA interference (RNAi) therapeutics for diseases, a range of driver “undruggable” indications and cancer with rare diseases involving genetically-defined targets in the liver, and delivers the Dicerna uses it Dicer Substrate (DsiRNA) to silence these disease target genes, oncogenes. DCR-M1711, most advanced program, Dicerna’s DsiRNAs using Dicerna EnCore™ drug delivery technology. and should begin human trials in early 2014. targets the MYC oncogene, MANAGEMENT CEO Douglas Fambrough, Jim Weissman, Bob Brown, CSO Bob Brown, Acting CMO Paul Nadler,

YEAR FOUNDED 2007 EMAIL [email protected] [email protected] FAX 617.252.0927 TELEPHONE 617.621.8097 CONTACTS Jim Weissman, ADDRESS Inc Dicerna Pharmaceuticals, 480 Arsenal St Suite 120 Building 1, MA 02472 Watertown, CBO Douglas Fambrough, CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u 1.45 million. e1.45 million. €

CEO CBO eADMET GmbH eADMET www.eadmet.com FINANCIAL SUMMARY The company was foundedin 2010 and received GO-Bio phase II funding that company supports the until Q4 Gründerfonds and Bayern Kapital that eADMET received additional funding from High-Tech In 2011, / 2013. of dilutive and non-dilutive capitalbrought the total funding to COMPANY PROFILE COMPANY ADME/ eADMET focuses on the creation of customised computational models for of important the prediction approach modular combines The Company’s drug-like molecules and peptides. properties of small Tox proprietary for and selected external algorithms in order to improve decision-making clients and partners in the pharmaceutical and biotechnology industry and to add value by savingand time and costs in drug design discovery. own experimental data eADMET incorporates the client’s In order to create a customised prediction model, prediction eADMET’s IT environment. existing and subsequently integrates client’s the resulting model into the models are developed using the Company´s proprietary web-based OCHEM database of over 750,000 chemical advanced integrative The Company’s characteristics. ADME/Tox structures linked to known physical and models to predict values that are directly tailor-made delivers including self-learning capabilities, approach, comparable to experimental results. eADMET´s product offer enables new types of data-sharing syndicates to further accelerate drug discovery eADMET promotes a free software version for Based on a 3-fold business model, and save time and costs. industry. Biotech and chemical and licenses its software suite to industry partners in the Pharma, academia, Additionally to offering proprietary web-based informatics systems that integrate and customers internal systems training and eADMET supports in a third step its customers with on-site data with software from other vendors, web-based training and data migration services. implementation, MANAGEMENT Ahmed Abdelaziz, Joachim Vogt, Joachim Vogt,

YEAR FOUNDED 2010 EMAIL [email protected] FAX (+49) 89 716801649 TELEPHONE (+49) 89 716801641 Office: (+49) 157 7688 7277 Mob: ADDRESS Lichtenbergstraße 8 85748 Garching bei München Germany CONTACT Ahmed Abdelaziz CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

CSO Head of Finance fRx business approach is to make existing good pharmaceuticals better, thereby Creating New and Improved fRx business approach make existing good pharmaceuticals better, is to argeting improvements to leading medications, focused on convenience, compliance and tolerability, thus and tolerability, compliance focused on convenience, leading medications, argeting improvements to  Ef patients and payers partners, Therapeutic Entities serving our investors, creating best in class products T • Provide improved quality of life to the patient by making medications easier to take • Create lifecycle management opportunities for industry the pharmaceutical • First product launched in USA MANAGEMENT Chairman & CEO Christer Rosén, CCO Lorenzo Bosisio, Timo Schmidt, Dr. Cheryl Varco, • EffRx Pharmaceuticals SA Pharmaceuticals EffRx www.effrx.com FINANCIAL SUMMARY Private company 2014 planning IPO PROFILE COMPANY Specialty Pharmaceutical company. •

YEAR FOUNDED 1998 EMAIL [email protected] [email protected] FAX +41 44 503 78 66 TELEPHONE +41 44 503 78 60 CONTACTS Christer Rosén Chairman and CEO Cheryl Varco, ADDRESS 41B Wolleraustrasse CH-8807 Freienbach Head of Finance WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

€

):7.5e € • Seventure LundbeckFonden • Shire LLC • Omnes Capital • Seventure LundbeckFonden • Danone te: March 2012 te: Da Postmoney FD:12.3 Me Investors: • Metabolic diseases • Inflammatory bowel diseases. Markets: PROFILE COMPANY Enterome is a Paris-based company technologies with the most advanced in the emerging field of the human gut Microbiome. Enterome develops a pipeline of metagenomic on profiling of the human gut microbiome. markers based stratify patients population or enable new treatments evolution, These biomarkers will be used to monitor disease and gastrointestinal, metabolic, e.g., with the goal to improve management of microbiota-related diseases, autoimmune. also but are (polymorphismsThese chronic disorders depend on genetic susceptibility of the human genome), triggered by (gut microbiota) is a of the intestinal bacterial ecosystem environmental factors where dysbiosis major contributor. MANAGEMENT CEO Pierre Belichard, COO Marie-Laure Bouttier, CTO James Clark, CBO Rodolphe Clerval, CMO Pierre Rimbaud, Enterome www.enterome.com FINANCIAL SUMMARY Premoney valuation:3.8 Me A round (M YEAR FOUNDED 2011 EMAIL [email protected] TELEPHONE +33 681 539 633 ADDRESS 94 avenue Ledru Rollin 75012 PARIS CONTACTS Pierre Belichard CEO Lancry Lydie PA WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

CEO/CFO Epigenomics AG Epigenomics www.epigenomics.com FINANCIAL SUMMARY ISIN DE000A1K0516) and (ECX, Prime Standard: Epigenomics is publiclyat listed the Frankfurt Stock Exchange, For financial information please refer to the EPGNY). (OTC: ADR program in the U.S.A. has established a Level 1 website. Investor Relations the Company’s section of PROFILE COMPANY diagnosticsEpigenomics is a molecular company pipeline of proprietary developing and commercializing a products enable doctors to diagnose cancer earlier and more accurately, The Company’s products for cancer. test is a blood-based Epi proColon®, Epigenomics’ lead product, leading to improved outcomes for patients. which is currentlyregulatory marketed in Europe and is under for the early detection of colorectal cancer, technology and products have been validated through multiple The Company’s review by the FDA for the U.S.A. Epigenomics is an international partnerships with leading global diagnostic testing laboratories. companies and company with operations in Europe and the U.S.A. MANAGEMENT Epigenomics is lead by a highly skilled and motivated management team with track records in the industry in the and Europe. U.S. & Company) Burrill and Venture, Deutsche Therapies, (formerly Biotie Taapken Thomas The team is headed by Dr. Digene and Qiagen). Abbott Diagnostics, Uwe Staub (formerly Dr. Thomas Taapken, Dr. COO Uwe Staub, Dr.

YEAR FOUNDED 1998 EMAIL [email protected] FAX +49 30 24 34 5 - 555 TELEPHONE +49 30 24 34 5 - 0 ADDRESS Epigenomics AG 1 Kleine Präsidentenstr. 10178 Berlin Germany CONTACT Antje Zeise Manager IR | PR WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

28 million IPO ~1 million Seed A 17 million Series € € €

ERYTECH Pharma SA Pharma ERYTECH www.erytech.com FINANCIAL SUMMARY 2004-2005: 2006-2010: 2013: PROFILE COMPANY is a French biopharmaceutical company that develops ERYP) Paris: Pharma SA (NYSE Euronext ERYTECH innovative treatments for leukemia and other oncology acute indications needs. with unmet medical is currently completing asparaginase encapsulated in red blood cells, lead product GRASPA®, The company’s Acute Leukemia (ALL) and is in Phase IIb clinical trial in Acute Lymphoblastic Phase III clinical development in ALL. in is launching a Phase Ib clinical trial ERYTECH In the United States, Myeloid Leukemia (AML) in Europe. has concluded distribution partnership agreements for Europe with the Recordati -Orphan Europe ERYTECH for Israël. TEVA and with group, (France) and a US location The company has its own GMP approved and operational site in Lyon manufacturing American Red Cross in Philadelphia (USA). for cGMP clinical batches production at the MANAGEMENT Chairman and CEO Gil Beyen, EVP and COO Pierre-Olivier Goineau, EVP and CSO Godfrin, Yann

YEAR FOUNDED 2004 EMAIL [email protected] FAX +33 4 78 75 56 29 TELEPHONE +33 4 78 74 44 38 ADDRESS Avenue Rockefeller 60, Bâtiment Adénine 69008 LYON France CONTACTS Gil Beyen Chairman and CEO Pierre-Olivier Goineau EVP and COO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u CEO

Esteve www.esteve.es FINANCIAL SUMMARY 2012 Million € 792 NET SALES : TOTAL SALES :421 (53%) INTERNATIONAL PROFILE COMPANY affiliates, and with operations, headquartered in Barcelona (Spain) group, Esteve is a European pharmaceutical The groupstructured in three main activities: is production sites in three continents. commercial partners and (with Spain and China) and generics (with facilities in Mexico, API production innovative pharmaceuticals, Turkey and the USA). commercial affiliates EU, in a number of countries in the production and commercialization in class and/or of first development, Core activity is centred on the discovery, best in class innovative pharmaceuticals. Sigma R&D pipeline is composed of proprietary small molecules to treat different types of pain. Esteve’s in Phase II clinical trials to treat proprietary drug, orally available, 1 receptor antagonist is a first in class, neuropathic pain. co-crystal of two very patent well protected, In addition Esteve is developing a proprietary first in class, A proof-of-concept Phase II clinical trial has been successfully for acute and chronic pain. API, established completed very recently. In addition Esteve is involved in two Public Private for Partnerships the development of biotech projects (HIVACAT project for the development of a therapeutic HIV vaccine and a gene therapy and/or prophylactic project to treat Sanfilippo A syndrome) Esteve has been extremely and commercialisation successful in the in-licensing of first and best-in-class drugs, Alliances have been forged in the last Such in-licensing deals and Strategic especially for the Spanish market. innovative Japanese companies and selected Biotechs. decades with Big Pharma, Unparalleled record of commercial success (especially co-marketing framework) is based on a very under rigorous and serious scientific approach and on a differentiated and innovative commercial structure covering medical and market access aspects. commercial, MANAGEMENT Albert Esteve, Mr. BDL Director Jordi Esteve, Mr.

YEAR FOUNDED 1929 EMAIL [email protected] [email protected] FAX +34 934 330 072 TELEPHONE +34 934 466 243 ADDRESS Mare de Déu de Montserrat 221, 08041 Barcelona, Spain CONTACTS Dr Jaume Masana Mr Marc Álvarez WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

to join the first investment round and to secure financing to join the first investment round € through the clinical POC of the novel endometriosis product and successful partnering of the programs. product and successful partnering through the clinical POC of the novel endometriosis MANAGEMENT Forendo team consists of the key by experts of Hormos headed Risto Lammintausta (MD,PhD) as CEO and board member. Jyrki Mattila (MD) and Hans Other board members are today from Novo Seeds, Stephan Christgau (chair) Ab. Postlind from KD Forendo Pharma Ltd Pharma Forendo www.forendo.com FINANCIAL SUMMARY in June 2013. to 10M€ (in two tranches) closed First financing round up PROFILE COMPANY discoveryForendo Pharma is a drug and development company focusingprograms on two acquired recently from Hormos Medical Fispemifene has demonstrated in men with secondary in phase II studies efficacy to normalize own testosterone testicular function with once daily It maintains oral dosing and offers significant advantages over hypogonadism. Forendo will develope fispemifene with partners. testosterone replacement. This first-to-man for17HSD1 inhibitor is in preclinical development targeted treatment of endometriosis. compound has demonstrated unique profile in primates elimination with of endometriosis lesions while maintaining normal hormonal cycle. Forendo is looking additional investor of up to 4M YEAR FOUNDED 2012 EMAIL [email protected] TELEPHONE +358 40 3108010 ADDRESS Itäinen Pitkäkatu 4B FI-20520 Turku Finland CONTACT Risto Lammintausta CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Galecto Biotech Galecto www.galecto.com PROFILE COMPANY focusedfor on developing novel drugs the treatment of fibrosis, Galecto Biotech is a newly founded company, a group of proteins galectins, products target The company’s inflammation human diseases. and other serious inhibitors may high potency galectin open new Galecto Biotech’s that playmany important roles in disorders. The company is led byscientists and biotech executives. top-level treatment possibilities for many patients. in close proximity to the founders’ groups. research Valley Galecto Biotech is located Medicon in MANAGEMENT CEO MD PhD, Hans Schambye, COO Anders Pedersen, CSO FRCP, Ph.D., M.A., B.Sc., Sethi, Tariq Prof Med Chem Head, PhD, Prof Ulf Nilsson, Immunology & Biology Head, MD PhD, Prof Hakon Leffler, YEAR FOUNDED 2011 EMAIL [email protected] [email protected] TELEPHONE +45 26 37 37 26 ADDRESS 3 Vej Ole Maaloes DK-2200 Copenhagen Denmark CONTACT CONTACT MD PhD T Schambye, Hans CEO Dorte Dannemann Executive Assistant WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Galmed Pharmaceuticals Ltd Pharmaceuticals Galmed www.galmedpharma.com FINANCIAL SUMMARY investment (soft close at up to $15M $3M). Current Round: PROFILE COMPANY proprietary family Fatty-Acid/Bile-Acid of synthetic Conjugates develops an innovative, Galmed Pharmaceuticals the for treatment of Metabolic and Liver Diseases. of naturally composed occurring compounds, (FABACs), These orally administrated have compounds the potential to treat manifestations NASH and improve other of the Metabolic as insulin resistance. Syndrome such Aramchol is potential disease-modifying treatment for NASH. is a first in class, Aramchol, Our lead candidate, to reduce double blinded clinical trial, in a randomized, the only safe compound that has been clinically shown, significantly liver fat content as well as improve metabolicparameters associated with fatty liver disease. of the key which is a partial selective and safe inhibitor of SCD1 (one Aramchol is a new chemical entity (NCE), (the universal cholesterol export Transporter ABCA1 upregulatesAramchol also the enzymes in lipid metabolism). from cells. Transport pump) stimulating the Reverse Cholesterol associated with insulin resistance, Non-alcoholic fatty of liver diseases, liver disease (NAFLD) is a spectrum It can be manifested NAFLD is diagnosed when infiltration of fat is increased in liver cells. diabetes & obesity. excess fat in the liver; as Steatohepatitis in which in addition to fat inflammation and liver cell as Steatosis, NAFLD is a major health and its complication liver cancer. injury occur; and the most advanced stage Cirrhosis, The prevalence of NAFLD problem and rapidly liver diseases worldwide. becoming one of the most common mainly countries is 16-35% due to the rapidly progressing epidemics of Western in the general population of that obese people (body mass index more The prevalence among 30kg/m²) in the United obesity and diabetes. States has been reported as 80-90%. There is currently no pharmaceutical therapy approved for and NASH are presently NAFLD devoid of therapy. MANAGEMENT Chairman Chaim Hurvitz, CEO Allen Baharaff, CMO Dr Maya Halpern,

YEAR FOUNDED 2000 EMAIL [email protected] FAX +972-3-6938447 TELEPHONE +972-3-693-8448 ADDRESS Blvd. Shaul Ha’melech 8, Aviv 6473307 Tel Israel CONTACT Allen Baharaff CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u tions in blood stream for early cancer diagnosticscompanion and

CFO Chairman  detecting extreme rare cancer gene muta diagnostics. GeneFirst www.genefirst.com FINANCIAL SUMMARY investor and license. The companyby is supported grant, PROFILE COMPANY detection of infectious diseases working in the fields of multiplex diagnosticsGeneFirst is a molecular company, sensitive and affordable diagnostics molecular products - GeneFirst offers simple, and cancer diagnostics. portfolio It has a rich of patented both established assays co-development for and bespoke novel targets. focus Our major is: which have some of been advanced into products. technologies, closed-tube PCR reaction; strains in a single, i) detecting and genotyping of all 14 high-risk HPV ii) MANAGEMENT Dr Luke Alphey, CEO/CSO Dr Guoliang Fu, Mr Andrew Wood,

YEAR FOUNDED 2011 EMAIL [email protected] FAX +44 1235 861138 TELEPHONE +44 1235 832393 ADDRESS 71 Milton Park Abingdon Oxford OX14 4RX UK CONTACT Guoliang Fu Co-founder and CEO/CSO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u recording an increase of EUR 3.49 recording an increase of respectively, compared with a basic and respectively, tient and cost recovery programs amounted to EUR 14.26 million which are included in operating costs and expenses, were EUR 6.91 which are included in operating costs and expenses,

Vice President Quality COO Gentium GmbH general and administrative expenses, which are also included in operating costs and expenses, were which are also included in operating costs and expenses, general and administrative expenses,  diluted net loss per share of EUR (0.01).   Selling, EUR 5.56 million compared with EUR 5.95 million. 0.18 and EUR 0.17, Basic and diluted net income per share was EUR  17.17 million compared with EUR 13.68 million, Product sales were EUR or 26%. million,  the named-pa Defibrotide net sales through Sales of the Company’s or 26%. recording an increase of EUR 2.91 million, million, compared with EUR 11.35 an active pharmaceutical ingredients with EUR 2.33 million, (APIs) amounted to EUR 2.92 million compared or 25%. increase of EUR 0.59 million, Research and development expenses, million compared with EUR 5.19 million. COMPANY PROFILE COMPANY Villa Guardia (Como) - headquartered in (GENT - NASDAQ) company, is a biopharmaceutical Gentium S.p.A. of active ingredients development and manufacture derived from natural sources focused on research, Italy, mission is to discover and provide new therapies to care-givers for Gentium’s as potential therapeutic agents. diseases that currently have few or no treatmentwith the aim to improve the lives of those faced with options rare diseases with high unmet medical needs. is Gentium’s an investigational drug based on single-stranded DNA extracted from pig intestines, Defibrotide, status by the Food “orphan” Defibrotide has been granted In the U.S., most advanced product candidate. the European The EU, In Administration (FDA) for the treatment of hepatic veno-occlusive disease. and Drug Agency (EMA) has granted Defibrotide orphan status for the prevention of hepatic veno-occlusive Medicines Defibrotide is under development for the treatment called and prevention of a rare disease Currently, disease. a condition in which some of the veins in the liver are blocked as a VOD, or hepatic veno-occlusive disease, that are given cell prior to stem such as chemotherapy or radiation treatments, result of cancer treatments, VOD and is associated with multiple-organ failure and high VOD is the most extreme form of Severe transplant. FDA or VOD by either the U.S. there are no approved treatments for Currently, rates of morbidity and mortality. EMA. VOD have been pivotal Phase II/III clinical trials with defibrotide for the treatment and prevention of Two Canada and Israel and Phase II/III pediatric VOD in the U.S., a Phase III trial for treatment of severe completed, VOD. trial in Europe for the prevention of defibrotide has been made available as an investigational new VOD, In the absence of approved treatments for VOD (in the U.S.) and on a named patient basis in IND Protocol for patients with Treatment through a drug, Europe. MANAGEMENT Chairman of the BoD and CEO Dr Khalid Islam, SVP Finance & CFO Mr Salvatore Calabrese, Mr Adrian Haigh, Ignoni, Mr Terenzio VP and Scientific Director Senior Dr Carin Heringa, • Operating with EUR 0.14 million. income was EUR 2.65 million compared with EUR 0.22 million. • Pre-tax income was EUR 2.77 million compared with EUR (0.09) million. • Net income/(loss) was EUR 2.65 million compared • • revenues were EUR 18.33 million compared with EUR 14.17 million. Total • • Operating million. million compared with EUR 14.02 costs and expenses were EUR 15.69 • • Gentium S.p.A Gentium www.gentium.com FINANCIAL SUMMARY 2013) Results Press Release (August 13, From First Half 2013 Financial •

YEAR FOUNDED 1993 as Pharma Research 2001 changed the name to Gentium S.p.A. EMAIL [email protected] FAX +39 031 5373 280 TELEPHONE +39 031 5373 261 (Serena Ramon) ADDRESS Piazza XX Settembre 2 Villa Guardia (COMO) 22079 Italy CONTACTS Adrian Haigh COO Gentium GmbH Salvatore Calabrese CFO Serena Ramon Executive Assistant WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Management Brabant Fund Lifesciences Seed Start-up Fund Brabant 1. 2. 3.

Glycostem Therapeutics Glycostem www.glycostem.com FINANCIAL SUMMARY Investment phase Investors are: PROFILE COMPANY Killer (NK) through Natural solution to eliminate cancer offers an innovative Therapeutics Glycostem cells. Glycostem produces NK-cells for cellular immunotherapy umbilical cord blood (UCB) through a proprietary from This technology enables ex-vivo generation of high numbers of very pure GMP-compliant platform technology. and highly activated NK-cells for clinical applications. These NK-cells offer a highly valuabletreatments addition to current in order to prevent recurrence of cancer and can be effective in many different types of cancer. on elderlyobjectives of a phase I trial first experimental product has fulfilled the patients suffering Glycostem’s The NK-cells actively migrated to the bone marrow and targeted leukemic cells. Acute Myeloid Leukemia. from Overall results which is a unique achievement. 1st patient treated21 months, is meanwhile disease free since AML-patients. indicate NK-cell therapy to offer a solution for unmet medical needs of the hitherto Multiple Acute Myeloid Leukemia, in In subsequent trials NK-cells will be appliedevidence study’s in phase I/II during 2014 and lung and breast tumor throat-neck, such as colon-rectal, Myeloma and EGFR+ solid tumors, 2015. The company seeks investors for supporting the above. MANAGEMENT CEO Dr Dirk Groenewegen, Head of Research Dr Jan Spanholtz, YEAR FOUNDED 1997 EMAIL dirk.groenewegen @glycostem.com TELEPHONE +31-73 624 2148) ADDRESS Onderwijsboulevard 219 PO Box 3016 ‘s Hertogenbosch 5203 DB CONTACTS Dr Dirk Groenewegen CEO Dr Jan Spanholtz Head of Research WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Co-Founder and CEO Heptares Therapeutics Ltd Therapeutics Heptares www.heptares.com FINANCIAL SUMMARY Novartis MVM Life Science Partners, Ventures, we have raised over $60 million in financing from Clarus date, To Ventures. Takeda the Stanley Family Foundation and Fund, Venture PROFILE COMPANY a superfamily of Heptares creates targeting previously new medicines undruggable or challenging GPCRs, design approach are pioneering a structure-based drug to GPCRs, We receptors linked to many diseases. and fragment-based leveraging structure determination, proprietary technologies for protein stabilisation, Our objective is Takeda. Cubist and Morphosys, MedImmune, AstraZeneca, Our partners include Shire, discovery. Alzheimer’s including to build a broad pipeline of novel medicines to transform treatment the of serious diseases, headache disorders and diabetes. addiction, schizophrenia, disease, Parkinson’s disease, disease and Alzheimer’s Our in-house pipeline is led by programme our selective muscarinic M1 for cognition in Our adenosine which is in preclinical development and slated for Phase 1 studies in late 2013. Schizophrenia, is also in development for neurological disorders. which has been licensed to Shire, A2a antagonist candidate, driven by our proprietary first-ever Family T2DM, Further discovery programmes include oral GLP-1 agonists for and CGRP antagonists for prophylaxis and treatment of migraine and Cluster Headache. B crystal structure, opening up new The Heptares technology platform GPCR capability represents a unique in the industry today, Heptares possibilities for both small molecule and antibody therapeutics across the GPCR target universe. which are typically highly unstable when removed from is the first and only company transforming GPCRs, StaRs® enable GPCR structures in their natural into stabilised receptors or StaRs®. cellular membranes, thereby overcoming a major historical barrier to structure- pharmacological conformations to be determined, which provides superior Biophysical Mapping™, Heptares has also invented based GPCR drug discovery. and has engineered new fragment-based and in silico technologies elucidation of GPCR-ligand interactions, coupled with These technology breakthroughs, specifically tailored to GPCR lead discovery and optimisation. form the nucleus of a powerful and fully-integrated drug deep expertise in GPCR chemistry and biology, discovery platform. please visit www.heptares.com learn more about technology the Heptares pipeline and platform, To MANAGEMENT Dr Malcolm Weir, Co-Founder and CSO Dr Fiona Marshall, CBO Dr Barry Kenny, President Dan Grau, Vice President of Chemistry Dr Miles Congreve, CMO and Head of Development Dr David McGibney,

YEAR FOUNDED 2007 EMAIL [email protected] FAX +44 (0)1707 35840 TELEPHONE +44 (0)1707 358 629 (dl) +44 (0)7968947268 (m) ADDRESS Heptares Therapeutics Ltd BioPark Broadwater Road Garden City Welwyn Hertfordshire AL7 3AX CONTACT Malcolm Weir CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Hermo Pharma Ltd Pharma Hermo www.hermopharma.com FINANCIAL SUMMARY Not publicly available. PROFILE COMPANY Hermo Pharmaclinical stage biopharmaceutical Ltd is a cutting- company discovering and developing edge therapeutic approaches products and for currently untreatable the field of neurology. medical needs in The company the majority of operational outsources R&D Finland. headquarter is located Helsinki, in Company’s while controlling the key technology assets and strategic partnerships. tasks to external vendors, These concepts are being R&D programs are based on scientifically innovative concepts. The company’s developed by the company trials and after that Phase II proof-of-principal through preclinical and clinical Hermo Currently Hermo worldwide. trials and market its products Pharma will seek partnerships to support Phase III product development focus treatments is on novel disease-modifying for amblyopia in adults and Pharma’s disease. Parkinson’s The project is currently very in Phase IIa clinical trials and the results seems promising. Adults. Amblyopia in Companylatest is expecting to out-license this product in early 2014. Company is currentlythe support finalizing the pre-clinical proof-of-concepts studies with Parkinson´s Disease. The therapy based on the neuroprotective and restorative is effects provided by of M.J.Fox Foundation financing. The clinical strategy of testing of intracrainial delivery includes platform to treat patients. the the CDNF protein. Toxicology The current data looks very promising and the company is expecting to proceed into the IND enabling phase during year 2013. MANAGEMENT CEO Juhani Lahdenperä, CSO Henri Huttunen, Head of Clinical Development Sigrid Booms, of Directors Board Jonathan Knowles, Veromaa, Timo Ari-Pekka Laitsaari, Henri Huttunen Jyrki Mattila Scientific Advisory Board Eero Castrén Mart Saarma Mary Baker Seppo Kaakkola Lamberto Maffei Heikki Rauvala Pekka Männistö. YEAR FOUNDED 2008 EMAIL [email protected] TELEPHONE +35 85 0366 9502 ADDRESS Hermo Pharma Ltd. Viikinkaari 4 00790 Helsinki Finland CONTACT Juhani Lahdenperä CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

VP Global Regulatory HFM – Hybrid Fusion Medicals AG Fusion Medicals – Hybrid HFM PROFILE COMPANY HFM is developing with state-of-the-art scientific and innovative early market entry strategies plant-derived virology (non-responders in chronic lymphedema after breast cancer), prescription drugs in oncology (e.g. (Parkinson). (auto)-immune diseases and CNS Hepatitis liver diseases), C including advanced patents medical need. high areas of and develops plant-derived pharmaceuticals in HFM identifies, are merging medical knowledge bases from different the human race during continents developed We high civilizations of mankind with latest in the evolution biotech tools and clinically driven highly innovative includes also the integrationThis tools and other data of broad based molecular bases for IT platforms. implementing 22nd century personalized medical technologies in our drug development. entering global markets with our first two products in 2014. are We MANAGEMENT CEO & Chairman of the Board M.D.Ph.D, Christoph von Keudell, CFO Bruno Odermatt, Gaby Wiederkehr,

YEAR FOUNDED 2013 EMAIL [email protected] [email protected] FAX +41 44 738 70 19 TELEPHONE +41 44 738 70 00 ADDRESS HFM-AG 23 Wagistrasse CH-8952 Schlieren CONTACTS Christoph von Keudell CEO Bruno Odermatt CFO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

immatics biotechnologies GmbH biotechnologies immatics www.immatics.com FINANCIAL SUMMARY of €108m. raising a total immatics successfully a total of three financing rounds, concluded VCs. comprised of family offices and The company is backed by a particularly strong investor group, PROFILE COMPANY immatics immunotherapy. active in the field of cancer immatics is a clinical stage company, biopharmaceutical Associated Peptides) therapeutic vaccines that are active against cancers (=Tumor TUMAP-based is developing were developed with its proprietary all of which Three product candidates, need. with a high unmet medical Phase II results from its products technology platform XPRESIDENT™ are currently development. in clinical IMA901 in RCC and IMA910 in CRC showed a correlation of the number of peptides that patients responded to is presently in RCC, IMA901 The furthest advanced product, and the clinical benefit these patients experienced. All of immatics’ current products are off shelf products. the which is fully recruited. in a clinical Phase III trial, to find out more about immatics. Please visit our website at www.immatics.com MANAGEMENT CEO Paul Higham, CSO Harpreet Singh, CMO Carsten Reinhardt, CBO Rainer Kramer,

YEAR FOUNDED 2000 EMAIL [email protected] FAX +49 7071 5397-900 TELEPHONE +49 7071 5397-0 ADDRESS immatics biotechnologies GmbH Paul-Ehrlich-Straße 15 72076 Tuebingen Germany CONTACTS Mark Bleckmann Director & Head of Finance Nikola Wiegeler Communications WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

COO & Co-Founder COMPANY PROFILE COMPANY offering two commercial products. diagnosticsImmunID is pioneering the field of molecular immune since 2005, T cell receptor repertoire diversity at evaluates the Its proprietary CE-marked flagship product ImmunTraCkeR The company certified and runs an ISO13485 accredited research and production is ISO9001 the genomic level. and provides research and testing services France, high-tech campus in Grenoble, facility in the MINATEC as Roche and Sanofi- pharmaceutical companies such worldwide to leading clinical centers and blue-chip Pasteur. MANAGEMENT President & CEO Bernhard Sixt, Sébastien Weisbuch, ImmunID www.immunid.com 2005-2012 FINANCIAL SUMMARY CSO & Co-Founder Nicolas Pasqual, VP Business Development Nadia Plantier, CTO Jean-François Mouret, YEAR FOUNDED 2005 EMAIL [email protected] [email protected] TELEPHONE +33 (0)4 38 78 57 70 ADDRESS 7 parvis Louis Néel CS 20050 38040 Grenoble Cedex 9 France CONTACT Bernhard Sixt President & CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

t was awarded Lauréat national, Emergence “Concours nationalla création d’aide à Emergence t was awarded Lauréat national,  Dr Gueda d’entreprise innovante” has 17 years of Drug Discovery experience. He led Drug Discovery at Vivalis from 2008, where he developed Vivalis from 2008, He led Drug Discovery athas 17 years of Drug Discovery experience. (Scientific Director for UPR – Scientific Adviser) PhD, (Scientific Director for UPR – Scientific Anne Bertolotti, where she is looking UK since 2006, Anne has been a groupleader at the MRC Laboratory of Molecular Biology in Cambridge, Associate Anne was Prior to this, at strategies that can help cells boost their natural defenses against misfolded proteins. Anne In 2013, Investigator award in 2005. Young Professor at Ecole Normale Supérieure (INSERM) and was awarded an EMBO was nominated EMBO member. InFlectis BioScience InFlectis www.inflectisbioscience.com FINANCIAL SUMMARY Looking for seed funds 02.07.13: PROFILE COMPANY is a privateInFlectis BioScience (IB) drug discovery companymolecule drugs that developing small specifically drugs aim at IB’s target Unfolded (UPR) to treat Protein Response neurodegenerative and age-related diseases. of improving the efficiency reducing endoplasmic reticulum (ER) stress by folding promoting correct of proteins, thus being useful in delaying or ER associated degradation of misfolded and/or enhancing the detection proteins, preventing neurodegenerative and/or age-related diseases. IFB-088 is a first-in-class orally available product candidate late in preclinical development stage targeting IB’s has a validated IFB-088 & Retinitis Pigmentosa). UPR to treat neurodegenerative diseases (Charcot-Marie-Tooth This project is supported by robust and efficacy profile. mechanism of action and has an excellent safety InFlectis Cambridge UK), Bertolotti (MRC, A. scientific program(2011) which was published in Science by BioScience co-founder. With its unique drug discovery platformfamily’s InFlectis BioScience is also developing additional compound drug candidates to go through several approvals for indications non-orphan to treat age-related diseases (such Huntington disease…). as Parkinson disease, MANAGEMENT Managing Director PhD, Philippe Guedat, Philippe anti-HCV molecules and the 3D-Screening technology. Prior to Vivalis, he was Director of Chemistry at Hybrigenics (Paris, he was Director of Chemistry at Hybrigenics (Paris, Vivalis, Prior to anti-HCV molecules and the 3D-Screening technology. focusing its interest on Protein-Protein Interaction and the discovery Protease inhibitors of the first Ubiquin-Specific France), Assistant at Cambridge University and SmithKline Beecham Philippe started his career in 1998 as a Research in oncology. UK) before joining Merck KGaA as Medicinal Chemist and Discovery working on the dyslipidemia field. Project Leader (Harlow, YEAR FOUNDED 2013 EMAIL philippeguedat @inflectisbioscience.com TELEPHONE +33 (0)6 19 55 21 66 ADDRESS INFLECTIS BIOSCIENCE Parc de la Chantrerie 95 route de Gachet 44307 Nantes cedex 3 FRANCE CONTACT Dr Philippe Guedat Managing Director WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

is a beta blocker (beta adrenergic inverse agonist) currently used in the treatment of high y data led to the US National Institutes of Health funding Invion’s phase II asthma clinical trial in excess of phase y data led to the US National Invion’s Institutes of Health funding INV102 (nadolol) asthma blood pressure and migraine thattreat is being repurposed to chronic inflammatory airway diseases (e.g. Data from completed phase II trials has demonstrated acceptable airway safety and dose-dependent and COPD). responsiveness. Earl and a second phase II trial in chronic bronchitis is also now underway. USD$4M, a key marker in the INV103 (ala-Cpn10) is a modified naturally to reduce IL-6, occurring human protein shown phase II lupus clinical trial is anticipated late in 2013. Data from Invion’s lupus. chronic inflammatory disease, Invion has an experienced management team in ManagingDirector & CEO Dr Greg Collier (former ChemGenex drugs Dr Mitchell Glass (5 approved with Chief Medical Officer, Vice President R&D and and Executive CEO), FDA). MANAGEMENT Chief Executive Officer and Managing Director Dr Greg Collier, Chief Medical Officer Dr Mitchell Glass, Invion Limited Invion www.invion.com.au FINANCIAL SUMMARY A$42.1 as at 12 Sept 2013 Market capitalisation: M as atA ~$3 30 June 2013 Cash in bank: $1.46M Anticipated R&D tax rebate inflow: cash 30-June-13) ~$6M Cash burn (12 months to PROFILE COMPANY Invion is a clinical-stage company life sciences focussed on the development of treatments for major opportunities in the inflammatory lupus diseases market including asthma and COPD ($34B) and systemic erythematosus (lupus) (to $4B). phase II clinical trials currently underway in the US. Invion has two drug assets in three FDA-regulated,

YEAR FOUNDED Invion was formed through a August 2012 merger in EMAIL [email protected] FAX +61 7 3295 0599 TELEPHONE +61 7 3295 0506 ADDRESS Circuit, 120 Bluestone Unit 2, 4073 Seventeen Mile Rocks QLD Australia CONTACTS Dr Greg Collier CEO & Managing Director Ms Melanie Farris WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Kala Pharmaceuticals Pharmaceuticals Kala www.kalarx.com PROFILE COMPANY advancing innovativeKala Pharmaceuticals is treatments foron a proprietary ocular diseases based platform to Mucus Penetrating platform Product (“MPP”) technology Kala’s deliver therapeutic agents mucus barriers. across MPP technology following eye topical drop delivery. such as the retina, facilitates penetration tissues, into target can enable delivery a diverse array of of small molecule compounds to treat of ophthalmologic a variety wet and age- diabetic macular edema (DME), blepharitis, dry eye, post-operative inflammation, indications (e.g., related macular degeneration(AMD)). most advanced program MPP formulation is an of loteprednol etabonate (“LE-MPP”) to treat post-surgical Kala’s The A registration study for this indication will commence under a US IND in 2014. ocular inflammation and pain. a Further, 2014. and DME in blepharitis, Company also will initiate in dry clinical trials in the U S of LE-MPP eye, is advancing toward selection of a product candidate research phase program involving a topically applied RTKi AMD. in 2014 for the treatment of wet MANAGEMENT MBA, President and CEO PhD, Guillaume Pfefer, Chief Medical Officer PhD, Kim Brazzell, Business Development Vice President, Executive Charlie McDermott,

EMAIL [email protected] [email protected] [email protected] [email protected] FAX 781-642-0399 TELEPHONE 781-996-5252 ADDRESS 135 Beaver St., Suite 309 MA 02452 Waltham, CONTACTS Kayla Parcells Caitlyn Murphy Angeli Kolhatkar WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Principal, Linus Consulting; Former VP Regulatory Affairs, Amgen. Affairs, VP Regulatory Linus Consulting; Former Principal, CDO M.Sc. Rosemina Merchant, Sophiris Bio; Management positions at Intelligene Expressions; Bioniche; KS Biomedix; Former SVP of Development and RA, GE Healthcare; Sanofi Canada Head of Discovery and Corp Dev Ph.D. Shafique Fidai, Xenon Pharm. Chromos; Director of BD, VP of BD, Sophiris Bio; VP of Corp Dev, Formerly Formerly President and CEO, Sophiris Bio (Nasdaq SPHS); President and CTO, KS Biomedix; President and CEO, KS Biomedix; President and CEO, and CTO, Sophiris Bio (Nasdaq SPHS); President Formerly President and CEO, Medica. Avicenna Chief MD. Scientific Advisor Samuel Denmeade, Scientific Founder, Sophiris Bio, Former CSO, Johns Hopkins University; Scientific Founder and Professor of Oncology, Inc. Genspera, Regulatory Advisor M.S. Ralph Smalling, Medicenna Therapeutics, Inc. Therapeutics, Medicenna www.medicenna.com FINANCIAL SUMMARY Privately held. 100% Management owned PROFILE COMPANY virtual company led by experienced executives and a team of stage is a clinical privately held, Medicenna, Medicenna is taking a promising Phase II programWith formultiforme recurrent glioblastoma (GBM), advisors. These fusion proteins are designed and best-in-class Empowered Cytokines™ (ECs). the lead in developing first- (engineeredto harness the targeting specificity of Superkines™ cytokines) to selectively deliver cell-killing cancer stem the pro-tumour micro-environment and agents in order to simultaneously ablate the bulk tumour, is a patient-centric therapy targeting at least a dozen different cancers in patients our lead drug, MDNA55, cells. Designation for the treatment of recurrent glioma by Track MDNA55 has received Fast with an IL-4/IL-4R bias. our exclusive licenses from In addition, the FDA and has been granted Orphan Drug Status by and FDA. EMA enables us to deploy our platforms to generate Empowered Hebrew University of Jerusalem and NIH, Stanford, providing Medicenna the ability to Leukine® and Ontak®, Cytokine™ and Superkine™ versions of Proleukin®, extend its pipeline with less risk. MANAGEMENT President and CEO Ph.D. Fahar Merchant,

YEAR FOUNDED 2011 EMAIL [email protected] FAX 1-604 558 0782 TELEPHONE 1 604 671 6673 ADDRESS Georgia Street West 220-1075 BC Vancouver, Canada V6E 3C9 CONTACT Ph.D Dr Fahar Merchant, President and CEO THERAPEUTICS, INC. THERAPEUTICS, MEDICENNA

WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Lucía Colmenero, Finance Manager Solid experience in financial management of technology start-ups. Pioneer in the photonic integration of optical coherence tomography (8+ yr. experience) and with a strong background in Pioneer in the photonic integration of optical coherence tomography (8+ yr. business administration and management. CTO PhD, Jose Luis Rubio, experience) with a deep understanding of the challenges and potential of integrated optics Expert in medical imaging (8+ yr. and an specialization in IP and innovation management. for optical coherence tomography, Miguel Eslava, COO a strong international with business network and a solid Ex-general manager at GE Healthcare for Spain and Portugal, quality management and team leadership. in operations, experience (over 30yr.) Pedro Oliveira, Marketing Manager Over 10yr international experience in Business Development and Product Management at J&J. MedLumics S.L. MedLumics www.medlumics.com FINANCIAL SUMMARY These funds take MedLumics is currently from 2014Q2. a B-Round of €11M to support its expansion seeking commercial launch in 2014H2 of The the company in 2017 and have to break-even two main application areas: a dermatology imaging providing high resolution information product first-line diagnostics of the skin to support Ablation catheter clinical validation launch of an RF and commercial the development, and and therapy guidance, Sales in in 2017 with fast-growingMedlumics reaches break-even years of operations. revenues in the last two reducing company minimizing capitalneeds, dermatology acceleratelaunch of the guided RF ablation the line, staging access and improving scalability market into a high upside market. risk, Guided by OCT in 2016. PROFILE COMPANY MedLumics is a diagnostic imaging company generation developing a new of portable clinical systems that devices are based on optical coherence tomographyThese (OCT), generate high resolution images of tissue. an established imaging modality in ophthalmologygrowing with fast applications in other fields of medicine. The company has developed an optical chip that reduction in system size and complexity while allows a radical Its unique technology also supports novel catheter designs. offering unprecedented image features. MedLumics’ is actively device developing a first-in-class hand-held for the diagnosis of skin tumors using OCT The product is expected to launch in the second a market of 180M$/yr. This opportunity represents information. By incorporating standard providing high-quality OCT at a price compatible with broad adoption. half of 2014, it allows for seamless integration with current clinical workflows. epiluminescence microscopy, RF ablation catheter for use in atrial fibrillation MedLumics is developing an OCT-guided In parallel, the target launch date for is 2015Q3. this product 1.3B$/yr., With an opportunity exceeding management. MedLumics’ unique catheter design shall provide accuratemonitoring of energy delivery to tissue and direct thus reducing recurrence rates and procedure time. visualization of lesion size and continuity, MANAGEMENT PhD, President & CEO Eduardo Margallo,

YEAR FOUNDED 2011 EMAIL [email protected] [email protected] FAX +34 91 804 93 21 TELEPHONE +34 91 803 39 25 Eduardo Margallo +34 610 01 27 48 CONTACTS Eduardo Margallo President & CEO ADDRESS Medlumics S.L. 1E Ronda de Poniente 16 – Cantos 28760 Tres SPAIN WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

formerly Vice President, Life Cycle Management, Actelion Pharmaceuticals Life Cycle Management, Vice President, formerly Advisor Lead Financial Patrick Scherrer, formerly Widmann Associates CEO, Metys Pharmaceuticals Metys www.metys-pharma.ch FINANCIAL SUMMARY name shares atCHF 100’000.- as 100’000 CHF 1.00 per share. Investment Objectives up to CHF 750’000 Seed investment round, up to CHF 18’000’000 round, A investment Series PROFILE COMPANY ZH, Schlieren, AG, Agreement Neurotune on 10 June 2013 with an Option Metys Pharmaceuticals signed giving Metys exclusive world-wide option for all indications to dimiracetam and related compounds. Switzerland, in clinical development for the treatment of the racetam class, Dimiracetam is a small molecular weight drug of (LyricaTM) and to pregabalin In animal models the compound has an efficacy profile superior neuropathic pain. as a safety- Dimiracetam has completed healthy subject testing as well other prominent anti-neuropathic agents. & tolerability-study in HIV patients. painful neuropathy. Metys is preparing the first dedicateddimiracetam in HIV-associated efficacy study of and other patent applications Dimiracetam is protected by method-of-use patents granted in major markets, granted or pending. preclinical development forMetys is also entered a successor compound into the treatment of neuropathic pain, including neuropathic pain of osteoarthritis. MANAGEMENT CEO & Founder Michael Scherz, YEAR FOUNDED 2013 EMAIL [email protected] [email protected] TELEPHONE +41-79-408 79 82 Michael Scherz +41 79 408 79 82 Patrick Scherrer +41 79 200 98 31 ADDRESS Steinenring 8 CH-4051 Basel CONTACTS Michael Scherz Officer Founder & Chief Executive Patrick Scherrer Lead Financial Advisor WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Nanobiotix www.nanobiotix.com FINANCIAL SUMMARY Public company PROFILE COMPANY Nanobiotix is a clinical-stage company nanomedicine pioneering novel approaches for treatment the local enhances radiotherapy energy to NanoXray, proprietary technology, first-in-class, The Company’s of cancer. NanoXray products are compatible with current more efficient treatment for cancer patients. provide a new, radiotherapy and brachytherapy treatments and are meant to treat via multiple a wide variety of cancers is currently under clinical based on NanoXray, lead product NBTXR3, Nanobiotix’s routes of administration. The Company has partnered with PharmaEngine for clinical development development for soft tissue sarcoma. France. The Company is based in Paris, Asia. and commercialization of NBTXR3 in Euronext ticker: FR0011341205, Nanobiotix is listed on the NYSE Euronext regulated in Paris (ISIN: market FP). NANO: Bloomberg: NANO, MANAGEMENT CEO Laurent Levy, CMO Elsa Borghi, CFO Philippe Mauberna, CBO Bernd Muehlenweg,

YEAR FOUNDED 2003 EMAIL Philippe.mauberna @Nanobiotix.com FAX +33 (0) 140 266 272 TELEPHONE +33 (0) 140 260 24 ADDRESS NANOBIOTIX Wattignies 60 rue de 75012 Paris France CONTACT Philippe Mauberna CFO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

6.5 million in second closing e6.5 million in second closing € 2.5m Strategic Translation Award from Wellcome Trust to develop experimental drug Trust Wellcome from Award Translation e2.5m Strategic 18.5 million from Atlas Venture and 3i Group plc in an initial closing of B Round. Newron B Round. and 3i Group plc in an initial closing of Venture Atlas e18.5 million from Chief Executive Officer Chief Medical Officer

candidate for ALS. Newron places new shares under the up to 10% share capital Newron places new increase ALS. candidate for PROFILE COMPANY is an international biopharmaceutical company focused of on the development Newron Pharmaceuticals S.p.A. to improve patients’ quality of life. novel therapies for diseases of the Central Nervous System (CNS) and pain, has completed safinamide, Our lead product, Newron has a promising pipeline of highly innovative compounds. and is expected to be filed with the US and disease (PD) phase III development for the treatment of Parkinson’s a Ltd., Safinamide is partnered with Meiji Seika Pharma Co., European regulatory authorities during Q4/2013. and with Zambon Group in all other Asian territories, in Japan and key Ltd., subsidiary of Meiji Holdings Co., markets including the US and Europe. other projects are primarily focused on treatments for rare CNS diseases and are at various stages Newron’s sarizotan for Rett’s disease, These include sNN0031 for Parkinson’s of preclinical and clinical development. NW-3509 with potential as the first and ralfinamide for specific pain indications, ALS, sNN0029 for syndrome, add on therapy for the treatment of schizophrenia. with a clinical development site in Basel Italy, near Milan, Bresso, Newron is headquartered in Founded in 1999, trading symbol NWRN. The Company is listed on the SIX Swiss Exchange, and an R&D site in Stockholm. MANAGEMENT Stefan Weber, VP Business Development Executive Marco Caremi, Ravi Anand, VP Finance Roberto Galli, AB General Manager NeuroNova Anders Haegerstrand, 2005 Newron completes e30 million Series C Financing 2006 Swiss Exchange raises e74.3 million Newron IPO on the SWX 2008 Newron awarded EUR 5 million by for the Italian government R&D and training support 2009 Newron raises CHF 7.9m in a private placement to international institutional investors 2010 LLC Newron raises CHF 3.5m through a private Great placement to Point Partners, 2011 R&D support programNewron receives EUR 3.7million under Italian government 2012 Newron enters in license agreement and Zambon for with Meiji Seika Pharma safinamide Newron raises CHF 4.7m through a private placement 2013 Newron receives Newron raises invests Apax Partners to e25 million – expands B round financing Newron Pharmaceuticals S.p.A Pharmaceuticals Newron www.newron.com FINANCIAL SUMMARY 2002

YEAR FOUNDED 1999 EMAIL [email protected] [email protected] FAX +39 02 6103 46 55 TELEPHONE +39 02 6103 46 1 +39 02 6103 46 30 ADDRESS 21 Ariosto, via Ludovico 20091 Bresso (Milan) Italy CONTACT Stefan Weber CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Founder and Chief Medical Officer Chief Executive Officer NLT SPINE Ltd. SPINE NLT www.nlt-spine.com FINANCIAL SUMMARY Raised $15.5M to date (pilot launch) $35,000 2012 Revenues: PROFILE COMPANY is committed to lead Minimally Invasive Surgery (MIS) revolution in Spine by developing innovative SPINE Ltd. NLT surgery with the goal of improving outcomes and proprietaryprocedures based on its platform technology, reducing the associated treatment cost. the company’s to the patient, and cause significant trauma While 70-80% of the spine surgeries are still open leading an Industryvision is to radically change the way spine surgery to the way revolution similar is performed, surgery. cardiovascular procedures have shifted from open surgery to catheter-based platform technology that enables the insertion of “non-linear” products are based on its proprietary SPINE’s NLT a small incision. large implants and instruments into the spine through and eSPIN™ discectomy (both instrument implant, first two products PROW FUSION™ interbody SPINE’s NLT or smoothly integrated to provide a full lumbar interbody cleared by the FDA),may be either used separately, stability to restore spine and “fused” a gold-standard procedure where two vertebrae are fusion procedure, and the Feedback from initial launch in 2012 has been positive treat pain associated with degenerated discs. company is currently preparing for phase. a commercial roll-out the Company plans to launch a total of 6 products in 2013-2015 Leveraging its powerful platform technology, all the major segments of the targeting etc), ARC pedicle screw, the (including other devices for interbody fusion, regulatoryThe paths for in the US, these products are 510(k) global $7.6 billion a year spinal implant market. largest market. enabling a relatively quick penetration of the world’s MA. in Boston, SPINE is headquartered in Israel with offices NLT MANAGEMENT Didier Toubia, Tzony Siegal, Dr. Chief Operation Officer and R&D Director Shterling, Avi VP Technologies Oded Loebl, Marketing VP Business Development and U.S. Keegan, Tom Assurance Affairs & Quality VP Regulatory Eti Zinger, Clinical Director Orly Schwartz, HR Manager Ada Gutgold,

YEAR FOUNDED 2007 EMAIL [email protected] [email protected] FAX 972-3-63441599 TELEPHONE 972-3-6344514 ADDRESS Harutzim St. Yad 6 Kefar Saba Israel CONTACTS Didier Toubia CEO Merav Saimon Administrative Manager WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

COMPANY PROFILE COMPANY companyNOXXON Pharma is a biopharmaceutical a new class of proprietary pioneering the development of alternative non-immunogenic to antibodies. the chemically synthesized, therapeutics called Spiegelmers*, portfolioNOXXON has a diversified of clinical stage Spiegelmer therapeutics: NOX-E36 for• anti-CCL2/MCP-1 Spiegelmer® diabetic nephropathy NOX-A12 for• anti-CXCL12/SDF-1 Spiegelmer® oncology NOX-H94 for• anti-hepcidin Spiegelmer® anemia of chronic disease which haveThe Spiegelmer platform the company provides with powerful and unique discovery capabilities, is a NOXXON Germany, Located in Berlin, generated investigation. a number of additional leads under preclinical and approximately 60 well-financed biotech company with a strong syndicate of international investors, mature, employees. MANAGEMENT Executive Board joined the board of directors in 2007) CEO (since 2010, Iain Buchanan, CMO (since 2011) Dr Matthias Baumann, co-founder of NOXXON (since 1997) CSO, Dr Sven Klussmann, CBO (since 2010) PhD, Aram Mangasarian, Chairman of the Supervisory Board Wenninger Dr Walter (since 2007) NOXXON Pharma AS Pharma NOXXON www.noxxon.com

YEAR FOUNDED 1997 EMAIL [email protected] [email protected] FAX +49 30 726 247 225 TELEPHONE +49 30 726 247 0 ADDRESS NOXXON Pharma AG Max-Dohrn-Strasse 8-10 10589 Berlin Germany CONTACTS Headquarters NOXXON Emmanuelle Delabre Business Development NOXXON PhD Aram Mangasarian, Chief Business Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Numab AG Numab www.numab.com FINANCIAL SUMMARY The Company its collaboration is financed through revenues. PROFILE COMPANY Numab is a privately Swiss biotech company owned focusing on the discovery of antibody and development The 13 people Company being operationalsince January 2012 has signed two fragment-based therapeutics. revenue-generating industry collaborations and is currently moving its first proprietary bi-specific lead molecule into preclinical development. lead product (ND007) is being developed for the treatment of severe chronic inflammatory diseases Numab’s ND007 psoriasis or inflammatory (IBD). bowels disease rheumatoid arthritis (RA), such as multiple sclerosis (MS), T cells by means autoreactive exploits a novel mechanism of action to specifically eliminatethe disease-causing, longer This approach carries the promise for better efficacy, of a bi-specific anti-CD3xIL23R antibody fragment. effect duration of care biologics. and better safety as compared to standard Numab is led by a Management in the biotech industry with proven track record (4 out of 5 Management members have been long lasting employees in key at positions ESBATech). Numab applies proprietary breakthrough technology that allows for fast and reproducible discovery of best-in- class antibody fragment based therapeutics. proprietary pipeline and for discovery partnerships with the The technology is used to broaden Numab’s pharmaceutical industry. A to expedite its lead program to its first The Company is currently in a Series looking to raise CHF 11 million by mid-2015. clinical trial application (CTA) MANAGEMENT PhD, CSO & Co-CEO David Urech, CBO & Co-CEO PhD, Oliver Middendorp, Head of Pharmacology PhD, Gunde, Tea Head of Biochemistry PhD, Sebastian Meyer, Administration Head of Finance and Roland Helfenstein,

YEAR FOUNDED 2011 EMAIL [email protected] FAX +41 44 533 0470 TELEPHONE +41 44 533 0471 ADDRESS Numab AG Einsiedlerstrasse 34 CH-8820 Wädenswil Switzerland CONTACT Oliver Middendorp CBO and Co-CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

2012 7 613 629

2011 6 730 986

2010 4 003 754 €

ANY PROFILE COMP in e Turnover Central and Eastern Europe. CIS and contract research organizationOCT is a leading mid-size (CRO) in Russia, OCT clients and OCT provides drug development services to its clients. on staff, With more than 90 people organizations. medical device and non-for-profit biotechnology, partners include pharmaceutical, Ukraine, clinical trials programsSince 2005 OCT has been involved in a number of which were placed in Russia, OCT provided program management and clinical development Lithuania and Estonia. Latvia, Belarus, Bulgaria, advance a product We as pre-clinical and bioequivalence studies. as well services for Phase I-IV clinical trials, Our experienced teams deliver quality budget. through development and approval a client’s on time and within results for needs which may our clients’ drug research and development vary from full clinical trial programto data management or statistics. monitoring, consultancy, standalone CRO service like medical writing, to including but not limited a wide range of therapeuticOCT expertise includes more than 150 projects in areas, ophthalmology and others. endocrinology, pediatrics, cardiology, oncology, MANAGEMENT President Dmitry Sharov, Head of Business Development Elena Startseva, Clinical Operations Director Irina Petrova, OCT www.oct-clinicaltrials.com FINANCIAL SUMMARY

YEAR FOUNDED 2005 EMAIL [email protected] FAX +7 (812) 449 86 35 TELEPHONE +7 (812) 449 86 34 ADDRESS 8/2 Bolshaya Moskovskaya suite 4-1 let-A, 191002 Saint Petersburg, Russia Business Development Assistant CONTACT Anna Yanaeva WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Chairman Finance Manager Origimm www.origimm.com FINANCIAL SUMMARY A fund raising Series PROFILE COMPANY Austrian biotech company leader in protective antigen striving to become a market Origimm is a young ambitious technology proprietary Using its platform Origimm its candidates supplies ProVaDis® to industry discovery. pipelines for innovative and immune therapy vaccine development. first therapeutic vaccine against acne vulgaris. first product is the innovative, Origimm’s Our vision is to bring innovation in the vaccine discovery and establish ourselves as a prime research oriented as well as developing our own products. biotech company supplying companies, pipelines of pharmaceutical ‘Origins of represent the essence or the most protective vaccine antigens strongly believe that best quality, We is dedication Our mission and purity in science for saving and improving Origimm). Immunity’ (hence the name, under the highest ethical standards. lives, people’s Assays at Sanja Selak – former Head of Department of Serology and Immune Origimm was founded by Dr. Austrian governmental institutions. It is now entering the seed phase backed up by Intercell. For more information please visit www.origimm.com MANAGEMENT CEO Dr Sanja Selak, Mag Thomas Fischer, Dr Anthony Sedgwick, YEAR FOUNDED 2012 EMAIL [email protected] TELEPHONE +43 676 448 4825 ADDRESS Leberstrasse 20 A-1110 Vienna Austria CONTACT Dr Sanja Selak CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u PhD in Biochemistry and Molecular Biology at the University of Barcelona (UB) in Spain. In 2000, he founded In 2000, PhD in Biochemistry Biology and Molecular at the University of Barcelona (UB) in Spain. In Oryzon and since 2001 he has served as Chief Executive Officer and Chairman of the Board of Directors. he sits on the board of other biotech companies He has taken the executive education programme addition, VC. a specialized Seed of Inveready Capital, He is also boardmember at the IESE Business School. (PADE) ORYZON www.oryzon.com FINANCIAL SUMMARY Stage of funding Last funding (9M€) was (15 M€ in total) + 15 M€ in Competitive Grants. 5 Funding rounds from inception These funds were also matched grants with a set of competitive and long-term / null- accomplished in 2008. very soft rates loans. public Capital plans – IPO plans The Company round of funding (15M) in late will need a new 2013 early development of the 2014 to keep the programs full speed and to achieve PoC by to Phase I-II in the end of 2017. VCs Other NAJETI as main stakeholder from 2003. VC firm The company has a French-Spanish Investors. Several Spanish family offices and private Invercat and Barcelona Empren. having minor stakes are CORSABE, minor investors are also present. PROFILE COMPANY Demethylases. Oryzon is a biopharmaceutical EPIGENETIC company with a strong focus in Histone Lysine 1 (18 patent with a dominant IP position Specific Demethylase-1 families, a global leader on Lysine are We viral diseases and LSD1/KDM1A has been proposed as a target for oncology, patent already granted in US). neurodegeneration. TRIAL The company is starting now its first Clinical therapeutic pipeline is strongly focused in oncology. Oryzon’s This LSD1/KDM1A inhibitor is Acute Leukemia in UK and Spain with its first molecule ORY-1001. Phase I/IIA in highly potent in vitro and in vivo and shows exquisitely and has been granted selectivity orphan-drug status by the EMA. Oryzon has another LSD1/KDM1A The company studies till Phase IIB. is raising 15M Euro to complete Clinical The Diagnostic activities have been allocated in an Alzheimer ready to enter in IND enabling tox. program in The company has now a independent Diagnostics company has been finalized. and the preclinical research of the programs.reduced head-count to lead the clinical development MANAGEMENT Chief Executive Officer Carlos Buesa,

YEAR FOUNDED 2000 EMAIL [email protected] [email protected] [email protected] FAX +34 93 377 40 28 TELEPHONE +34 93 515 13 13 ADDRESS C/San Ferran 74 08940 Cornella de Llobregat SPAIN (Barcelona), CONTACTS Carlos Buesa CEO Emili Torrell BDO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

tegy, business development tegy, collaborations & legal issues, IP strategy collaborations & legal issues, gement, strategic implementation gement, CFO Cephalon, Serono, establishment of revenue generating business & buy and build (Cephalon Europe) Serono, Cephalon, ­– Leadership & stra Watts, Tim over 20 years’ industry experience Archimedes Pharma, AstraZeneca, ­– Financial mana SVP Commercial Development Peter Nolan, successful litigation history IP management, 16yrs at Oxford BioMedica. ­–In/out-licensing, non-Executive team commercial Supported by Martin Diggle Blake, Paul Andrew Heath, • Nick Rodgers, Oxford BioMedica plc BioMedica Oxford www.oxfordbiomedica.co.uk FINANCIAL SUMMARY 2012 audited financial results: £7.7m) • Revenue £7.8m (2011: £17.8m) • R&D costs of £14m (2011: £12.6m) • Net loss of £8.7m (2011: £16.5m) (2011: • Net cash burn of £10.5m £14.3m) at• Net cash of £14.1m as Dec 2012 (2011: 31 Including income from the the Company (unaudited). had a net cash1 balance of £9.2m April 2013, At 30 the Company has sufficient cash resources to fund operations Novartis collaboration (announced May 2013), into Q2 2014. PROFILE COMPANY Oxford in gene therapy BioMedica is one of the leading companies and immunotherapy with a platform of Our develop and manufacture unique gene-based medicines. exclusive and pioneering technologies to design, pipeline addresses diseases for which there is currentlytreatment no or that are inadequately treated today, and our product candidates have the neurodegenerative disorders and cancer, including ocular diseases, Through our in-house development programmes and collaborations potential to transform treatment landscapes. improve the lives of patients our goal is to with debilitating and life-threatening with leading industry partners, diseases. MANAGEMENT management team has strong experience in Oxford BioMedica’s Chief Executive Officer, Led by John Dawson, due business development, manufacturing, management, intellectual property clinical development, research, diligence and finance. Executive Directors: CEO John Dawson,

YEAR FOUNDED listed December 1996 (AIM), 1995, April moved to LSE main market 2001 EMAIL [email protected] FAX +44 (0) 1865 783 001 TELEPHONE +44 (0) 1865 783 000 John Dawson +44 (0) 1865 783 012 Watts Tim +44 (0) 1865 783 099 Lara Mott +44 (0) 1865 783 011 ADDRESS Oxford BioMedica Medawar Centre Robert Robinson Avenue The Oxford Science Park Oxford OX4 4GA CONTACTS John Dawson, CEO* Watts, Tim CFO (presenting) Lara Mott, Head of IR* *not in attendance WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u licensing and strategic project evaluation at globally operating

Chief Executive Officer

Revenues 26,812 R&D -3,251 G&A -4,709 Result 16,009 EPS 0.63

ANY PROFILE  pharmaceutical companies Over 20 years experience in clinical development, PAION AG is a publicly-listed biotech company headquartered in Aachen, Germany with a second site in Aachen, AG is a publicly-listed biotech company headquartered in PAION The company has a track record in developing hospital-based treatments for which there UK. Cambridge, AG is transforming development its business model from a pure PAION is substantial unmet medical need. company to a specialty pharmaceutical company with a focus on anaesthesia products to take advantage of the Remimazolam. unique profile of its main compound, MANAGEMENT Dr Wolfgang Söhngen, Diploma in Pharmaceutical Medicine (DGPharMed) and Master of Business Communication • PhD, AG (2004) (2000) and PAION Deutschland GmbH • Founder of PAION • Over 20 years experience in drug development and strategic planning at globally operating pharmaceutical companies Chief Medical Officer Dr Mariola Söhngen, Diploma in Pharmaceutical Medicine (DGPharMed) and Master of Business Communication • PhD, AG (2004) Deutschland GmbH (2000) and PAION • Co-founder of PAION • COMP PAION AG PAION www.paion.com FINANCIAL SUMMARY 2012:

YEAR FOUNDED 2000 EMAIL [email protected] FAX +49-241-4453-523 TELEPHONE +49-241-4453-152 ADDRESS Martinstrasse 10-12 52062 Aachen Germany CONTACT Ralf Penner WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Dr. Stefan Sperl, Co-founder and COO Stefan Sperl, Dr. responsible for all development programs AG, Therapeutics Prior to this position he was global Project Manager at Nabriva Before that he headed the project management at Biovertis ranging from early preclinical to clinical phase 2 programs. where he was responsible for lead AG, Wilex Sperl headed the small molecule research unit at Dr. From 2000 to 2005, AG. Stefan Sperl received his PhD in Chemistry from the Max Planck Institute in Martinsried, Dr. optimization and GMP production. Germany in 2000. Previously he was Head of Clinical Development at Nabriva Therapeutics. His earlier career involved various positions at His earlier GPC- Therapeutics. Previously he was Head of Clinical Development at Nabriva studies at He completed his postdoctoral the Max-Planck Biotech - most recently as Principle Scientist and Director Discovery. Franz Obermayr earned his PhD in Biochemistry at the Imperial Cancer Research Dr. Institute for Immunobiology in Freiburg. Fund in London in 1996. Panoptes Pharma Panoptes www.panoptes-pharma.com FINANCIAL SUMMARY Austria Panoptes is funded by private from the equity and obtained 1 million e interest free seed financing Wirtschaftsservice. A financing round to enable completion of pre-clinical intends to conclude a series By end of 2013 Panoptes clinical studies studies and first in man by 2014/2015. PROFILE COMPANY Panoptes is a privately company held biotech focused based therapies on developing small molecule for The development of Panoptes´ clinical the treatment of severe eye medical need. diseases with high unmet a disease which is one of the major candidate PP-001 focuses on a new treatment for uveitis, autoimmune a disease for which to adenoviral conjunctivitis will be pursued, As a second indication, causes of blindness. PP-001 has therapeutic for potential additional unique mode of action, Due to its no treatment is available. date, inflammatory and viral indications. of developing and experts with a proven track record Panoptes has an experienced team of development is developing a focusedThe team portfolio of high-performance small commercializing innovative products. with its lead clinical candidate PP-001 in preclinical development. molecule products, Panoptes’ aim is to generate future growth by development milestones and by achieving major entering into believe the combination of our technology and cost- We partnerships with leading pharmaceutical companies. has and efficient development strategy will help ensure a rapidmore predictable and path to commercialization, the potential of making needed therapies availablepatients. to more MANAGEMENT Co-founder and CEO Dr Franz Obermayr,

YEAR FOUNDED 2013 EMAIL Franz.Obermayr @panoptes-pharma.com FAX +43 1 516 33 3000 TELEPHONE +43 664 8557 369 ADDRESS Parkring 10 1010 Vienna Austria CONTACTS Dr Franz Obermayr CEO Dr Stefan Sperl COO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Chief Executive Officer PCI Biotech www.pcibiotech.com FINANCIAL SUMMARY 60 at raised MNOK NOK 20 per share IPO 2008, MNOK 90 at raised NOK 40 per share Share issue 2010, Cash of MNOK 60 at Q2 2013 end of PROFILE COMPANY The company is company Exchange. listed on the Oslo Stock PCI Biotech is a clinical stagecancer-focused small developing a product that photochemical internalisation induces (PCI) of a wide array modalities; e.g. of and siRNA; this patented therapeutic approach delivers drugs through triggered endosomal ADCs, molecules, with two programmesclinical in primary focustreatment is localised of cancer, PCI Biotech’s release. head & neck cancer (Phase II) and cholangiocarcinoma (Phase I/II). development: It has The PCI technology platform can also be used as an adjuvant for therapeutic and prophylactic vaccination. been demonstrated both in vivo and ex vivo that PCI can dramatically increase the number of activated Killer by enhancing the MHC I antigen presentation cells. of antigen presenting T-cells MANAGEMENT Per Walday, Chief Financial Officer Bernt-Olav Røttingsnes, Chief Scientific Officer Anders Høgset, Head of Business Development Gaël L’Hévéder,

YEAR FOUNDED 2000 (subsidiary to the pharmaceutical company Photocure until 2008) EMAIL [email protected] FAX +47 6711 5401 TELEPHONE +47 6711 5400 ADDRESS Strandveien 55 N-1366 LYSAKER Norway CONTACTS Gaël L’Hévéder Head of BD Bernt-Olav Røttingsnes CFO Per Walday CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Phenex Pharmaceuticals AG AG Pharmaceuticals Phenex www.phenex-pharma.com FINANCIAL SUMMARY in four Euro raised financing rounds. 22 Mio. PROFILE COMPANY AG is a drug discovery and development company with a focus on chronic inflammatory Phenex Pharmaceuticals and liver diseases. programPhenex´ preclinical RORg was recentlyvalued at partnered with Janssen in a deal 135 M USD. Phenex plans Phenex FXR agonist has just entered a phase IIa clinical trial in patients Px-104 with NAFLD/NASH. to raise additional money to demonstrate in NASH and one more liver disease indication proof of principle prior to going for an IPO or to partnering the program pharma company. with a major MANAGEMENT CEO Dr Claus Kremoser, CFO Thomas Hoffmann,

YEAR FOUNDED 2002 EMAIL [email protected] FAX +49 6221 65282 10 TELEPHONE +49 6221 65282 0 ADDRESS Phenex Pharmaceuticals AG Donnersbergweg 1 67059 Ludwigshafen Germany CONTACTS Dr Claus Kremoser CEO Thomas Hoffmann CFO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Chief Executive Officer Dr Vladimir Cmiljanovic, Chief Financial Officer Gaudenz von Capeller, Chief Scientific Officer Doriano Fabbro, Chief Development Officer Frances Betts, Chief Medical Officer Richard Herrmann, Chief Business Development & Licensing Hervé Girsault, ⋅ ⋅ ⋅ ⋅ ⋅ ⋅ PIQUR Therapeutics AG Therapeutics PIQUR www.piqur.com PROFILE COMPANY targeted anti-cancer PIQUR is a biotech company focused on the discovery of innovative, and the development two rapamycin) target of 3-kinase) and mTOR (mammalian drugs based on PI3K (phosphoinositide inhibition, PI3K While mTOR is a clinically validated drug target, of the most promising therapeutic targets in oncology. proof of concept statusinhibition achieved clinical in Phase-III. efforts concentrate with dual weight molecules development of best-in-class small molecular on the PIQUR’s balanced inhibition appears the combined to be more Generally, mTOR and PI3K. both, of e.g. inhibition, jointly PQR 309, dual inhibitor Furthermore PIQUR’s of either target alone. efficacious than the inhibition differentiates itself from other existing dual PIQUR team members, discovered and developed entirely by today’s better drug properties and toxicological profile. inhibitors through proven brain permeability, and has successfullyPIQUR has raised CHF 5 million in 2012 and 2013 completed toxicology studies in rats and beings) in It is planned to enter Phase-I (safety testing in human dogs for its most advanced compound PQR309. for which PIQUR is raising between 7 and 11 Mio CHF. Q1/2014, including efficacy studies most often related to Phase-II, IA and IB, PIQUR will divide Phase-I into two Phases, financing round will A The funds raised in this Series and will thereby data. gain significant amounts of time and mainly be destined to Phase-IA. As mTOR and PI3K inhibitors have reached clinically validated drug target and proof of concept status, PIQUR is optimistic to provide considerably reduced investment risk as compared to other early respectively, stage biotech companies as well as highly options for interesting exit the investor in the next one to three years. MANAGEMENT YEAR FOUNDED 2011 EMAIL [email protected] [email protected] TELEPHONE +41 61 695 3140 +41 76 516 87 72 ADDRESS PIQUR Therapeutics AG Mattenstrasse 24A CH-4058 Basel Switzerland CONTACTS Dr Vladimir Cmiljanovic CEO Gaudenz von Capeller CFO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u ys for assessment of CD4+ T cell responses to peptides, proteins and T cell responses to peptides, ys for assessment of CD4+ ineered non-immunogenic therapeutic proteins through removal of T cell epitopes ineered non-immunogenic therapeutic removal of proteins through Antibodies – humanized, non-immunogenic antibodies through T cell epitope avoidance non-immunogenic antibodies through Antibodies – humanized, COO    EpiScreen – human ex vivo assa Composite Human Composite Proteins – re-eng antibodies – Julian Smith, CFO Julian Smith, Deimmunisation – Manufacturing cell line development Celtic Pharma (TheraPEG), PolyTherics has announced technologyBiotech (TheraPEG), deals with Nuron Antibodies and Composite Composite Human Antitope’s and MacroGenics (ThioBridge), Spirogen (ThioBridge), Kolltan, Opsona, among others, Proteins technology has been used to createdevelopment by, products in NasVax and Therapure. MANAGEMENT CEO John Burt, CSO Matthew Baker, Sally Waterman, PolyTherics Ltd PolyTherics www.polytherics.com FINANCIAL SUMMARY Antitope. round (July£13.5 million financing 2013) in connection with merger of PolyTherics with • Imperial InnovationsMercia Fund Management • Invesco Perpetual • • PolyTherics’ investors include: The Capital Fund VCT • Longbow Capital • Growth & Income Advantage Enterprise & Innovation Fund • ProVen PROFILE COMPANY PolyTherics provides technology solutions to enable and offers the development of better biopharmaceuticals a portfolio of proprietary and complementary technologies and services to address key needs in biopharmaceutical development. PolyTherics’ portfolio of proprietary services and technologies includes: Site-specific conjugation technologies: ADCs stable ThioBridge™ for homogeneous, – CyPEG for site-specific pegylation HiPEG, TheraPEG, – – PolyPEG as a low viscosity alternative to PEG for extension half-life Immunogenicity assessment T-cell epitopes – iTOPE/TCED – In silico identification of – YEAR FOUNDED 2001 EMAIL [email protected] [email protected] TELEPHONE +44 (0) 207 691 4927 ADDRESS 2 Royal College Street, London NW1 0NH UK Antitope: Babraham Research Campus Babraham Cambridge CB22 0AT UK CONTACTS John Burt CEO Neil Butt Business Development WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

1st in-class oral antudiabetic agent, having already achieved its clinical proof of concept. Excellent having already achieved its clinical proof of concept. 1st in-class oral antudiabetic agent,  benefit/risk ratio. Imeglimin, – A direct AMPK activiator program lead close to first-in-man. with a A direct – – 4 other innovative programs in early stage development – Strong IP position Pharma Industry– Seasoned team of executives coming from the experts and suppliers – Network of re-known international key opinion leaders, MANAGEMENT CEO Thomas Kuhn, CBO Pascale Malgouyres, CMO Pascale Fouqueray, CSO Sebastien Bolze, CFO Eric Massou, VP Diabetes R&D Sophie Bozec, POXEL www.poxelpharma.com FINANCIAL SUMMARY Me 16 1st round : Me 13 2nd round : PROFILE COMPANY POXEL POXEL operates independently as a lean organization expertise. with strong in-house drug development on glucose metabolism, with an activity pipeline consists in innovative projects with new mechanisms of action, currently to factors and with an improved safety profile compared other cardiovascular risk available therapies. Key features of the company: –

YEAR FOUNDED 2009 EMAIL Pascale.malgouyres @poxelpharma.com FAX +33 (0)4 37 70 88 15 TELEPHONE +33 (0)4 37 37 20 10 ADDRESS Jean JAURES Avenue 200, 69007 LYON FRANCE CONTACT Pascale Malgouyres Chief Business Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Christoph Burdack studied chemistry at the Technical University of Munich. He specialized in organic chemistry with the focus University of Munich. Technical Christoph Burdack studied chemistry at the one of the fathers of Multicomponent Ivar Ugi, in the groupon new Multicomponent Reactions and earned his PhD of Prof. a company for chemistry medicinal He and drug discovery In 2001 he founded the Priaton GmbH, services. chemistry. for From 2008 he worked as a consultant Biotech various remained in the company until 2007 as a managing director. AG. of Priaxon Since 2009 he has been CSO companies. Priaxon AG Priaxon www.priaxon.de FINANCIAL SUMMARY Capital structure: 56% held by investor one institutional 32% held by Founders PROFILE COMPANY is a drug discovery development company and focused on developing Germany, in Munich, based AG, Priaxon proprietary using a unique, small molecule therapeutics against hard-to-drug protein-protein interaction targets, technology platform PriaXplore®. one one with Boehringer Ingelheim and Priaxon has already made two big pharma license/collaboration deals, proprietarytechnology platform for PPI drug discovery. validating Priaxon’s with GlaxoSmithKline, at in the world-renowned Fox Chase Cancer Center Priaxon Inc., With the recently founded subsidiary, assays an additional access to all the high class Priaxon has now and novel United States, Philadelphia, which significantly strengthens its drug discovery efforts in oncology by adding promising targets in oncology, chemistry world-leading technology. world-class biology capabilities to complement Priaxon’s Priaxon has focused on partnering projects at an early stage so far and decided now to develop selected in- So the business house oncology projects on its own to later stages incorporating a higher level of value added. minimize the risk in drug discoverymodel is based on the goal to maximize value and by both retaining selected projects in-house and establishing multiple licensing deals. MANAGEMENT CSO Dr Christoph Burdack,

YEAR FOUNDED 2008 EMAIL [email protected] FAX +49-(0)89-4521308-22 TELEPHONE +49-(0)89-4521308-0 ADDRESS Priaxon AG 37-37a Gmunder Str. D-81379 München CONTACT Dr Christoph Burdack, CSO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Probiodrug Probiodrug www.probiodrug.de PROFILE COMPANY based on inhibiting Disease (AD), Alzheimer’s a novel therapeuticProbiodrug has developed approach against the enzyme Glutaminyl (QC). Cyclase QC catalyzes the formation of the pyroglutamic versions of amyloidbeta (pGluABeta) – species with AD, In They account for about 50% half-life and increased aggregation prolonged propensity. increased neurotoxicity, AD animal models has been of QC in several Inhibition AD plaques. in the typical ABeta deposited of the whole and improve cognitive abilities.shown to reduce pGluABeta The main program by is paralleled an anti pGluABeta antibody approach. Probiodrug is private and backed by pharma investors. major institutional and MANAGEMENT CEO Dr Konrad Glund, CFO Hendrik Liebers. CDO Dr Inge Lues, CMO Dr Ronald Black,

YEAR FOUNDED 1997 EMAIL [email protected] FAX +49 345 555 9900 TELEPHONE +49 345 555 9900 ADDRESS 22 Weinbergweg D-06120 Halle (Saale) Germany CONTACT Hendrik Liebers CFO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

py isolated product based on the use of allogeneic stem cells from ferent, non-therapeutic product that uses the same adult human liver- ferent,  Promethera® HepaScreen is a dif Promethera® HepaStem is a cell thera These cells can be HHALPC). Adult Liver Progenitor Cells, healthy adult human livers (Heterologous Human from rare inborn metabolic diseases (which can be classified used to treat a wide variety of liver diseases, such as fulminant to acquired deficiencies affecting adults, and mainly affect children), “orphan diseases” as This treatment already received the orphan drug designation has from the European hepatitis or liver fibrosis. Agency for the treatment of two very debilitating paediatric pathologiesMedicines and from the Food and Drug Administration (USA) for boths indications. This product derived stem cells as a biotechnology tool designed for evaluation of new chemical entities. which currently lacks sufficiently predictive models to assess the hepatic meets a real need in the market, cell model will be made availableThis unique to the metabolism of chemical compounds in the body. pharmaceutical industry to evaluate the metabolism and toxicity of new drugs in humans in a more reliable thereby reducing the need and number of animals for such experiments. way than animal experimentation, • founded in 2009 by Professor Etienne The company is a spin-off of the Université Catholique Louvain (UCL), de CEO of the company. Sokal and Eric Halioua, Promethera Biosciences has 45 employees led by management an experienced team. MANAGEMENT Chief Executive Officer Mr Eric Halioua, Chief Medical Officer Vos, Dr Béatrice De Chief Financial Officer Mr Philip Parkinson, COO Mr Claude Dedry, Chief Scientific Officer Prof Etienne Sokal, VP Business Development Dr Carole Monterrat, Promethera Biosciences Biosciences Promethera www.promethera.com FINANCIAL SUMMARY region Walloon Capital and grant the and loand from Venture has been funded byPromethera® Biosciences (Belgium) financing. of two rounds a total of 34M Euros has been invested through since 2009 and of 23.6 million (B-Round) round has completed in March 2012 a second financial Promethera® Biosciences euros (~USD 31.4 million). PROFILE COMPANY is a pharmaceutical companyPromethera Biosciences that develops innovative therapies for the treatment the It is currently developing two products based on a newly discovered and patented cell, of liver disease. Adult Liver Progenitor Cells (HHALPC): Heterologous Human •

YEAR FOUNDED 2009 EMAIL [email protected] FAX +32 1039 43 01 TELEPHONE +32 10 39 43 00 ADDRESS Promethera Biosciences & Crick Hill Watson 11 Rue Granbonpré, B-1435 Mont-Saint-Guibert Belgium CONTACT Eric Halioua Co-founder and CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

1.7 M 0 -551.951 5.0 M

e e e 4 e

Biologist & business economist, more than 15 years of experi-ence in research & industry Biologist & business economist, Advisor & Co-founder Bufe, A. Prof Dr more than 20 years expertise in allergology paediatrician, Bo-chum, Head of Experimental Pneu-mology Ruhr-University including clinical trials Business Development Ruppert, Dr M. more than 15 years of experience in Pharma-/Biotech industry Biologist & MBA, Sales 2013 (exp): Sales 2013 (exp): EBIT 2012: Employees: Intended use: Production of clinical batch material and conduct of earlyII) in 2014 - 2015 clinical trials (Phase I and PROFILE COMPANY Protectimmun is a pharmaceutical R&D company inno-vative developing drugs in the field of allergic and The product develop-ment is based on natural and specific sub-stances chronic-inflammatory airway diseases. bacteria that epidemiological based on compre-hensive were identified in particular farm environments studies. Protectimmun develops a first-in-class primary to induce allergy-prophylaxis intranasal As its lead project, Start of clini-cal phase is scheduled for long-time protection from hay fever and allergic early asthma in life. 2014. USP: Primary prevention from allergic sensitization against aero-allergens by application of probi-otic bacteria no direct competition. First-in-class develop¬ment, via the nasal mucosa. population 5 million newborns eligible are all healthy infants in the first year of life resulting in Target Market: for treatment thereof with an increased allergy each year in EU and US; 1.5 million risk due to allergic parents. Establishment as prevalence in allergicThere is a high unmet medical need due to the increasing diseases. 1 bn. Peek sales expecta-tions exceed EUR standard therapy is envisaged. (such as recom¬mended vaccines) per year in EU and US. Licensing to an established pharma-ceutical Business model: Development up to clinical proof-of-concept. company and revenues from milestone payments and royalties. MANAGEMENT Kauth, Chief Executive Officer Dr M. Protectimmun GmbH Protectimmun www.protectimmun.de FINANCIAL SUMMARY Raised seed capital: Capital demand:

YEAR FOUNDED 2007 EMAIL [email protected] FAX +49 (0)209 3897 1364 TELEPHONE +49 (0)209 3897 1363 ADDRESS Ückendorfer Straße 237e 45886 Gelsenkirchen Germany CONTACTS Dr Marion Kauth CEO Dr Michael Ruppert Director Business Development Ms Andrea Patzer Management Assistant WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

450,000 100,000 2013 (E) 2,200,000 (1,200,000)

2012 340,844 529,410 1,527,339 (3,349,776)

ANY PROFILE

Provista Diagnostics, Inc. Diagnostics, Provista www.provistadx.com FINANCIAL SUMMARY FINANCING Series A Preferred: • $4.95MM Feb 2012 • $2.55MM Sep 2012 • $6.00MM Mar 2013 EBIT Current Assets Current Liabilities Capital Exp. is a privately diagnostics held molecular company focused on developing and Inc. Provista Diagnostics, tests for prognostic and predictive cancers proprietary diagnostic, commercializing through its dtectDx platform, Provista also offers diagnostic and clinical testing and ovarian. endometrial including breast, affecting women, laboratory services and biotechnology to the pharmaceutical industries through Provista Diagnostics Reference licensed in 49 states to perform human GLP capable a CLIA-accredited and laboratory, Laboratory (PDxRL), clinical testing. MANAGEMENT President/Chief Executive Officer PhD, Reese, Dr David E. Chief Operational Officer Joseph Cooper, Chief Financial Officer John Fermanis, Chief Commercial Officer Joseph Eggler, Vice President of Laboratory Operations Laboratory Director, HCLD/CC (ABB), Ph.D., Sherri Borman, COMP YEAR FOUNDED 2010 EMAIL [email protected] TELEPHONE +1 917 261 3907 Tel. Cell +1 917 880 9118 ADDRESS 1101a Suite St, Varick 160 New York NY 10013 CONTACT Reese Dr David E. Officer President/Chief Executive WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Sensorion www.sensorion-pharma.com FINANCIAL SUMMARY e4M + non-dilutive grants Funding to date: PROFILE COMPANY Sensorion is a private company specialty dedicated treatments to the development of new drug for the inner ear, Sensorion selected developed at On the basis of academic research INSERM, disorders. vestibular and cochlear, several clinically validated and pathways targets of interest and consolidated a pharmacology-driven proprietary at R&D activity aims moving into clinical technology platform to study potential drug candidates. now used testing several firs-in-class programs at latestage pre-clinical and progress 2nd generation programs. MANAGEMENT CEO MPH, MD, Laurent Nguyen,

YEAR FOUNDED 2009 EMAIL [email protected] Nadine.rahmani @sensorion-pharma.com FAX +33(0)4 99 54 58 84 TELEPHONE +33 (0)4 67 20 77 30 ADDRESS SENSORION SAS Le bruyère 2000 (bat 2) Zone le Millénaire 650 rue Henri Becquerel 34 000 MONTPELLIER France CONTACT Nadine Rahmani Executive Assistant WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u ting free DNA (cfDNA) in the plasma of patients colorectal with advanced CEO tients with metastatic detect new somatic colorectal cancer over time to mutations and changes tched fresh-frozen, FFPE, and plasma samples with clinical data and plasma samples available for the vast majority of the FFPE, tched fresh-frozen, Monitoring pa of mutations frequencies under therapy Ma patients Ultra-deep sequencing test of circula cancer Business opportunity NGS is used to determine the Next generation sequencing (NGS) is presently focused on FFPE tumor tissue. Under EGFR and others at baseline (before treatment). BRAF, mutation status of key driver genes like KRAS, treatment with chemotherapy or targeted drugs patients often develop resistance to the drug /drug combination. Resistance often occurs due to new mutations in driver gene. At present there is no way to monitor the mutation profile over time as tumor tissue is only available at the NGS of circulating free DNA (cfDNA) opens a new way to the monitoring of cancer beginning of treatment. ultra-deep coverage is required to detect somatic mutations at low allele frequency. However, patients. Monitoring patients with colorectal cancer is an indication of high medical need and offers an attractive new business opportunity as several tests per year can be done for each patient over a period of several years. Company owns CLIA lab in Germany and will start offering OncoDetect by the end of year to German and European market Company will seek partnerships with Dx and NGS companies for development and marketing OncoDetect in the US and Asia MANAGEMENT Dr André Rosenthal, Lead product is OncoDetect: Lead product is OncoDetect: • • 10 colorectal cancer driver genes (49 amplicons)are deep sequenced • 10 colorectal cancer driver genes (49 amplicons)are • Multiplexed test possess extremely high median coverage of 20.000fold for the 49 amplicons Test • • Detects mutations at low allele frequency Clinical application for OncoDetect • Monitoring micro-metastasis in patients with stage III CRC • Signature Diagnostics AG AG Diagnostics Signature www.signature-diagnostics.de FINANCIAL SUMMARY Seed round in 2004 C round in 2008 Follow-on C round 2010 Follow-on C round in 2011 far 17 million EUR raised so PROFILE COMPANY Colorectal cancer molecular Dx company prediction of response and sequencing test forDevelops blood-based and tumor tissue-based deep prognosis, monitoring. cancer bank in colorectal prospective-ly collected tumor/plasma large Company owns • 40 hospitals in 8 German states for are clinical partners biobank this • >8.000 patients with colorectal cancer of all four stages recruited •

YEAR FOUNDED 2004 EMAIL andre.rosenthal @signature-diagnostics.de FAX +49 331 2000 209 TELEPHONE +49 331 2000 200 ADDRESS Hermannswerder 20A 14473 Potsdam Germany CONTACT Dr André Rosenthal CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

President & CEO SironRX Therapeutics, Inc. Therapeutics, SironRX www.sironrx.com FINANCIAL SUMMARY August 2011 of $3.4M in A Financing Series PROFILE COMPANY Therapeuticsis a private clinical-stage company developing novel therapies for dermal wound repair SironRX lead product, The company’s with a specific focus on mitigating scar formation and accelerating wound healing. SDF-1 (SDF-1). non-viral DNA plasmid that factor-1 encodes stromal cell-derived JVS-100 is a clinically tested, native own repair is naturally produced by body in response to tissue injury the human activating the body’s damaged and other progenitor cells to the processes through recruiting endogenous stem cells region. randomized clinical trial for surgical wounds. placebo-controlled, SironRX is currently enrolling in a double-blind, The company is evaluating ability JVS-100 drug safety and its to reduce scar formation and accelerate wound Previous clinical studies with JVS-100 have demonstrated the drug is well tolerated and safe. repair. MANAGEMENT Evan A. Facher,

YEAR FOUNDED 2010 EMAIL [email protected] TELEPHONE 216-4450830 ADDRESS 10000 Cedar Ave. OH 44106 Cleveland, CONTACT PhD Facher, A. Evan President & CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Physician and Professor of Physiology as head of research projects with more than 15 years of experience main components Developed the Nanocarrier based on knowledge of the Founder and Managing Director Dr Désirée Garten, Fellow Physician and in the previous years postdoctoral Research Advancement of the Nanocarrier during the last years Soluventis GmbH Soluventis www.soluventis.de FINANCIAL SUMMARY Financed with venture capitalfrom a renowned single investor PROFILE COMPANY RNA interference therapeutic of Soluventis is the future an entirely new type of Nanocarrier The Soluventis-platform on the most powerful drug delivery is based system, The Soluventis Nanocarrier characterized by incomparable high efficacy and a very good safety profile. completely and reaches contact system active substances from blood and immune shields the transported have the capability to transport therapeutic We reliable target organs including poorly tissue. vascularized tumor whereas on the other The frozen Nanocarrier has a long shelf life in ampoules microRNA and peptides. siRNA, hand in the organism it is completely eliminatedday. within one Soluventis has a portfolio of oncologic siRNAs which significantly improve tumor reduction and elimination of In combination with the novel drug delivery metastases in comparison to standard chemotherapeutic agents. system we offer a faster and more effective of innovative development therapeutics for pharmaceutical companies. Soluventis stands for the development of innovativecandidates clinical which promise a pronounced increase in life expectancy of patients. MANAGEMENT Founder and CEO Prof Dr Sören Schreiber,

YEAR FOUNDED 2009 EMAIL [email protected] FAX +49 (0) 234 32 14191 TELEPHONE +49 (0) 234 32 29125 ADDRESS Soluventis GmbH Im Lottental 36 44801 Bochum Germany CONTACTS Sören Schreiber Founder & CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u 109.000 6.000.000 €201.000 €653.000 €800.000 € €261.000 €100.000 €500.000 € €1.392.600

€60MM in 2015

> Advisor & Member of the Board

2011 2012 Funding capital required: in humans. most advanced products to Phase IIa p.o.c. secure the two To Funding application: Expected sales: PROFILE COMPANY SOM Biotech has developed a proprietary Drug Repurposing technology platform for discovery of new which we are offering to partners for expanding their drug pipeline. therapeutic indications for given drugs, of which 3 cover clear with 18 positive hits (43%), During the last 3 years we have validated 41 new indications, medical need indications: Argon Pharma. already licensed to SOM0777 for the treatment of Glioma, Phase II planned for 3Q 2013. Disease. Orphan TTR-Amyloidosis. SOM0226 for the treatment of Phase II expected for 1Q 2014. Orphan indication. SOM3355 for the treatment of Huntington Disease, 25 more repurposing programs file the advanced company per year are running to pipeline. MANAGEMENT Chief Executive Officer MBA., PhD, MD, Raúl Insa, PhD., Joaquim Trias, MBA., Part-time Chief Financial Officer BS, Ramon Morera, Chief Scientific Officer PhD., Núria Gavaldà, Project Coordinator PhD., Núria Reig, Officer Chief Technology BSc., Oscar Huertas, Head Scientific Operations PhD, Santiago Esteva, SOM Biotech SOM www.sombiotech.com FINANCIAL SUMMARY of Financing Sources Founders: FFFs: VC firm: Institutional: Grants & loans: Investment in R&D 2010

YEAR FOUNDED 2009 EMAIL [email protected] [email protected] FAX +34 93 403 4510 TELEPHONE +34 93 402 0150 / 969 +34 69 062 3263 ADDRESS Barcelona Science Park 4 Baldiri Reixac, 08028- Barcelona Spain CONTACTS Dr Raúl Insa Chief Executive Officer Dr Santiago Esteva Head Scientific Operations WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Spiber Technologies AB Technologies Spiber www.spiber.se PROFILE COMPANY spider silk for Functionalized recombinant use in for A Company founded inventions of a new biomaterial: on the example: • Stem Cell Culture • Wound Care • Beta Cell Culture for diabetes treatments • Regenerative Medicine • Coating of implants • Diagnostics sensitivity enhancement MANAGEMENT CFO CEO, Monika Hagman, COO Mats Grahn, Marketing Ekaterina Medvedeva, Production Kristina Martinell, R&D My Hedhammar, YEAR FOUNDED 2008 EMAIL [email protected] [email protected] [email protected] ADDRESS AB Spiber Technologies Husargatan 3 BMC, Box 575 751 23 Uppsala Sweden CONTACTS Mats Grahn COO Ekaterina Medvedeva Marketing Director WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

t-cell Europe GmbH Europe t-cell www.t-cell.de FINANCIAL SUMMARY 1.45 Million EUR Capital raised to date: 5.5 Million EUR Additional capital sought: PROFILE COMPANY is aiming to Therapies (BCRT), spin-off a of the Berlin Brandenburg Center for Regenerative t-cell Europe GmbH, therapies used in transplantation medicine. T-cell-based become global technology in the application leader of the company will develop and with its three proprietary platform technologies (PT), Over the next few years, t-cell will products to regulate the immune system and treat viral infections. T-cell-based clinically validate novel then market these products gradually in a number of different indications in collaboration with strategic partners. Treg cell product/therapy for kidney transplantation lead reference product will be a first-in-class Our company’s a cure rather which is the first to promise innovativeThe approach, that suppresses organ rejection in recipients. will significantly improve quality of life for patients who currently have to take than simply ongoing treatment, high-dose immunosuppressive therapies for lives after receiving a donor kidney. the rest of their which opens up huge technologies can be applied indications, in a range of additional t-cell Europe’s the In the pursuit of these promising applications, growth and development. opportunities for the company’s company has developed three technology platforms on key based patents and licenses that ensure exclusivity over the long term. MANAGEMENT CEO Dr med Claudia Ulbrich, Chief Clinical Advisor Prof Dr med Petra Reinke, Chief Scientific Advisor Volk, Prof Dr med Hans-Dieter

YEAR FOUNDED 2010 EMAIL [email protected] FAX + 49 331 2797 56 98 TELEPHONE + 49 331 2797 56 90 ADDRESS 189 Zeppelinstr. 14471 Potsdam Germany CONTACT Dr Claudia Ulbrich CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

General Manager – end user sales and science TNC Bio TNC Bio www.tncbio.com FINANCIAL SUMMARY Product redesigned and successfully and reintroduced in 2013, tested in 2012. First production and turnover Turnover is projected to be 10s of mlns in New products to be introduced q4. first gmp production may 2013. the coming years atmargin. a high seeking vc for second round. + 400k short, Angel funded 700k long PROFILE COMPANY derived products. and distributes XerumFree and XerumFree markets TNC Bio produces, hydrolisates fetal bovine serum, thus animal component free additive replacing e.g. XerumFree is a fully defined, primary and stem cultures It is universal for most cell lines, and other undefined components in cell culture. cells. and has a constant composition Due to its defined nature and animal contamination, it is certified free of viruses are no restrictions in production volumes and it is GMP produced. There reduces costs in testing and storage. These revolutionary products focuss on the essence off cell growth and and removing hurdles in production regulatory affairs. first serumfree FBS but is also core to special growthXerumFree can be used as an additive to replace kits (e.q. HUVEC kit). vaccine producers and advance therapeutics and developers. researchers The company focusses on big pharma, USD in the to 5 Bln. The market currently dominated byis projected to grow fetal bovine serum from 1 Bln. exceeding this year already the natural maximum of FBS supply (1 Bln.USD). coming 5 years, MANAGEMENT operations finance, General Manager – distribution sales, Diederik Klaassen, Maarten van Tiel, Chief Scientific Officer TBA, YEAR FOUNDED 2011 EMAIL [email protected] TELEPHONE T +31 40 30 400 80 M +31 627 32 9008 ADDRESS Smalle Haven 95 5611 EH Eindhoven The Netherlands CONTACT Diederik Klaassen General Manager WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

TRION Pharma GmbH Pharma TRION www.trionpharma.com PROFILE COMPANY TRION Pharma is a privately biopharmaceutical company held that has established approach a novel to cancer TRION has antibodies are based on a proprietaryThe trifunctional platform technology for which immunotherapy. Triomab®, called unique familyantibodies, of trifunctional The company’s the world. secured IP rights around tumor cells as As a result, simultaneously activates immune defense mechanisms against multiple cancer. Moreover, are specificallywell as cancer stem cells and precision. destroyed with hitherto unknown potency individual a vaccination against the patient’s abletrifunctional antibodies are to induce anti-tumor immunity (i.e. tumor) and therefore passive with active immunization. combine approval received market family, Triomab® the most advanced candidate of the Removab® (catumaxomab), Canada and Israel for the intraperitoneal treatment of malignant ascites in patients with EpCAM– Russia, in EU, three further Currently, Removab® is the first approved multispecific antibody worldwide. positive carcinomas. are in development: Triomabs Rexomun/ertumaxomab (anti-Her2 x anti-CD3), (anti-CD20 x anti-CD3) and Lymphomun/Bi20 Ektomun (anti-GD2 x anti-CD3) website at www.trionpharma.com. For more information please visit the company’s MANAGEMENT CEO Dr Horst Lindhofer, COO Dr Dirk Pelster,

YEAR FOUNDED 1998 EMAIL [email protected] FAX +49 89 32 42 66 199 TELEPHONE +49 89 32 42 66 800 ADDRESS Frankfurter Ring 193a 80807 München Germany CONTACT Dr Dirk Pelster COO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

10m in Q1/2014. e10m in Q1/2014. € ugichem GmbH ugichem www.ugichem.at FINANCIAL SUMMARY e9.7m Funding to date: private investors V+ investment fund, Group, Venture BioScience Investors: The company investors alongside existing shareholders for is seeking new a new financing round the closing of of PROFILE COMPANY privatelyAustrian held biotech company dedicated of a new generation to the development of ugichem is an antisense drugs. ugichem is developing innovative antisense drugs with a unique Based on its proprietary Ugimer® platform, therapeutic efficacy profile for immune mediated inflammatory diseases (IMID) where existing therapies are ugichem initially focuses on rheumatoid arthritis (RA) as lead indication. insufficient or do not work. The first product medicine. major breakthrough in molecular Antisense drugs are assessed to become the next the However, drugs are currentlyhas entered the market and numerous new antisense in clinical development. The reasons are insufficient activity have antisense concepts failed so far in the IMID field. RNA based, standard, in immune system relevant organs and cells in combination unspecific immune system stimulation. with efficacy and safety Ugimers a unique combination are non RNA based antisense drugs with of delivery, specific therapeuticparameters confirmed to provide a new and more efficacy profile for immune mediated inflammatory diseases with high medical need. MANAGEMENT CEO Holger Bock PhD, CSO Thomas Lindhorst PhD, CTO Jürgen Soutschek PhD,

YEAR FOUNDED 2003 EMAIL [email protected] FAX +43 512 282285 11 TELEPHONE +43 512 282285 10 ADDRESS Mitterweg 24 A-6020 Innsbruck Austria CONTACT Holger Bock PhD CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Head of Clinical Operations Wilson Therapeutics AB Therapeutics Wilson www.wilsontherapeutics.com PROFILE COMPANY company is an orphan drug focused on developing novel treatments founded in 2012, AB, Therapeutics Wilson is the proprietary salt of tetrathiomolybdate. WTX101, Our lead compound, Wilson Disease (WD). for a very is strong and highly selective chelator with proof of concept previously of copper Tetrathiomolybdate established in WD. MANAGEMENT CEO Jonas Hansson, CMO David Clark, Cecilia Wadell, Head of CMC Lars Olsson, YEAR FOUNDED 2012 EMAIL [email protected] Tanya.syed @wilsontherapeutics.com ADDRESS Wilson Therapeutics AB Västra trädgårdsgatan 15 SE-11153 Stockholm Sweden CONTACTS Presenter: Jonas Hansson CEO Contact: Syed Tanya Project Manager WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

y focus of niche products for on the development the treatment of Oral borations are with experienced teams in localized oral formulations, pre-clinical, pre-clinical, borations oral formulations, are with experienced teams in localized round and experience is based on our’s team experience in oral inflammatory diseases, intervention inflammatory team experience in oral diseases, round and experience is based on our’s tented and lead products as medical devices are focustented and lead products on the prevention of progression of Inflammatory diseases such as inflammation around teeth, medical devices or dental implants, skin and medical devices or dental implants, Inflammatory diseases such as inflammation around teeth, hospital acquired infections   host modulators and localized delivery of antibacterials. targets,  Our partnerships and colla collaborationsinvitro research institutions and our global ongoing with local distributors around the world. Our business strategies are focus on bringing and medical device products to the market in a pharmaceutical short time and with a low cost in development. Specialized pharmaceutical compan Specialized pharmaceutical Our pa Our backg inflammatory diseases. We collaborate with other Pharmaceutical and Oral care companies, as well as We collaborate Oral care companies, with other Pharmaceutical and inflammatory diseases. (eg.IT,COL,US) the world. academic institutions across 3. 3. 4. 4. MANAGEMENT Founder Manager, Director, Dr Sonia Divney, Delegate President, Massimo Radaelli, Zarzatech Europe Sarl Europe Zarzatech www.zarzatech.com FINANCIAL SUMMARY Private Funding. PROFILE COMPANY 1. 2.

YEAR FOUNDED 2012 EMAIL [email protected] FAX +61 740 136 59 TELEPHONE +61 741 798 34 ADDRESS Route de Chenaux 9 1091 Grandvaux Switzerland CONTACT Dr Sonia Divney Director Manager, WELCOME

Supporting Organisations

Bio Deutschland www.biodeutschland.org

As the sector association of the biotechnology industry, BIO Deutschland has set itself the objective of supporting SPEAKERS and promoting the development of an innovative economic sector based on modern biosciences.

The Berlin-based association currently has over 300 members. It is run by a board of ten members consisting of CEOs and managing directors of biotechnology companies, as well as directors of BioRegions. This committee comprehensively represents the various fields in the sector.

The member companies and their experts are organised in working groups that deal with the following topics: finance and taxation; licences and technical contracts; regulatory matters; innovation and entrepreneurship; HR; German-US cooperation; health policy; competition and regulatory policy; technology transfer; and PR. Using a wide range of political initiatives, BIO Deutschland lobbies for improvements to the legal parameters for innovative small and medium-sized enterprises.

BIO Deutschland is Germany’s biotechnology sector representative at the European association, EuropaBio, in Brussels. BIO Deutschland also works closely with other biotech organisations in Europe and the USA in order to PRESENTING COMPANIES lobby for the interests of the sector in an internationally coordinated way. The association is also very active in a broad range of events with the aim of providing biotechnology with a platform for discussion and interaction.

BIO Deutschland Am Weidendamm 1a 10117 Berlin Tel: +49-30-726 25 130 Fax: +49-30-726 25 138 E-Mail: [email protected] SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME

Supporting Organisations

Biotechgate www.biotechgate.com

Your source for life science companies and licensing information. SPEAKERS

If you are about to negotiate a licensing deal between a Biotech and a Pharma company. Or you are looking for a big Pharma company to out-license your Biotech product. Or you are active in the medical technology (Medtech) sector and just want to identify potential cooperation partners or customers. Or you are an investor looking for investment opportunities - or you just want to know about historical financing rounds and valuations in the life sciences, Biotech, Pharam and medical device field. This portal can solve all of these problems - and even more. PRESENTING COMPANIES SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME

Supporting Organisations

BioTOP Berlin-Brandenburg www.biotop.de

BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning biotechnology SPEAKERS in the German capital region. It is our objective to coordinate all regional activities in biotechnology by networking with all key players and to initiate specific projects in order to turn Berlin-Brandenburg into a globally leading life science cluster. The services provided by BioTOP include: • Technology transfer science - industry • Initiation and support of networks • Support for technology-oriented start-ups • Funding support for innovative projects • Providing information on biotechnology • Building and coordination of scientific and interdisciplinary networks • Establishing contacts between experts from all disciplines PRESENTING COMPANIES • Design and organization of events • Public relations work for the biotech region Berlin-Brandenburg

For more information, including a database with comprehensive profiles of all companies and scientific work groups, please visit our website at www.biotop.de.

Dr. Kai Bindseil BioTOP Berlin-Brandenburg Fasanenstr. 85 10623 Berlin - Germany Tel: +49 30 318 622 11 Fax + 49 30 318 622 22 SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME

Supporting Organisations

Citigate Dewe Rogerson www.citigatedr.co.uk

Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and corporate communications across the UK, Europe, North America and Asia. SPEAKERS Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from the company’s overall strength and from the cross-fertilisation of ideas across sectors. The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia. Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As. We have advised on a number of IPO transactions across Europe including; METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera

Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China PRESENTING COMPANIES MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - £35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million).

Citigate Dewe Rogerson 3 London Wall Buildings London Wall London EC2M 5SY Tel: +44 (0)-207-638-9571 SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME

Supporting Organisations

College Hill www.collegehill.com/lifesciences Life Sciences

College Hill Life Sciences provides a full service communications consultancy focused on science-based

sectors. Within the life science field we have established a leadership position by working in partnership with our SPEAKERS clients to deliver high quality communications that build corporate value and promote leading edge products, technologies and services).

London Sue Charles The Registry, Royal Mint Court, London EC3N 4QN, UK T: +44 (0)20 7457 2020 F: +44 (0)20 7866 7900 Email: [email protected] Manchester Dr Eileen Paul / Chris Fisher Meadowside, Mountbatten Way, Congleton, CW12 1DN, UK Tel: +44 (0)1260 296500 Fax: +44 (0)1260 296501 Email: [email protected] Munich PRESENTING COMPANIES Dr Douglas Pretsell Augustenstraße 79, 80333 Munich, Germany Tel: +49 (0)89 57 00 18 06 Fax: +49 (0)89 52 38 80 06 Email: [email protected] San Francisco Erik Clausen 201 Spear Street, Suite 1100, San Francisco CA 94105, USA Tel: +1 (415) 230 5385 Email: [email protected] SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME

Supporting Organisations

FreeMind www.freemindconsultants.com

FreeMind is a consulting group whose goal is to assist its clients in maximizing their potential to SPEAKERS receive funding from non-dilutive sources. Established in 1999, FreeMind is the largest consulting group of its kind with over 400 active clients, academics and Industry alike. FreeMind’s proven long-term strategic approach has garnered its clients over 1.5 billion dollars to date.

Our expertise in applying for grants and contracts extends throughout every government mechanism open to funding the life sciences including all NIH institutes, DoD, NSF, FDA, CDC, BARDA, etc., as well as private foundations such as Michael J Fox, Bill and Melinda Gates and Susan G Komen.

FreeMind’s knowledgeable and experienced team of Analysts and Project Managers are dedicated to guiding its clients non-dilutive funding efforts from identification of the most suitable

opportunity through to submission and subsequent award. Our team of experts will assist our PRESENTING COMPANIES clients in making non-dilutive funding a key tool in their long-term financial strategy.

Tel: (617) 648-0340 Fax: (617) 904-1767 Email: [email protected]

Boston FreeMind Group 423 Brookline Ave. #124 Boston, MA 02215

Washington DC

FreeMind Consultants SUPPORTING ORGANISATIONS 4094 Majestic lane # 269

Fairfax, VA 22033 t back ::

Jerusalem FreeMind Group next u Hi - Tech Center Hebrew University Jerusalem 95702 Israel ORGANISERS WELCOME

Supporting Organisations

Going Public Media AG www.goingpublic.de

Founded in 1998, Going Public Media AG is one of the leading specialist magazine publishers SPEAKERS about corporate finance, technology, investment / stock market. The Group publishes more than 100 journal issues annually and operates 10 sites in conjunction with print magazines and online formats.

GoingPublic Media AG Hofmannstr. 7a 81379 München Tel.: 089 – 20 00 339 – 0 Fax: 089 – 20 00 339 – 39 PRESENTING COMPANIES SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME

Supporting Organisations

Life Science Austria www.lifescienceaustria.at

Life Science Austria – LISA – is a program acting as a hub for people from all over the SPEAKERS world who are interested in the life science sector in Austria. Together with its associates in the Austrian regions, LISA is the first point of contact for anyone with questions about scientific collaboration, setting up an operation, or funding and sponsoring projects and businesses in Austria.

Working with all existing life science clusters in the Austrian regions – ecoplus, human. technology.styria, Life Science Austria Vienna Region, Health Technology Cluster, and Life Science Cluster Tirol - LISA is able to build on their expertise and services. The aims of LISA and its partners are: contribute to the success of life science enterprises in Austria by helping to introduce scientific discoveries to the market, assist in the search for funding, and provide general business consultancy and support to ensure healthy PRESENTING COMPANIES commercial development.

Austria Wirtschaftsservice GesmbH (aws), is responsible for running this program on behalf of the Austrian Federal Ministry of Economics, Family and Youth (BMWFJ).

Austria Wirtschaftsservice Gesellschaft mbH, Ungargasse 37, 1030 Wien, Austria

Tel.: +43 (1) 501 75 - 0 • Fax: +43 (1) 501 75 - 900 • Email: [email protected] SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME

Supporting Organisations

MC SERVICES MC Services AG www.mc-services.eu

MC Services AG, based in Munich and Duesseldorf, is an international Public Relations and SPEAKERS Investor Relations firm specializing in life sciences. The Company’s long-standing clients include leading, international public and private companies as well as venture capitalists and investment firms. Established for many years as a link between industry and the financial markets, MC Services provides comprehensive services in the fields of IR, PR, financial reporting as well as capital and corporate transactions. We leverage our extensive network in the international financial community and in the industry in a targeted way for the benefit of our clients in order to best prepare for financing rounds by means of qualified investor relations and media work, for example, or to visibly position our clients and their successes in the German and international finance, economic and trade media.

Anne Hennecke (Managing Partner) PRESENTING COMPANIES Raimund Gabriel (Managing Partner)

Tel: +49-89-210228-0 Fax: +49-89-210228-88 Email: [email protected]

MC Services AG Schubertstraße 10 80336 Munich Germany SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME

Supporting Organisations

Swiss Biotech Association www.swissbiotech.org

SwissBiotech – One Nation – One Biotech Cluster SPEAKERS

Swiss Biotech unites the four leading biotech regions of Switzerland (BioAlps, BaselArea, Biopolo Ticino and Greater Zurich Area). The regions have early on combined efforts with the SWX Swiss Exchange which holds a leading position in terms of life-science listings and services.

The National Industry Association named Swiss Biotech Association Represents more than 150 companies to date and acts as the operational arm for the marketing alliance. Swiss Biotech raises Switzerland’s profile as an economic center in Europe and profiles the biotech industry with its key research institutions and companies. PRESENTING COMPANIES Swiss Biotechs’ mission is to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of the drivers of biotechnology including research, education, economics, finance and industry. The bases for success in biotechnology are the critical mass of research institutes and accelerated technology transfer. The early integration of industry and well-trained workforce is another critical success factor for rapid economic growth. More than 40 technology parks throughout the country support the increasingly important and successful TechTransfer process.

Further inquiries: SwissBiotech, Executive Office Tel. +41 (0)44 455 56 78 [email protected] SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME

Supporting Organisations

Tiberend Strategic Advisors, Inc. www.tiberendstrategicadvisors.com SPEAKERS Tiberend Strategic Advisors, Inc. is a corporate communications firm providing media strategy and execution for life science companies – biotech (therapeutics), medical devices and diagnostics. We work with both public and private emerging growth companies.

1. To enhance valuation

2. To build visibility for partnerships and strategic alliances

Tiberend Strategic Advisors, Inc. 35 W. 35th Street, 5th Floor, New York, NY 10001-2205 Tel: 212.827.0020 Fax: 212.827.0028 Fax PRESENTING COMPANIES SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME

Supporting Organisations

Torreya Partners LLC www.torreyapartners.com

Torreya Partners LLC is a leading boutique advisory firm that provides strategic advice SPEAKERS and assistance with Mergers & Acquisitions, Partnering and Financings to life science companies worldwide. Torreya Partners provides the long-term thinking and objective advice required for life science companies to create lasting value. We take great pride in handling complex financial and strategic matters for some of the most sophisticated private and public life science companies in the world. Our reputation has been built on quality advice, excellence in deal execution and good outcomes for our clients. We bring the caliber of people and quality of relationships found in some of the largest investment banks along with the attentive, detailed service you expect from a boutique advisory firm. Torreya Partners has offices located in New York, Philadelphia and San Francisco. PRESENTING COMPANIES SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME

Supporting Organisations

Venture Valuation www.venturevaluation.com

Venture Valuation specializes in independent assessment and valuation of technology- SPEAKERS driven companies in growth industries, such as the Life Sciences (Biotech, Pharma, Medtech), ICT, high-tech, Nanotech, Cleantech and Renewable energy.

In addition to valuation products, Venture Valuation offers high-quality, focused information services. Through our focus and unique position, we strive to fulfill and surpass our customer needs and add value to the partnership. Clients include investors, companies and development agencies.

Venture Valuation AG Kasernenstrasse 11 CH-8004 Zurich

Switzerland PRESENTING COMPANIES

Phone: +41 (43) 321 86 60 Fax: +41 (43) 321 86 61 SUPPORTING ORGANISATIONS t back :: next u ORGANISERS WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS www.sachsforum.com • Conference Sponsor – including workshops and social events • Exhibition stands • Distribution of Promotional Material Sachs Associates Ltd is a London-based company, which organises and produces securities and emerging which organises and produces Associates is a London-based company, Ltd Sachs Associates is dedicated Sachs markets conferences in association with major exchanges and news agencies. produces only a limited number of events each as a result, in conferencing and, to the highest quality standards Technology, European Equities and Associates investment conferences focus on Emerging Markets, Sachs year. Associates is focused on Sachs York and Zurich. New centres such as London, and are held in major financial and the the exchange of ideas and information, participation, the practical benefits accruing from conference facilitating of business transactions. Associates may be summarised as follows: participation with Sachs The benefits of conference Multimedia Exposure Associates is uniquely able to provide its conference sponsors maximum exposure across extremely well Sachs conferences is carried out Regular extensive coverage of all the Company’s focused electronic and print media. through video streaming and extensive events coverage major international through financial news agencies, Associates has a number of long established Sachs In addition, Dow Jones and Reuters. including Bloomberg, which allow further effective distribution on relationships with other financial press organisations globally, behalf of its clients. Eminent Speakers Associates is committed to ensuring that its events continue to provide forums with the participation of Sachs Through its reputation and its long-established the most eminent speakers from the public and private sectors. the Company has attracted very senior political and economic personalities as speakers local relationships, at its events. Opportunities for forthcoming events Sponsorship and Marketing Associates has developed an extensive knowledge of the key individuals operating within the European Sachs Associates at the This together with a growing reputation for excellence puts Sachs and global biotech industry. forefront of the industry and provides a powerful tool by which to increase the position of your company this in market. profile directly with your potential clients. Sponsorship of any of our events allows you to raise your company’s allowing your organisation to gain the most out All of our sponsorship packages are tailor made to each client, of attending our industry driven events. conferences: at future available opportunities are sponsorship and marketing The following or sponsorship opportunities please call in exhibiting If your company is interested Sian Rodgers on +44 203 463 4890. Sachs Associates Organisers WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS London NW3 5QS 7th Annual 27 Belsize Lane 14th Annual Tel: +44 203 463 4890 +44 203 Tel: Fax: +44 (0) 207 691 7919 Fax: 4th – 5th March 2014 • Zurich 4th – 5th March 7th – 8th October 2014 • Zurich 21st November 2013 • Düsseldorf 21st November www.sachsforum.com Biotech & Pharma Industry BIOTECH IN EUROPE FORUM BIOTECH PARTNERING & INVESTING in PARTNERING We look forward to seeing you at: forward to seeing you look We EUROPEAN LIFE SCIENCE CEO FORUM EUROPEAN LIFE SCIENCE

MEDTECH & DIAGNOSTICS INNOVATIONS SUMMIT INNOVATIONS MEDTECH & DIAGNOSTICS BIOTECH IN EUROPE INVESTOR FORUM INVESTOR EUROPE IN BIOTECH